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Summary 
 
A genome-wide association study in chronic thromboembolic pulmonary 
hypertension and the ADAMTS13-VWF axis 
 
Michael Newnham 
 
Chronic thromboembolic pulmonary hypertension (CTEPH) is an important and severe 
consequence of pulmonary embolism (PE), resulting from failure of thrombus 
resolution.  Identifying genetic risk factors for CTEPH would provide important insights 
into pathobiology and might allow risk-stratification following PE.  A genome-wide 
association study (GWAS) was performed in 1250 CTEPH patients, 1492 healthy 
controls and ~7 million single-nucleotide polymorphisms to identify novel disease loci. 
 
The ABO locus was identified as the most significant common variant genetic 
association with CTEPH in both a discovery and validation cohort.  The A1 subgroup 
of ABO was enriched in CTEPH and this may result in multiple functional 
consequences including variation in plasma von Willebrand factor (VWF) levels. 
 
Abnormalities in haemostasis are implicated in CTEPH pathobiology, including 
elevated levels of VWF, which is cleaved by ADAMTS13 (a disintegrin and 
metalloproteinase with a thrombospondin type 1 motif, member 13).  The ADAMTS13-
VWF axis was investigated in 208 CTEPH patients including its relationship to ABO 
blood groups and ADAMTS13 genetic variants. 
 
Plasma ADAMTS13 levels are markedly reduced in CTEPH.  This is independent of 
pulmonary hypertension, disease severity or systemic inflammation.  Plasma VWF 
levels were confirmed to be markedly increased in CTEPH.  These findings implicate 
dysregulation of the ADAMTS13-VWF axis in CTEPH pathobiology. 
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1  Introduction 
 
1.1  Literature search 
 
A literature search was performed to ensure that there was a systematic approach to 
the evidence included in the introduction.  A Healthcare Databases Advanced Search 
(HDAS) was conducted using the databases Medline and PubMed.  The following 
search terms (including variations and acronyms) were used: 
1. Chronic thromboembolic pulmonary hypertension AND  
a. Aetiology OR pathobiology OR pathophysiology OR review OR update 
b. Genetics OR genome-wide association study OR single nucleotide 
polymorphism 
c. ADAMTS13 OR von Willebrand Factor OR haemostasis OR coagulation 
OR fibrinolysis 
2. (Venous thromboembolism OR pulmonary embolism OR deep-vein 
thrombosis) AND (genome-wide association study OR single nucleotide 
polymorphism) 
3. Genome-wide association study AND (review OR guideline) 
 
References lists from articles were reviewed for additional citations.  Literature and 
resources utilised during the PhD programme were also included where appropriate. 
 
1.2  Chronic thromboembolic pulmonary hypertension 
 
1.2.1  Overview 
Pulmonary hypertension is defined as an increase in mean pulmonary arterial 
pressure (mPAP) ≥25 mmHg at rest.(1)  Chronic thromboembolic pulmonary 
hypertension (CTEPH) is classified in group 4 pulmonary hypertension in the 
European Society of Cardiology / European Respiratory Society 2015 guidelines.(1)  
CTEPH can result from failure of thrombus resolution in the pulmonary 
arteries following acute pulmonary embolism (PE).(2)  Organisation and fibrosis of 
thrombotic material leads to obstruction of proximal pulmonary arteries and the 
subsequent development of a secondary small vessel (distal) vasculopathy, both of 
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which contribute to pulmonary hypertension and subsequent right heart failure.(3, 4)  
CTEPH is an infrequent but important complication of PE, a common disease affecting 
1/1000, which increases with age.(5)  In a meta-analysis, the pooled incidence of 
CTEPH was ~3% in survivors of PE.(6)  
 
The diagnosis of CTEPH is based on international criteria and requires an mPAP ≥ 
25mmHg at right heart catheterisation (with a pulmonary arterial wedge pressure 
(PAWP) £15mmHg) and specific radiological defects after at least 3 months of 
effective anticoagulation.(7)  The most common imaging modalities to diagnose 
CTEPH are computed tomography pulmonary angiography (CTPA) and ventilation-
perfusion (VQ) scans, with  magnetic resonance angiography (MRA) and invasive 
pulmonary angiography performed less frequently (Figure 1.1).(8) 
 
CTEPH represents the most severe long-term consequence of acute PE, but there are 
a range of more common manifestations within post-PE syndrome.  Following PE, 
~50% of patients will have functional limitations, 25-33% have persistence of thrombi 
and 10-30% have persistent or worsening right ventricular function / pulmonary artery 
pressures.(9)  Also, within the post-PE spectrum is chronic thromboembolic disease 
(CTED), which is characterised by persistent pulmonary arterial thromboembolic 
occlusions without pulmonary hypertension (mPAP <25mmHg) in symptomatic 
patients.(10) 
 
Risk factors for CTEPH include previous venous thromboembolism (VTE), with 
preceding PE and deep vein thrombosis (DVT) occurring in 75% and 50% of patients 
respectively in European cohorts.(11)  The risk of developing CTEPH following VTE 
is higher with recurrent VTE, unprovoked VTE, larger PEs and right heart dysfunction 
at the time of the acute PE.(12-14)  Additional risk factors include: non-O blood groups, 
splenectomy, antiphospholipid antibodies / lupus anticoagulant, malignancy, thyroid 
replacement therapy and a putative association with ventriculo-atrial shunts / infected 
pacemakers.(12-14)  
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Figure 1.1  Imaging modalities for diagnosing CTEPH 
Different imaging modalities in a patient with CTEPH deemed to be operable. 
Perfusion (A) and ventilation (B) (VQ) scans showing typical mismatched perfusion 
defects.  C Computed tomography pulmonary angiogram (CTPA) displaying marked 
right ventricular dilation and a paucity of pulmonary arteries in the lower lobes. D 
Invasive pulmonary angiogram showing web and stenotic lesions in the pulmonary 
arteries of the right lung.  ANT (anterior), POST (posterior), LPO (left posterior 
oblique), RPO (right posterior oblique).  Figure reproduced with permission of the © 
ERS 2020, from (19). 
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1.2.1.1  CTEPH management 
 
Management of CTEPH consists of lifelong anticoagulation.(1)  Traditionally, vitamin-
K antagonists (e.g. warfarin) have been used for anticoagulating CTEPH patients and 
more recently direct oral anticoagulants (DOACs).(16)  The main side effect of long-
term anticoagulation treatment is major and clinically relevant non-major bleeding 
however, in CTEPH the major bleeding rate is low (<0.7%/person-year).(16)  There is 
no evidence that additional treatments including thrombolytic medications that result 
in blood clot dissolution, can prevent CTEPH following acute pulmonary embolism.(17, 
18) 
 
Suitable CTEPH patients should have a multi-disciplinary evaluation of surgical 
operability. Eligible patients are offered pulmonary endarterectomy (PEA), which 
involves removing obstructive thromboembolic material in surgically accessible 
pulmonary arteries.(7)  The procedure requires a midline sternotomy followed by 
cardiac bypass and deep hypothermic cardiac arrest (DHCA) to minimise bleeding in 
the surgical field.(19)  The obstructive thromboembolic material together with the 
intima and superficial medial layer of the pulmonary artery can be removed to the level 
of the subsegmental pulmonary arteries if required (Figure 1.2).(19)  PEA surgery is 
the optimal treatment in eligible patients, offering the best chance of symptomatic and 
prognostic improvement.(7)  Patients have marked improvements in haemodynamics, 
World Health Organisation (WHO) functional class, 6-minute walk distance (6mwd), 
patient reported outcomes including quality of life, and survival following PEA.(17, 20) 
 
Percutaneous balloon pulmonary angioplasty is a CTEPH treatment that involves 
dilating the stenotic pulmonary arterial segments with a balloon catheter.  It is a 
treatment modality that can be considered for selected CTEPH patients ineligible for 
PEA due to distal disease or alternatively, in those with persistent or recurrent 
pulmonary hypertension (PH) following PEA.(17, 21-23) 
 
Patients with surgically inaccessible disease, disproportionate distal predominant 
disease or with co-morbidities precluding PEA can be treated with licensed pulmonary 
artery vasodilator medication and emerging therapies.(24, 25) 
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Figure 1.2  Pulmonary endarterectomy specimen 
Pulmonary endarterectomy specimen removed from right and left pulmonary arteries.  
Figure reproduced with permission of the © Elsevier, from (26) 
 
 
1.2.2  CTEPH pathobiology 
1.2.2.1  CTEPH histology 
CTEPH occurs due to proximal occlusion of pulmonary arteries by organised fibrotic 
clots and a micro-vasculopathy in smaller pulmonary vessels.(3, 27)  Resected PEA 
specimens show remodelling of thrombi at various stages with different degrees of 
inflammation and cellularity, which is distinct from the fresh clot found in PE 
specimens.(2, 28)  In a series of 54 CTEPH patients undergoing PEA, the specimens 
were comprised of:  collagen (100%), elastin (67%), haemosiderin (56%), 
atherosclerosis (32%) and calcification (15%), with inflammation present in 53%.(29)  
Plexogenic lesions (a dynamic network of vascular channels) are a hallmark of 
idiopathic pulmonary arterial hypertension (IPAH) and have been identified in some 
studies of CTEPH, suggesting a degree of histopathological overlap with other types 
of pulmonary hypertension.(3, 30)  A more recent study utilising PEA specimens, 
CTEPH transplant tissue and a porcine model identified the importance of post-
capillary remodelling (venopathy) and anastomosis between the pulmonary and 
systemic circulation in CTEPH.(31) 
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1.2.2.2  CTEPH pathobiology: introduction 
There are a number of unanswered questions related to the pathobiology of CTEPH.  
Potential mechanisms and pathways that are involved include: excess thrombus 
formation, failure of fibrinolysis, endothelial dysfunction, failure of neovascularisation, 
inflammation, endothelial dysfunction and others including right ventricular adaptation 
and genetics.(2, 27, 32) 
 
1.2.2.3  Increased thrombus 
A thrombus (blood clot) is the final product of blood coagulation.  Coagulation involves 
a complex biological cascade and is a component of haemostasis, the process of 
stopping bleeding.  Haemostasis comprises vascular spasm, platelet activation and 
coagulation.  Following damage to the endothelium of a blood vessel, platelets are 
activated and recruited to the site of injury to form a platelet plug (described further in 
Section 1.6) (primary haemostasis).(33)  Injury to the endothelium leads to the release 
of tissue factor and a cascade of coagulation serine proteases that ultimately results 
in the formation of a cross-linked fibrin clot (secondary haemostasis) (Figure 1.3).(33) 
 
The observation that the risk of CTEPH is increased with larger and recurrent PEs is 
consistent with increased thrombus formation being important in CTEPH 
pathobiology.(12, 14)  Plasmatic factors associated with thrombus formation are 
increased in CTEPH including antiphospholipid antibodies / lupus anticoagulant, von 
Willebrand Factor (VWF) / Factor VIII, tissue-type plasminogen activator (t-PA) and 
type 1 plasminogen activator inhibitor (PAI-1) (Figure 1.4).(34-36)  Increased 
thrombus formation alone is unlikely to be the sole contributing factor to CTEPH 
pathobiology and  other studies have suggested that traditional thrombophilic risk 
factors and antiphospholipid antibodies are not over-represented in CTEPH (see 
Section 1.3.1).(34, 37)  Furthermore, ~25% of patients with CTEPH will not have a 
preceding (known) VTE and thrombolysis treatment of acute pulmonary embolism that 
decreases the thrombus burden has no effect on the development of CTEPH.(11, 18) 
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Figure 1.3  Blood coagulation overview 
Roman numerals (i.e. VII) denote clotting factors and a lowercase “a” denotes the 
active form. The coagulation cascade has two components, the initiation phase 
(extrinsic pathway) and the amplification phase (intrinsic pathway).  APC (activated 
protein C), TF (tissue factor), aTHR (antithrombin). 
Figure reproduced under creative commons license, from (38). 
 
 
1.2.2.4  Fibrinolysis 
If fibrinolytic mechanisms are involved in CTEPH pathobiology this may result in 
reduced thrombus dissolution (Figure 1.4).  Fibrin from CTEPH patients is partially 
resistant to plasma mediated lysis suggesting impaired fibrinolysis.(39)  Five 
fibrinogen variants have been described in CTEPH that result in differences in the 
molecular structure of fibrin.(40)  However, fibrin resistance is not specific to CTEPH 
and occurs in other forms of pulmonary hypertension and to a lesser extent PE 
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suggesting an epiphenomenon.(41)  There may be differences in fibrinogen genetic 
polymorphisms which account for fibrin resistance in CTEPH that is discussed further 
in Section 1.3.2.(42)  The fibrinolysis inhibitor thrombin-activatable fibrinolysis 
inhibitor (TAFI) is increased in CTEPH and plasma levels correlate with resistance to 
clot lysis, suggesting an additional fibrinolysis pathway that may be affected in 
CTEPH.(43) 
 
 
 
 
Figure 1.4  The fibrinolysis pathway 
A simplified diagram of the fibrinolysis pathway.  Fibrinolysis is the process of breaking 
down a fibrin blood clot formed during coagulation.  Blue arrows indicate stimulation 
and red inhibition. 
Figure reproduced under creative commons license, from (44) 
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1.2.2.5  Neoangiogenesis 
Restoration of pulmonary artery patency following thrombus obstruction is important 
following an acute pulmonary embolus and abnormalities in neoangiogenesis may be 
important in CTEPH pathobiology.  PEA specimens have reduced vascular structures 
and lower expression of vessel-specific genes.(45)  Impaired neoangiogenesis is 
associated with increased mortality and persistent PH following PEA.(46)  
Furthermore, factors that inhibit neoangiogenesis (e.g. platelet factor 4) are increased 
in PEA specimens, which may result in altered calcium homeostasis and endothelial 
dysfunction.(47)  These findings suggest neoangiogenesis is defective in CTEPH, 
although it is unclear whether this is causative. 
 
1.2.2.6  Inflammation and endothelial dysfunction 
Inflammation is important in other forms of pulmonary hypertension (e.g. PAH) and 
may be involved in CTEPH pathobiology.(48)  Some risk factors for CTEPH are also 
associated with inflammation including cancer, inflammatory bowel disease and 
infected indwelling lines.(12, 49)  Plasma C-reactive protein (CRP) is increased in 
CTEPH and may contribute to mechanisms involved in fibrotic vascular remodelling 
and endothelial dysfunction.(50, 51)  Inflammatory cells (macrophages, T-
lymphocytes and neutrophils) have been found to accumulate in PEA specimens and 
correlate with raised plasma CRP.(46)  Inflammatory mediators are also upregulated 
in PEA specimens including interleukin-6 (IL-6), monocyte chemoattractant protein-1 
(MCP-1), interferon-γ-induced protein-10 (IP-10) and macrophage inflammatory 
protein (MIP)-1α.  A number of circulating inflammatory markers are elevated in 
CTEPH including MCP-1, IL-6, IL-8, IP-10, MIP-1α and matrix metalloproteinase 9.(46, 
52, 53) 
 
1.2.2.7  Problems investigating CTEPH pathobiology 
Elucidating the pathobiology of CTEPH has been challenging for several reasons.  
Firstly, the haemostasis and fibrinolytic pathways have been implicated but are difficult 
to study in anticoagulated CTEPH patients.  Secondly, whilst risk factors for 
progression from acute PE to CTEPH have been described, identifying causative 
pathological mechanisms in the post-PE disease spectrum would require large well-
characterised prospective PE cohorts.(54)  Lastly, animal models do not appropriately 
recapitulate failure of thrombus dissolution or the chronic changes that occur in 
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CTEPH.(55)  Therefore, an alternative approach to investigating CTEPH pathobiology 
and circumventing these issues is to perform exploratory genetic studies. 
 
1.3  Genetics of CTEPH 
 
1.3.1  Traditional thrombophilia risk factors 
A thrombophilia is an abnormality of blood coagulation that increases the risk of 
thrombosis and can either be acquired or inherited.(56) The traditional heritable 
thrombophilias can be divided into loss of function mutations (antithrombin, protein C 
and protein S deficiencies) and gain of function mutations (prothrombin gene and 
factor V Leiden mutations).(57)   
 
1.3.1.1  Heritable thrombophilia overview 
The factor V Leiden (FVL) mutation is the most common heritable thrombophilia in the 
UK with the heterozygous form affecting 3-7% of Caucasian European 
populations.(56)  It is caused by a missense variant (rs6025) in the clotting factor V 
(F5) gene.(58)  The FVL mutation results in activated factor V (FVa) being resistant to 
the proteolytic effects of activated protein C (APC resistance) leading to increased 
FVa levels and increased generation of thrombin (Figure 1.5).(56) 
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Figure 1.5  Activated protein C and the factor V Leiden mutation 
Activated protein C (in the presence of protein S (S) and calcium (Ca)) will usually 
inactivate factor Va.  When the FVL mutation is present, FVa is resistant to the 
proteolytic effects of activated protein C predisposing to clot formation 
Ca (ionised calcium), S (protein S). 
Figure reproduced with permission of the © CMAJ group, from (59) 
 
The prothrombin gene mutation is the second most common heritable thrombophilia 
in the UK affecting 1-2% of Caucasian Europeans.(56)  It is caused by a 3' 
untranslated region (UTR) variant (guanine to adenine; rs1799963) in the prothrombin 
(F2) gene at nucleotide position 20210 (termed the prothrombin G20210A 
mutation).(60)  This results in an increase in prothrombin (factor II) levels and a 
hypercoagulable state (Figure 1.6). 
 
Protein C and S are both vitamin-K dependent glycoproteins that have anticoagulant 
properties.(58)  Inherited protein C and S deficiencies affect approximately 0.3% and 
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0.1% of Caucasian European populations respectively.(56)  Deficiencies in either 
protein C or S lead to impaired inactivation of factors Va and VIIIa resulting in 
increased thrombus formation (Figure 1.6).(61)  Most mutations causing protein C / S 
deficiencies are heterozygous with homozygous being very rare and often fatal.  There 
have been over 160 different protein C gene (PROC) and ~200 protein S gene 
(PROS1) mutations described that exhibit an autosomal dominant pattern of 
inheritance.(62, 63) 
 
 
 
Figure 1.6  Activation and inhibition in the coagulation system 
Overview of the blood coagulation cascade with additional details related to inhibition 
(red arrows) and activation (blue arrows) 
Figure reproduced with permission of the © BMJ Publishing Group Ltd, from (56). 
 
 
Antithrombin is the main natural inhibitor of blood coagulation (Figure 1.6).(64)  
Antithrombin deficiency affects approximately 0.02% of Caucasian European 
populations.(56)  Deficiency in antithrombin leads to reduced inhibition of factors Xa 
and thrombin, thereby creating a hypercoagulable state (Figure 1.6).  The majority of 
mutations that lead to antithrombin deficiency are heterozygous with over 130 
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described in the SERPINC1 gene and exhibiting an autosomal dominant pattern of 
inheritance.(64)  
 
The heritable thrombophilias are summarised in Table 1.1 and the risk of VTE 
associated with heritable thrombophilias are described in Section 1.4.1. 
 
 
Thrombophilia Prevalence 
(%) 
Type of mutation 
/ inheritance 
Mechanism of 
thrombosis 
FVL, heterozygous 4 missense FVa resistant to 
proteolysis by 
activated protein C 
Prothrombin 
(G20210A) gene 
mutation 
1.5 missense Increased prothrombin 
(factor II) levels 
Protein C deficiency 0.3 >160 mutations 
Autosomal 
dominant 
Impaired inactivation of 
factors Va and VIIIa 
Protein S deficiency 0.1 ~200 mutations 
Autosomal 
dominant 
Impaired inactivation of 
factors Va and VIIIa 
Antithrombin 
deficiency 
0.02 >130 mutations 
Autosomal 
dominant 
Reduced inhibition of 
factors Xa and 
thrombin 
 
Table 1.1  Heritable thrombophilias 
Summary of prevalence (in a Caucasian European population), type of mutation and 
inheritance pattern and the consequence by which the thrombotic risk is increased. 
FVL (factor V Leiden). 
Adapted from (56)  
 
 
1.3.1.2  Heritable thrombophilias and CTEPH 
Genetic associations have been inferred from observational studies that have 
identified CTEPH risk factors.  Thrombotic risk factors (not including ABO) occurred in 
27.7% of 426 CTEPH patients in an international prospective register.(11)  Of the 
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heritable thrombophilias, 9.6% and 8.9% had protein S and C deficiencies, 7.7% had 
the factor V Leiden (FVL) mutation, 3.5% had the prothrombin gene (G20210A) 
mutation and 0.7% had antithrombin III deficiency (some patients had more than one 
thrombophilia).(11) 
 
Early studies found no difference in the prevalence (see below) of FVL mutation 
between CTEPH and PAH or between CTEPH and healthy controls.(34, 65)  A study 
by Wolf et al, investigated the heritable thrombophilic risk factors between 46 patients 
with CTEPH and 100 healthy controls and found no statistical difference.(34)  
However, the FVL mutation occurred in 6.5% of CTEPH patients and 3% of healthy 
controls, and antitrypsin III deficiency, protein S deficiency and protein C deficiency 
did not occur at all in CTEPH or healthy controls.  The study conclusions were limited 
by a lack of power to detect group differences, which is compounded by the rarity of 
some of the heritable thrombophilias (see Section 1.3.1.1).  In a study by Wong et al, 
29% of CTEPH patients (n=45 total) were heterozygous for the FVL mutation 
compared with 8% in a group with other forms of pulmonary hypertension (n=200 
total).(37)  Study participants were all Caucasian, which is important as the FVL 
mutation occurs in ~5% of Caucasian populations but is rare in other ethnic 
groups.(37)  There was no difference in antithrombin III deficiency, protein C / S 
deficiency and prothrombin gene mutations between CTEPH and control groups.(37) 
There was a nominally significant difference in the frequency of the FVL mutation in 
another study by Suntharalingam et al of 214 CTEPH patients and 200 healthy 
controls (FVL: 3.6% versus 1.5%).(66)  There was no difference in antithrombin III 
deficiency, factor XIII, plasminogen activator inhibitor and tissue plasminogen activator 
polymorphisms between CTEPH and the healthy control groups.(66)  Both the Wong 
et al, and Suntharalingam et al studies were underpowered and only examined a 
limited number of genetic variants. 
 
1.3.2  ABO and fibrinogen genes 
ABO groups are another heritable thrombotic risk factor.  Non-O blood groups are 
more prevalent in CTEPH than the general population occurring in 76% and 54% 
respectively.(67, 68)  The frequency of non-O blood groups in CTEPH and VTE 
appears similar across studies.(67)  However, there has not been a direct study 
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comparison in the same population to determine if ABO groups are different in 
resolved PE versus CTEPH. 
 
A genetic variant (rs6050) in the FGA gene encoding Fibrinogen Aα chain protein is 
more common in CTEPH than healthy controls. (42, 66)  A study of 101 patients with 
CTEPH and 102 with pulmonary embolism in a Han Chinese population reported an 
over-representation of this FGA polymorphism in CTEPH compared to PE.  This study 
was limited by the inability to adjust for population stratification (a potential difference 
in the allele frequencies of subpopulations; discussed further in Section 1.5) and small 
sample size for genetic associations.  Furthermore, rs6050 has been associated with 
VTE in genetic studies and the FGA-FGB-FGG gene region is associated with VTE in 
genome-wide association studies (Section 1.5).(69-71)  The allele (a variant of a gene 
at a given location) frequencies of the rs6050 FGA genetic variant between CTEPH 
and VTE have not been investigated in an adequately powered study. 
 
1.3.3  Genetic variants associated with pulmonary arterial hypertension in 
CTEPH 
Genetic variants associated with pulmonary arterial hypertension (PAH) have been 
investigated in CTEPH and are described below (Section 1.3.3.2) together with the 
background to PAH (Section 1.3.3.1) for context and comparison with the genetics of 
CTEPH. 
 
1.3.3.1  Pulmonary arterial hypertension overview 
PAH  is classified as group 1 (pre-capillary) pulmonary hypertension in the European 
Society of Cardiology / European Respiratory Society 2015 guidelines.(1)  The 
pathobiological processes in PAH involve endothelial dysfunction, pulmonary arterial 
smooth muscle proliferation and accumulation of fibroblasts, myofibroblasts and 
inflammatory cells in the pulmonary arterial wall.(72)  The net effect is pulmonary 
vascular remodelling and vessel obstruction resulting in pulmonary hypertension and 
eventually right heart failure.(72)  It is diagnosed according to right heart catheter 
haemodynamic criteria (mPAP > 20mmHg, a pulmonary vascular resistance (PVR) ³ 
3 Wood units and a PAWP £ 15mmHg) in the absence of other causes of pre-capillary 
PH (e.g. left heart disease, chronic lung disease, CTEPH).(1, 73)  PAH has an 
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incidence of 2.0 - 7.6 cases per million adults per year with a female preponderance 
affecting them four times more often.(74)  There are a number of sub-types of PAH 
including idiopathic PAH (IPAH), heritable PAH (HPAH), drug / toxin induced PAH and 
PAH associated with other diseases (e.g. connective tissue disease or congenital 
heart disease) (Table 1.2).(73)  Current licensed medical treatments are pulmonary 
artery vasodilating medications that aim to improve the vasoconstriction, but do not 
alter the underlying disease pathobiological mechanisms.  PAH is an incurable 
disease with a median survival of 6 years, which varies depending on the particular 
type of PAH.(74) 
 
1 PAH 
1.1  Idiopathic PAH 
1.2  Heritable PAH 
1.3  Drug- and toxin-induced PAH 
1.4  PAH associated with: 
1.4.1  Connective tissue disease 
1.4.2  HIV infection 
1.4.3  Portal hypertension   
1.4.4  Congenital heart disease 
1.4.5  Schistosomiasis 
1.5  PAH long-term responders to calcium channel blockers 
1.6  PAH with overt features of venous/capillaries (PVOD/PCH) involvement 
1.7  Persistent PH of the newborn syndrome 
 
Table 1.2  Clinical classification of PAH (group 1 PH) 
PAH (pulmonary arterial hypertension), PVOD (pulmonary veno-occlusive disease), 
PCH (pulmonary capillary haemangiomatosis) 
Table from (73) 
 
HPAH describes patients with an identified germline mutation or a family history of 
PAH (not associated with other diseases).(75)  In 70–80% of families with PAH and 
10–20% of IPAH cases the cause is a mutation in the gene encoding the bone 
morphogenetic protein receptor type II (BMPR2).(76)  There are over 400 
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heterozygous germline BMPR2 mutations that have been identified to date.(75)  
BMPR2 is a receptor for the transforming growth factor-b (TGF-b) superfamily and is 
expressed on the surface of a wide range of cells particularly the pulmonary vascular 
endothelium.  Mutations in BMPR2 cause abnormal signalling that can adversely 
impact endothelial barrier function, DNA repair, cell proliferation, inflammation, 
metabolism and mitochondrial function.(72)  A number of other rare gene variants 
have been identified for PAH and are summarised in Figure 1.7.  There have also 
been common genetic variant associations with PAH that are described further in 
Section 1.3.4. 
 
 
 
 
Figure 1.7  HPAH pathways and gene variants 
Rare gene variants that have been associated with HPAH are summarised in the figure 
(in addition SMAD1 and SMAD4; not shown).  EIF2AK4 mutations are associated with 
PVOD (pulmonary veno-occlusive disease) / PCH (pulmonary capillary 
haemangiomatosis). 
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ABCC8 (ATP binding cassette subfamily C member 8), ACVRL1 (activin A receptor 
like type 1),  ADP (Adenosine diphosphate), AQP1 (Aquaporin 1),  ATP (Adenosine 
triphosphate), ATP13A3 (ATPase 13A3), BMP (bone morphogenetic protein), BRE 
(BMP-responsive element), CAV1 (Caveolin 1), EIF2AK4 (Eukaryotic translation 
initiation factor 2 alpha kinase 4), ENG (Endoglin), GCN2 (general control 
nonderepressible 2), GDF2 (growth differentiation factor 2), KCNK3 (potassium two 
pore domain channel subfamily K member 3), SMAD (SMAD family member), SOX17 
(SRY-box transcription factor 17), TBX4 (T-box transcription factor 4). 
Figure reproduced with permission of the © Springer Nature, from (75) 
 
 
1.3.3.2  Pulmonary arterial hypertension genetic variants and CTEPH 
Genetic variants that occur in other types of pulmonary hypertension have been 
investigated in CTEPH.  A study of 49 patients with CTEPH and 17 with PE in a Han 
Chinese population reported a higher frequency of variants in genes associated with 
PAH including BMPR2, ACVRL1, ENG, SMAD9, CAV1, KCNK3, and CBLN2.(77)  
However, this candidate gene approach was potentially confounded by the small 
sample size, incomplete assessment of variant deleteriousness and inability to adjust 
for population stratification.  Larger studies in Caucasian CTEPH cohorts have not 
identified mutations in the bone morphogenetic protein type II receptor (BMPR2) gene 
that occur in heritable and idiopathic pulmonary arterial hypertension.(78, 79)  
Prostacyclin is an important regulator of vascular tone and proliferation, and variants 
in genes related to prostacyclin have been implicated in PAH.(80)  A study in 90 
CTEPH patients and 144 healthy controls in a Japanese cohort investigated a 
variable-number tandem repeat (VNTR) polymorphism in the 5'-upstream promoter 
region of the PGIS gene that has also been associated with PAH.(80, 81)  However, 
this specific VNTR PGIS gene promotor variant was not associated with CTEPH.(81)  
Importantly, some candidate genes (e.g. PGIS) putatively associated with PAH and 
used in studies of CTEPH genetic associations, have not been replicated in larger 
studies of PAH using robust methodology.(82)  In summary, genetic variants 
associated with PAH do not convincingly occur in CTEPH in the limited studies 
performed. 
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1.3.3.3 Other CTEPH genetic associations 
There are apparent differences in CTEPH between Japanese and Caucasian 
populations with a female preponderance, less preceding DVT and a lower overall 
incidence of CTEPH in Japanese patients.(83)  Consequently, studies have 
investigated the human leukocyte antigen (HLA) region in Japanese CTEPH cohorts 
and potential associations in the HLA-DPB1 (DPB1*0202 allele) and NFKBIL1 
(IKBLp*03 allele) genes have been identified, which require validation.(84, 85)  The 
HLA class II histocompatibility antigen, DP(W2) beta chain (HLA-DPB1) protein is 
expressed on antigen presenting cells and plays a key role in the immune system, 
whereas the role of the NF-kappa-B inhibitor-like protein (NFKBIL1) protein is unclear 
but may also be involved in immune function as it is located in the major 
histocompatibility complex class I region.(86, 87)  In a separate Japanese study of 97 
patients with CTEPH, variants in the ACE gene that expresses the protein angiotensin-
converting enzyme, which has a role in vascular remodelling and endothelial 
dysfunction, were investigated.(88)  There was no difference in genotype frequencies 
between CTEPH and healthy controls.(81, 88)  A small, unvalidated whole exome 
sequencing study in 30 patients with CTEPH in a Chinese population identified one 
patient with a MUC6 missense variant (rs201234174), a gene encoding a glycoprotein 
expressed by epithelial tissues.(89) 
 
1.3.4  CTEPH genetic architecture 
There are limited observational case reports of presumed “familial” CTEPH however, 
genotyping was not performed to establish shared genetic mutations.(90-92)  A recent 
study of 66 prevalent CTEPH cases used genealogy data (without genotypes) to infer 
genetic relationships.(90-92)  They found that whilst a classical Mendelian inheritance 
was not observed in CTEPH, there was an excess of familial clustering, which implies 
shared risk factors that may be genetic.(90-92)  Interestingly, the relative risk of VTE 
was increased in the 1st degree relatives of CTEPH patients, which could suggest an 
excess of heritable thrombophilias.(90-92)  Whether the familial clustering was due to 
shared genetic risk factors for VTE, CTEPH or shared environmental risk factors 
remains an unanswered question. 
 
Whilst the genetic architecture of CTEPH has not been fully elucidated in robust 
studies, a Mendelian inheritance pattern is not clearly observed. As CTEPH 
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predominantly occurs following VTE, its genetic architecture may mirror VTEs, which 
is primarily a complex polygenic disease (Section 1.4).  In complex, polygenic 
diseases, common genetic variants exert small effect sizes on disease risk compared 
with highly penetrant Mendelian diseases whereby rare mutations exert large effects 
on disease risk (Figure 1.8). 
 
 
 
Figure 1.8  The disease effect size of alleles with varying frequencies  
The disease effect size (Odds ratio) of an allele is plotted against the frequency of the 
allele. In highly penetrant Mendelian diseases (top left of the figure) rare mutations 
exert large effects on the disease risk, whereas in most polygenic diseases 
investigated with genome-wide associations studies, common variants exert small 
effects on disease risk (bottom right of figure). 
Figure reproduced with permission of the Copyright: © 2012 Bush, Moore, from (93). 
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CTEPH can be juxtaposed with the genetic architecture of PAH, which is a Mendelian 
disorder with an autosomal dominant inheritance and incomplete penetrance, whereby 
not all individuals with the genetic mutation (e.g. in BMPR2) exhibit the PAH 
phenotype.(76)  The incomplete penetrance suggests there are additional causative 
factors that may include additional genetic, epigenetic or environmental 
contributors.(76)  Recent studies have identified common genetic variant associations 
with PAH in the HLA-DPA1/DPB1 region (rs2856830) and near the SOX17 (SRY-Box 
Transcription Factor 17) gene locus (rs10103692 and rs10103692).(94)  The HLA-
DPA1/DPB1 gene region is within the major histocompatibility class II region and 
involved in the immune system, whereas the SOX17 gene has a pivotal role in 
angiogenic processes including the development of the lung microvasculature.(75) 
 
1.3.5  CTEPH epigenetics 
Differences in gene expression and epigenetic mechanisms that do not involve 
changes in the DNA sequence have been implicated in CTEPH pathobiology.(95, 96) 
These include changes in microRNAs, DNA methylation and transcription factor 
expression.(97-99)  These epigenetic studies are also limited by small sample sizes, 
lack of replication cohorts and establishing the functional consequences of the 
potential epigenetic differences.(95) 
 
1.3.6  Genetics of CTEPH: summary 
Overall, genetic studies in CTEPH have been small, underpowered and unvalidated.  
Familial clustering suggests shared risk factors, which may be genetic.  A Mendelian 
pattern of inheritance does not occur in CTEPH, and it is more likely to follow a 
complex disease paradigm with common variants exerting small to moderate effects.  
This would be consistent with CTEPH being a severe consequence of VTE, itself a 
polygenic disease, which is described in Section 1.4.  Non-O blood groups are over-
represented in CTEPH, but other heritable thrombophilias and PAH associated gene 
variants have not been conclusively associated.  To fully understand CTEPH genetic 
associations, the genetics of VTE need to be considered. 
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1.4  Genetics of venous thromboembolism 
 
1.4.1  Traditional thrombophilia risk factors 
There are a number of risk factors for venous thromboembolism including 
environmental (e.g. cancer, surgery, trauma, immobilisation, pregnancy, age, body 
mass index, medications) and genetic.(100)  VTE is highly heritable with family-based 
studies estimating the variation in VTE that is attributable to genetics to be ~60%.(101)  
This is consistent with the incidence of VTE varying with ethnicity, being higher in 
Caucasians and Africans compared with Asians.(102) 
 
Genetic risk factors for VTE include the traditional heritable thrombophilias (Section 
1.3.1).  Loss of function mutations in the anticoagulant genes (antithrombin, protein C 
and protein S deficiencies) increase the risk of VTE 5-20 fold but they are rare, being 
present in <1% of the population.(103)  Gain of function (heterozygous) mutations in 
procoagulant genes (prothrombin (G20210A), and factor V Leiden mutation) have a 
more moderate impact on VTE risk of 2-5 fold.(57)  In a meta-analysis of 126,525 
patients with VTE from 173 case-control studies, the significant risk associations were: 
FVL mutation (OR 9.45 95% CI 6.72-13.30) and prothrombin gene mutation (OR 3.17; 
95% CI 2.19-3.46).(104)  The VTE risk from the FVL mutation is lower in subsequent 
genetic studies (see Section 1.4.3), and varies from 5 fold in heterozygotes to 50 fold 
in homozygotes.(103)  The risk of VTE with different hereditary thrombophilias is 
summarised in Table 1.3.  Fibrinogen variants (FGG gene) are also associated with 
VTE (OR 2.4; 95% CI 1.5-3.9) and result in a decrease in plasma levels of fibrinogen 
gamma.(105)  A combination of more than one hereditary thrombophilias has a 
synergistic effect on VTE risk.  In a pooled analysis of 2310 VTE cases and 3204 
healthy controls, patients with heterozygous FVL and prothrombin gene mutations had 
a 20 fold increased risk of VTE (95% CI 11-36).(106) 
 
Heritable thrombophilias can further increase the risk of VTE when combined with 
other pro-thrombotic risk factors including pregnancy, and oestrogen containing 
medications (e.g. the oral contraceptive pill (OCP) and hormonal replacement therapy 
(HRT)).  In pregnancy, a number of clotting factors (I, II, VII, VIII, IX and XII) are 
increased, and fibrinolysis is inhibited, which increases the risk of VTE.(59)  In a case-
control of pregnant women 44% with VTE had the FVL mutation (heterozygous) 
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compared to 8% without VTE (relative risk (RR) 9; 95% CI 5-17).(107)  In the same 
study, 17% of pregnant women with VTE had the prothrombin (G20210A) gene 
mutation compared to 1% without (RR 15; 95% CI 4-53).(107)  The risk of VTE is also 
increased in pre-menopausal women with the FVL mutation that are taking oestrogen 
containing OCPs (RR 35; 95% CI 8-154) and post-menopausal women with the FVL 
mutation taking oestrogen containing HRT (RR 7; 95% CI 3-14).(108, 109)  However, 
whilst the relative risks are synergistically increased by the combination of heritable 
thrombophilias and pregnancy or oestrogen containing medications, the absolute risk 
remains low, particularly in the latter.(110) 
 
Thrombophilia VTE relative risk 
FVL, heterozygous 3-5 
FVL, homozygous 10-50 
Prothrombin (G20210A) gene mutation 2-4 
Antithrombin deficiency 10-20 
Protein C deficiency 5-15 
Protein S deficiency 10 
 
Table 1.3  Risk of VTE with different hereditary thrombophilias 
The relative risk of VTE with different heritable thrombophilias.  Heterozygous is the 
carriage of a mutation of only one allele, whereas homozygous is of two alleles.  
FVL (Factor V Leiden). 
Adapted from (56, 103, 110)  
 
 
Studies on VTE risk factors including genetic associations, will often consider DVT 
and PE together rather than separately.  This is partly due to their co-occurrence, with 
(predominantly asymptomatic) PE occurring in 40-50% of proximal DVT, and 
(predominantly proximal and asymptomatic) DVT occurring in 70% of patients with 
PE.(111)  Therefore, to define isolated DVT (DVT without PE) or isolated PE (PE 
without DVT) for comparative studies would require imaging of both the lower limbs 
(e.g. doppler ultrasonography) and lungs (e.g. CTPA), which is not routinely performed 
in clinical practice.  Nevertheless, differential risk factors between DVT and PE have 
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been observed.  The FVL mutation occurs more frequently in  DVT  than PE, which is 
termed the factor V Leiden paradox.(112)  A meta-analysis identified significantly more 
patients with DVT had the FVL mutation compared to those with isolated PE (OR 2.39; 
95% CI 2.08-2.75).(113)  The mechanism by which the FVL mutation exerts its 
increased risk on DVT is unclear.(112)  
 
Common variant genetic associations in venous thromboembolism that have been 
discovered by genome-wide associations studies are described in Section 1.5.5. 
 
1.4.2  Venous thromboembolism and ABO 
Non-O blood group is the most important population attributable genetic risk factor for 
VTE, as it occurs more commonly than other heritable thrombophilias, despite 
conferring a lower individual risk (OR 2.09; 95% CI 1.83-2.38).(114)  In a US study, 
non-O blood group occurred in 64.2% of VTE cases (n=492) compared with 52.5% of 
controls (n=1008).(115)  Furthermore, the combination of non-O blood group and a 
thrombophilia has a supra-additive effect on VTE risk.(115)  Interestingly, non-O blood 
groups are more common in recurrent and idiopathic VTE, which are also risk factors 
for progression from acute PE to CTEPH.(116, 117)   
 
The ABO groups vary by the ABH(O) antigens (oligosaccharide residues) and are 
found on red blood cells, platelets and VWF, a protein involved in haemostasis and 
described in Section 1.6.(118)  The ABO gene encodes glycosyltransferase enzymes 
that transfer specific monosaccharides to the H precursor antigen.(119)  Individuals 
with blood groups A and B have terminal sugar moieties consisting of N-
acetylgalactosamine and d-galactose, respectively, whereas those with blood group 
O lack transferase enzyme activity and therefore only express the H antigen.(120)  
Whilst the exact mechanism(s) linking ABO antigen group to thrombotic risk has not 
been defined, it may be mediated by VWF levels, which are 25% lower in O group 
individuals.(121) 
 
1.5  Genome-wide association studies 
 
Performing a genome-wide association study in CTEPH is an opportunity to 
investigate genetic associations that may inform disease pathobiology.  GWAS is a 
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method of examining genetic variants across the genome of individuals to identify 
associations with a disease or trait.  This section will provide an overview of the 
background, methods, statistics and challenges of GWAS. 
 
1.5.1  GWAS background 
GWAS has been transformative in identifying genetic variants associated with multiple 
common traits.(122)  Common (polygenic) traits are caused  by a combination of many 
genetic and environmental factors in contrast to Mendelian single-gene 
disorders.(123) 
 
In contrast to linkage studies in highly penetrant genetic conditions that identify 
causative variants, GWASs have found many genetic variants with relatively small 
effect sizes that predispose to disease.(124)  Family-based linkage studies utilise 
family pedigrees with the disease of interest together with genetic markers to identify 
associated genes based on the concept that chromosomal regions co-segregate in 
families.(93)  However, linkage analysis is limited by low power for complex traits that 
are associated with multiple genes and the challenge in narrowing down causative 
variants from large co-segregated chromosomal regions. (93, 124)  GWAS 
predominantly investigate the genetic variation in single nucleotide polymorphisms 
(SNPs), which are single base pair changes in the DNA sequence.(93)  There are over 
80 million SNPs in the human genome with an individual’s genome varying from a 
reference genome by 4-5 million SNPs. (125)  Common variants have traditionally 
been defined as those with a minor allele frequency (MAF; for a biallelic SNP the 
frequency of the second most common allele) > 5%, low-frequency variants are those 
with a MAF 1-5% and rare variants have a MAF <1%.(126)  More recently, common 
variants have been defined as those with a MAF ≥1% and rare variants having a MAF 
<1%, although as allele frequencies are continuous the cut-offs are arbitrary.(122)  As 
individual GWAS associations are predominately common SNPs with modest effect 
sizes, they are neither necessary nor sufficient to cause disease.(124)  The concept 
that common diseases have a different genetic architecture to rare Mendelian and are 
associated with common variants is termed the common-variant common disease 
hypothesis.(127) 
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The first GWAS was performed in 2005 and identified a common genetic variant  in 
the complement factor H gene in age-related macular degeneration (AMD).(128)  
There have subsequently been over 5000 GWAS performed for over 70,000 variant-
trait associations (Figure 1.9).(129)  Whilst the first GWAS included only 96 cases 
with AMD, modern GWAS from the largest consortia have included hundreds of 
thousands of cases and a continued increase in case numbers is likely.(128, 130)  
GWAS is superior to candidate gene approaches (for example a study of genes 
associated with thrombosis and fibrinolysis), which are limited by widespread false-
positive associations and the inability to evaluate unknown (a priori) genetic 
variants.(131)  With a hypothesis free approach, GWAS has identified multiple genes 
that were not previously implicated in disease pathogenesis and variants in genomic 
regions containing no genes (intergenic).(132)  The transition from candidate gene 
studies to GWAS for the investigation of complex diseases was possible due to the 
reduced cost of SNP genotyping over the last two decades.(124) 
 
GWAS has many different applications in addition to identifying SNP-trait associations 
that can inform disease pathobiology.  The proliferation of international consortia and 
biobanks (i.e. DeCODE, UK Biobank) have enabled larger GWAS to be performed 
that have identified an increasing number of common variant associations.(133, 134)  
These risk variants can be combined into polygenic risk scores together with traditional 
environmental risk factors to predict an individual’s disease susceptibility, a tenet of 
personalised medicine.(135)  GWAS can inform clinical treatments by identifying 
genetic variants that are associated with efficacy, drug metabolism and side 
effects.(93)  Another benefit of large biobank cohorts is they contain a number of 
diseases and traits that enables genetic variants of interest to be studied across 
different phenotypes in phenome-wide association studies (PheWAS).(136)  PheWAS 
has shown that many individual genetic variants are associated with multiple traits, 
which is termed pleiotropy.(137)  Risk variants identified by GWAS can be used as 
genetic instruments in Mendelian randomisation studies, the process of investigating 
causal relationships between potentially modifiable risk factors (e.g. CRP) and health  
outcomes (e.g. coronary artery disease).(137-139)  An overview of the different 
genetic applications for GWAS is summarised in Table 1.4. 
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Figure 1.9 GWAS SNP-trait associations have increased over time 
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Data for the GWAS associations was from the GWAS Catalog.(140)  SNPs were included if they had a p<5x10-8 and were not in 
linkage disequilibrium (LD; see Section 1.5.2) (r2 < 0.5) with another associated SNP (if they were in LD, the SNP with the lowest p-
value was retained).  Only the top three traits and diseases with the largest number of SNP associations for each year have been 
included to improve visualisation.  
Figure from (122) 
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Analysis 
 
Purpose 
GWAS  
 
Detecting trait-SNP associations 
Estimation of SNP 
heritability 
 
Evaluation of genetic architecture  
Population differences in 
allele frequencies 
  
Reconstructing human population history and 
detecting evidence of natural selection  
Polygenic risk scores  
 
Detecting pleiotropy; validating GWAS discoveries  
Mendelian randomization 
 
Testing causal relationships  
Trait GWAS with -omics 
GWAS 
 
Fine-mapping; detecting target genes and functional 
consequence of genetic variant  
 
Table 1.4 GWAS genetic applications 
SNP heritability involves estimating the proportion of genetic variation captured by 
common SNPs.  Pleiotropy is the concept that individual genetic variants are 
associated with multiple traits.  Fine-mapping is discussed further in Section 1.5.3. 
In addition, GWASs have a role in estimating genetic correlation to detect pleiotropy, 
detect copy number variant (CNV) – trait associations, and quantify the genome 
architecture by assessing linkage disequilibrium (Section 1.5.4)  
Table adapted from (122) 
 
 
1.5.2  GWAS methods 
Since the understanding that candidate gene studies produced many false positive 
associations, GWAS methodology has been developed to be systematic and robust 
with a focus on quality control and reducing bias.  The stages include sample 
preparation, microarray clustering and genotyping of SNPs, sample and SNP quality 
control, statistical analysis and validation/replication of results.  Additional steps 
include genetic imputation and meta-analysis, which are discussed in Section 1.5.3.   
 
Genomic DNA is extracted from individual samples (e.g. whole blood) and quantitively 
assessed to ensure sufficient DNA for genotyping.  SNPs are genotyped using high-
throughput microarrays, whereby wells are coated with an allele-specific 
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oligonucleotide probe (short DNA sequence) that binds with sample DNA fragments 
and is then labelled with fluorescent dyes to produce an intensity signal.(141)  The 
signals are detected and then converted to genotypes (Figure 1.10).  SNP microarrays 
vary in the number of SNPs they genotype, which is usually 200,000 to over 2 
million.(122)  Whilst GWASs still predominantly use SNP microarrays, there is 
increased utilization of SNPs from whole genome sequencing for association testing 
and this is likely to increase in the future.(122) 
 
Following genotype calling, comprehensive quality control is undertaken for individual 
samples and SNPs followed by any necessary exclusions to reduce potential 
confounding.(142)  The quality control steps are further explained in detail in Chapter 
2.  In a case control study design, the different allele frequencies can then be 
compared between disease cases and healthy controls or a disease comparator 
group.  This should then be followed by a confirmation of associated SNP-traits in a 
separate validation cohort.(143)  An overview of the GWAS process is shown in 
Figure 1.11. 
 
 
   
 
 31 
 
 
Figure 1.10 SNP microarray overview 
Genomic DNA (gDNA) is amplified (left panel), followed by DNA fragmentation and 
direct hybridisation of sample DNA with microarray (in this example “BeadChip”) 
bound oligonucleotides (short DNA sequences) (middle panel) and finally fluorescent 
staining to produce an intensity signal (red or green) that is computationally analysed 
to provide genotype calls (right panel). 
Figure reproduced with permission of the © Illumina from Illumina Infinium 2 assay 
schema, (https://dnatech.genomecenter.ucdavis.edu/infinium-assay/; accessed 
22/1/20) 
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Figure 1.11 GWAS overview 
A SNPs across the genome are microarrayed for each individual (small segment of 
chromosome 9 displayed) 
B In a case-control GWAS, each SNP (SNP1, SNP2, …, SNPx) is compared between 
cases and controls.  For a biallelic hypothetic SNP there would be two alleles (A/a) 
and 3 potential genotypes (AA (common homozygote), Aa (heterozygote), aa (variant 
homozygote)).  The statistical comparison results in a p-value for each SNP based on 
the allele frequencies between cases and controls.  
C Following quality control steps, the SNP associations (p-values) are visualised on 
the y-axis of a Manhattan plot, with SNP genomic position plotted on the x-axis 
Figure reproduced with permission of the © Massachusetts Medical Society, from 
(123) 
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1.5.3  GWAS association testing and statistics 
GWASs are able to capture variation across the whole genome without directly 
measuring all SNPs due to linkage disequilibrium (LD), which is the non-random 
association of alleles at two or more loci (Figure 1.12).(144)  Alleles at flanking loci 
tend to be inherited together, with specific combinations termed 
haplotypes.(145)  Whilst a single genotyped (tag) SNP is unlikely to have direct 
functional (causal) effects, it may be in LD with common variants that do, thus acting 
as a proxy marker.(146)  GWASs rely on LD to infer SNP associations without 
genotyping them all individually.  As genetic variation and associations are affected by 
ancestry, samples with different ancestry could introduce confounding from genotype 
differences between (and within) cases and controls that are related to population 
(ethnicity) differences rather than SNP-trait associations.(147, 148)  This population 
structure can result in a difference in allele frequencies due to ancestry rather than 
SNP-trait associations and needs to be accounted for in the analysis.   
 
After quality control steps and any appropriate exclusions, association testing is 
performed.  In a case-control study, allele frequencies can be statistically compared 
between cases and controls using a simple chi-squared test.  However, there are 
usually other potential confounders (including population structure) that require 
adjusting for and therefore, multivariable logistic regression (for binary case/control) 
or linear regression (for continuous traits) is performed.  GWAS case-control 
association testing results are often presented as an odds ratio for each SNP.  For a 
hypothetical biallelic SNP (A/a) the allelic OR would represent the odds of disease in 
an individual with allele A compared with the odds of disease in an individual carrying 
allele a.(145)   
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Figure 1.12 Linkage and linkage disequilibrium 
Within families, when a pair of genetic markers remains linked due to co-segregation of chromosomal regions rather than being 
separated by recombination events (red lines) then linkage has occurred (left panel).  In contrast, in populations where there are a 
number of recombination events over time, genetic markers move from linkage disequilibrium to linkage equilibrium (right panel).  
Linkage disequilibrium is the non-random association of alleles at two or more loci. 
Figure from (93) 
 
   
 
 36 
In a GWAS, the number of genotyped SNPs ranges from hundreds of thousands to 
millions and a statistical test is performed on each, which creates a problem of multiple 
testing and false positive associations.(132)  This is addressed in GWAS by adjusting 
p-values for multiple testing or setting a more stringent threshold for p-value 
significance.  This is often performed using the Bonferroni correction method, whereby 
the p-value (alpha) is divided by the number of SNPs (i.e. 0.05 / 1,000,000 = p < 5x10-
8).  A p-value <5x10-8 has become the standard to denote genome-wide 
significance.(143)  GWAS association testing results are often visualised using 
Manhattan plots as shown in Figure 1.14.  In addition to a case-control GWAS, sub-
phenotypes and continuous variables within diseases and traits can be explored using 
GWAS methodology. 
 
The SNP coverage across the genome can be increased with genetic imputation, 
which is the statistical inference of unobserved genotypes that have not been directly 
measured by microarrays (Figure 1.13).(149)  The measured alleles are compared 
with reference haplotypes (i.e. HapMap) and a statistical probability is estimated for 
the unmeasured genetic variants.(149)  This allows more genetic variants to be tested 
for phenotype associations. 
 
The increased utilisation of GWAS has led to results from different studies for the same 
diseases or traits.  These results can be pooled together in a GWAS meta-analysis 
using the individual level genotype data or the summary statistics generated from 
association testing.(150)  This increases sample size and the power to detect genetic 
variants with smaller effects on disease risk.  
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Figure 1.13 Genetic imputation 
Genetic imputation is a method of predicting missing genotypes by utilising reference haplotypes 
a Genotypes of individuals (rows) for different SNPs (columns), some of which are missing and denoted by a question mark.  For a 
hypothetical biallelic SNP (A/a) there are 3 potential genotypes which are displayed as 0 (aa), 1 (aA) and 2 (AA) 
b GWAS association testing does not reveal any significant associations prior to imputation 
c Individual genotypes are phased (a statistical process of estimating haplotypes) and this process is displayed for 3 example 
individuals (the colours denote which reference haplotype they match to in d) 
d Phased haplotypes are compared to a reference panel of dense haplotypes 
e Missing genotypes are imputed using the matched reference haplotypes and this is performed statistically to take account of the 
uncertainty of each imputed SNP. 
f Repeat association testing using imputed SNPs can lead to more significant associations 
Figure from (149) 
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1.5.4  GWAS challenges 
There was initial concern that the common variant associations that were discovered 
by GWAS did not sufficiently explain the heritability that was estimated from pedigree 
studies, which was termed “missing heritability”.(151)  In 2009, GWASs of height had 
identified ~40 SNP-trait loci which only explained 5% of the variance in height 
compared to 80% that was estimated from pedigree studies.(151, 152)  However, as 
GWAS sample sizes increased and methodology improved it was recognised that 
most “missing” heritability in common traits could be explained by a combination of 
common variants below the genome-wide statistical threshold and to a lesser extent 
rare variants with larger effect size.(153-155) 
 
A key challenge following a GWAS is to identify causal variants, which are the variants 
that have a direct or indirect functional effect on disease risk.(124)  Whilst linkage 
disequilibrium enables variation in the genome to be investigated without directly 
genotyping all SNPs it presents a challenge when associations are discovered.  As 
adjacent variants are correlated and there are more segregating variants than 
genotyped using SNP micro-arrays, any associated SNP is unlikely to be the causal 
variant and the association due to LD in the haplotype structure.(124, 137)  The 
process of narrowing down the GWAS association to a causal variant or set of variants 
is termed fine mapping.  Fine mapping is made more challenging as most GWAS 
associations are in non-coding and inter-genic genomic regions and their functional 
consequences are more difficult to interrogate than for causal variants within coding 
sequences in Mendelian diseases.(137, 156)  The genetic correlation across common 
diseases also makes fine mapping more challenging as GWAS associated variants 
can be associated with multiple traits (pleiotropy).(157)  To date, whilst limited studies 
have bridged the gap between GWAS associations and biological disease 
mechanisms, progress is now being made as methodologies improve and datasets of 
functional annotations have become available.(122) 
 
Fine mapping methods for narrowing down causative variants include increasing SNP 
density, statistical methods (e.g. Bayesian), utilising genomic functional annotations 
and trans-ethnic fine mapping.(158)  Increasing SNP density by either genetic 
imputation (Section 1.5.3) or additional genotyping is able to narrow down causal 
variants by filling in the missing genotypes between SNP micro-array markers.(158)  
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A number of statistical methods for fine-mapping have been developed including those 
utilising Bayes theorem, a probability theory based on the probability of prior 
events.(159)  The posterior probabilities generated by a GWAS Bayesian analysis can 
be used to form “credible sets” of causal variants however, statistical methods alone 
cannot determine causality.(158, 160)  Trans-ethnic fine mapping involves combining 
separate GWAS for the same trait in different populations and using the difference in 
LD structure to narrow down causative variants.(158, 161)  Most GWAS have a bias 
towards European populations and a future challenge will be to expand GWAS in other 
populations, which could uncover novel risk variants and improve trans-ethnic fine 
mapping.(137)  
 
As most GWAS associations are in non-coding and inter-genic regions of the genome, 
they may be exerting their effects by influencing transcriptional regulation of 
genes.(156)  In such cases, linking the GWAS association to a biological disease 
mechanism requires an understanding of the role of non-coding variants in 
transcriptional regulation.  Functions assigned to non-coding variants (annotation) 
include promoters and enhancers (of transcription), transcription factor binding sites, 
chromatin accessibility, histone modification and DNase hypersensitivity sites.(158, 
162)  Genomic annotation has been possible due to the development of genome-wide 
databases of functional activity including the Encyclopaedia of DNA Elements 
(ENCODE), Roadmap Epigenomics Project and the Genotype-Tissue Expression 
(GTEx) project which have mapped regulatory elements across multiple cell types and 
tissues.(137, 163-165)  GWAS associations can be fine-mapped by identifying non-
coding variants enriched for regulatory functions from these annotation databases, 
which can narrow down causative variants for subsequent experimental investigation 
of functional consequences.(158) 
 
1.5.5  Venous thromboembolism GWASs 
Prior to genome-wide associations studies, most VTE genetic risk factors were in 
genes associated with coagulation and fibrinolysis. Whilst there is strong heritability 
for VTE, identified genetic risk factors occur in only half of people, suggesting 
additional genetic associations.(70) 
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Additional VTE genetic risk factors have been described in several genome-wide 
association studies (GWAS), a method of identifying common single nucleotide 
polymorphisms (SNPs) associated with disease (Section 1.5).  A meta-analysis of 
7,507 VTE cases from 12 case-control studies and testing ~7 million SNPs, reported 
9 significant loci.  Of these loci, 6 were involved in the haemostasis / fibrinolytic 
pathways (ABO, F2, F5, F11, FGG, PROCR genes) and 3 novel loci (TSPAN15, 
SLC44A2 and ZFPM2) were identified (Figure 1.14).(70)  The ZFPM2 locus was not 
replicated in an additional 3009 VTE subjects, but has been identified in a subsequent 
separate GWAS.(166)  The function of the SLC44A2 and TSPAN15 loci is unclear, 
but the locus in SLC44A2 may be a shared genetic risk factor for coronary artery 
disease (CAD) and stroke.(167)  Other studies have suggested that currently, ABO is 
the only shared genetic risk factor between VTE and CAD.(168)  Epidemiological 
studies have identified older age, smoking and increasing body mass index (BMI) as 
shared risk factors between VTE and CAD.(169)   
 
 
Figure 1.14  Manhattan plot of VTE associated genetic loci 
7,507 VTE cases, 52,632 control subjects and 6,751,884 SNPs in the discovery 
cohort.  P-values (-log10) are plotted against genomic position, with those above the 
dotted line (Bonferroni p-value threshold = 5x10-8) representing significant 
associations.  Figure reproduced © Elsevier, from(70). 
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Genetic studies have also been used in several other ways to investigate VTE.  An 
individual’s risk of VTE has been investigated by combining multiple genetic risk loci 
associated with VTE in polygenic risk scores with and without traditional 
epidemiological risk factors.(170, 171)  This method has the potential to be applied to 
risk stratify patients with PE for the likelihood of developing CTEPH.  This is an unmet 
clinical need where currently no validated tools exist.(172)  Genetic studies using 
Mendelian randomisation, a method to investigate putative causal relationships 
between modifiable risk factors and disease have found a causal relationship between 
obesity and VTE.(138, 166, 173) 
 
1.6  Von Willebrand Factor and ADAMTS13 
 
As described in Section 1.2.2, abnormalities in haemostasis are implicated in CTEPH 
pathobiology.(39, 174)  This includes elevated VWF, a multimeric plasma glycoprotein 
that is synthesized by vascular endothelial cells and megakaryocytes.(35, 175)  VWF 
is stored in Weibel-Palade bodies and alpha-granules, and secreted after activation of 
the endothelium or platelets.(175)  VWF plays an important role in platelet recruitment 
by mediating adhesion of platelets to the endothelium and is also a carrier protein for 
the pro-coagulant blood clotting Factor VIII.(175)   
 
VWF activity is normally regulated by ADAMTS13 (a disintegrin and metalloproteinase 
with a thrombospondin type 1 motif, member 13), a plasma protein that specifically 
cleaves the more active high molecular weight VWF multimers, thus preventing 
excessive aggregation of platelets.(176)  ADAMTS13 is predominately produced by 
hepatic stellate cells, in addition to vascular endothelial cells and 
megakaryocytes.(177)  Shear stress causes VWF to undergo a conformational 
change exposing its active binding site to platelets.(178)  This also exposes its A2 
domain, which allows ADAMTS13 to bind and cleave ultra-large VWF into smaller and 
less pro-thrombotic multimers.(178)  The mechanism by which ADAMTS13 is 
regulated has not been fully elucidated.  ADAMTS13 is unusual for coagulation 
enzymes as it is secreted in a constitutively active form and has no known endogenous 
inhibitor.(177)  Plasma proteins that inhibit other members of the ADAMTS family (i.e. 
alpha-2 macroglobulin) do not affect ADAMTS13 activity towards VWF.(177)  It has 
been proposed that ADAMTS13 is regulated at the VWF substrate level.(177) 
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1.6.1  Thrombotic thrombocytopenic purpura 
The critical role of ADAMTS13 levels in haemostasis is exemplified by thrombotic 
thrombocytopenic purpura (TTP).  TTP is a rare disease that is characterised by micro-
angiopathic haemolytic anaemia, low platelet levels (thrombocytopenia) and 
microvascular thrombi formation (Figure 1.15).(179)  TTP occurs due to severely 
reduced plasma levels of ADAMTS13 (activity levels < 10%) that is predominately a 
result of ADAMTS13 autoantibodies and less frequently due to rare ADAMTS13 
mutations.(180, 181)  The autoantibodies are mainly anti-ADAMTS13 immunoglobulin 
G (IgG) in three quarters of acute TTP that inhibit the ADAMTS13 mediated proteolysis 
of VWF.(179, 180)  TTP has a prevalence of ~10 cases per million individuals and the 
autoantibody form is more common with increasing age, in females and with black 
ethnicity.(182, 183)  Acute episodes of autoantibody TTP are associated with diseases 
that increase VWF levels including bacterial infections, other autoimmune diseases 
(e.g. systemic lupus erythematous and antiphospholipid syndrome), pregnancy, 
certain drugs and cancer.  However, in 50% no precipitating cause is identified 
(idiopathic TTP).(179)  Acute episodes of TTP can be life threatening and are treated 
with plasma exchange to remove the ADAMTS13 autoantibodies and/or 
immunosuppression, with recombinant ADAMTS13 an emerging treatment with 
ongoing clinical trials.(184-187) 
  
Congenital TTP (Upshaw-Schulman syndrome) is caused by rare ADAMTS13 
mutations and occurs in <10% of all TTP.(188)  Over 130 heterozygous and 
homozygous mutations in ADAMTS13 have been reported and inheritance is primarily 
autosomal recessive.(189, 190)  Parents of index-cases with congenital TTP do not 
have clotting abnormalities but do have mildly reduced ADAMTS13 levels consistent 
with heterozygous ADAMTS13 variant carriage.(188)  Mutations have been described 
throughout the ADAMTS13 gene, with 60% being missense mutations and the 
remaining truncating mutations (nonsense, frame-shift or splice-site mutations).(189, 
190)  These mutations cause abnormalities in ADAMTS13 synthesis, activity or 
secretion.(189)  
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Figure 1.15  Pathophysiology of thrombotic thrombocytopenic purpura  
The top right of the figure demonstrates that under normal physiological conditions, 
ultra-large VWF is secreted from endothelial cells and cleaved by ADAMTS13 into 
smaller, less pro-thrombotic VWF multimers. 
In TTP (top left of the figure) there is a severe reduction of ADAMTS13, leading to 
much less cleavage of ultra-large VWF multimers and consequently higher circulating 
levels.  The ultra-large VWF bind to platelets that can aggregate within microvessels 
resulting in tissue ischaemia, platelet consumption (thrombocytopenia) and micro-
angiopathic haemolytic anaemia (demonstrated by schistocytes on a blood film). 
Figure reproduced © the American Society of Hematology, from (179) 
 
 
1.6.2  VWF, ADAMTS13 and thrombotic diseases 
Plasma VWF is increased in a range of thrombotic conditions including CAD, 
ischaemic stroke and VTE.(191, 192)  Conversely, plasma ADAMTS13 is modestly 
reduced in CAD and ischaemic stroke.(191, 193)  There are discordant findings in 
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patients with acute PE, with increased, no difference and decreased ADAMTS13 
reported.(194-196)  VWF and Factor VIII are known to be elevated in CTEPH and do 
not change following PEA suggesting a role in pathogenesis.(35, 37)  Furthermore, 
the VWF multimer distribution in CTEPH mirrors healthy controls indicating the 
increase in plasma levels is not just driven by ultra-large VWF.(35) However, the role 
of ADAMTS13 in CTEPH has not been investigated to date.   
 
VWF and ADAMTS13 have been correlated with d-dimers, a fibrin degradation 
product that acts as a proxy marker of hypercoagulability.(194, 197)  Elevated d-dimer 
has a well described clinical application in the diagnosis of venous thromboembolism 
and is also raised in CTEPH. (198, 199) 
 
A large proportion of the variation in VWF levels is genetically determined, with 30% 
due to ABO groups.(200)  ADAMTS13 is situated ~200 kilobases (kb) distal to ABO 
and is genetically regulated with 20% of its variance attributable to common variants 
at the ADAMTS13 locus.(201)  ADAMTS13 is not known to vary with ABO groups in 
healthy cohorts.(202)  Similar to other thrombotic diseases, the non-O blood groups 
are over-represented in CTEPH suggesting a mechanism by which VWF levels are 
increased.(68)   
 
1.7  Pilot CTEPH GWAS data 
 
Royal Papworth Hospital is the UK national referral centre for pulmonary 
endarterectomy, making it suitably placed to co-ordinate a GWAS, which requires 
large sample numbers and multi-centre collaboration.  In 2014, a pilot CTEPH GWAS 
was performed by Royal Papworth Hospital and the University of Cambridge. 
 
Provisional GWAS results from 500 patients with CTEPH and 1500 healthy controls 
identified significant associations in chromosome 9 corresponding to the ABO and 
ADAMTS13 gene loci.  These genes are associated with thrombosis and haemostasis 
which are plausible pathways involved in CTEPH pathobiology. 
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1.8  Hypotheses and Aims 
 
The hypothesis of this thesis is that chronic thromboembolic pulmonary hypertension 
is a polygenic disease with common variant genetic associations.  Furthermore, 
ADAMTS13 may be a novel genetic association in CTEPH.  Functional consequences 
that have an impact on CTEPH pathobiology may be related to genetic variant 
associations including dysregulation of the ADAMTS13-VWF axis, which will be 
investigated.   
 
The study aims are:  
 
1. To perform a genome-wide association study in chronic thromboembolic 
pulmonary hypertension 
2. To investigate the ADAMTS13-VWF axis in CTEPH patients including its 
relationship to ABO groups and ADAMTS13 genetic variants 
3. To investigate CTEPH sub-phenotype genetic associations  
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2  Materials and Methods 
 
2.1  GWAS 
 
2.1.1  Sample size calculations 
The required GWAS sample size was estimated using the GAS (Genetic Association 
Study) online power calculator 
(http://csg.sph.umich.edu/abecasis/cats/gas_power_calculator/index.html, accessed 
20/1/16).(203)  Multiple sample sizes were estimated by varying the SNP effect odds ratio 
(OR), minor allele frequency (MAF), power, and genetic model (additive, multiplicative, 
autosomal dominant and autosomal recessive) (Figure 2.1).  An estimated 1000 cases 
would be required for a power of 80% to detect an odds ratio of 1.75 assuming a MAF of 
0.1 for an additive genetic model.(93)  In GWAS, the underlying genetic model is unknown 
and the additive model is most commonly applied to avoid multiple testing.(145)  A higher 
sample size is required to detect associations with lower MAFs and smaller ORs. 
 
2.1.2  Study samples and participants 
The study was approved by the regional ethics committee (REC no. 08/H0304/56 and 
08/H0802/32) and all study participants provided written informed consent from their 
respective institutions.  
 
To date, 1555 self-reported Caucasian CTEPH patients have been recruited from 5 
European and 1 United States specialist pulmonary hypertension centres.  This includes: 
Bad Nauheim (Kerckhoff Heart and Lung Centre, Bad Nauheim, Germany); Papworth 
(Royal Papworth Hospital, Cambridge, UK), Imperial (Hammersmith Hospital, Imperial 
College Healthcare NHS Trust, London, UK), Leuven (KU Leuven - University of Leuven, 
Leuven, Belgium), San Diego (University of California, San Diego, USA) and Vienna 
(Medical University, Vienna, Austria).  CTEPH was diagnosed using international 
criteria.(1)  Patients were excluded if they had a PH diagnosis other than group 4 PH.  
Centres supplied all available bio-banked samples that had been consented for genomic 
studies and were suitable for DNA extraction.  CTEPH samples were compared to 1536 
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healthy Caucasian controls from the UK Blood Service (UKBS) arm of the Wellcome Trust 
Case Control Consortium (WTCCC).(204)  Shared controls were used in the original 
WTCCC study and were utilised in the current methodology as the sample numbers were 
limited by re-genotyping controls (Section 2.1.3).(204) 
 
 
 
Figure 2.1  GWAS sample size calculations 
The estimated number of cases required for a one-stage GWAS when different conditions 
are varied assuming an equal number of healthy controls:  Minor allele odds ratio (top 
axis: 1.5, 1.75, 2), MAF (minor allele frequency) (right axis: 0.1,0.25,0.4), and genetic 
models (coloured lines).  The odds ratio is the ratio of the probability that SNP minor allele 
is associated with disease to the probability that is not.(205)  The genetic models describe 
the specific relationship between the genotype and phenotype and included  additive, 
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multiplicative, recessive and dominant.  For two hypothetical alleles (a and A) at a biallelic 
SNP locus the three possible genotypes are a/a, a/A and AA.  In a multiplicative model 
the disease risk is increased n-fold for each additional risk allele (e.g. allele A), in an 
additive model n-fold for a/A and 2n-fold for A/A, in a recessive model two copies of A are 
required and in a dominant model either one or two copies of allele A for an n-fold increase 
in disease risk.(145)  The dashed red horizontal line represents a power of 80%.  
Replotted from data obtained from the online GAS power calculator.(203)   
 
 
2.1.3  DNA extraction and DNA microarray 
Genomic DNA was extracted and processed from whole blood or buffy coat fractions and 
quantified with ultraviolet-visible spectrophotometry (LGC, Hoddesdon, Herts, UK).  DNA 
was normalised to a concentration of 50ng/μL and a total volume greater than 4μl (total 
DNA > 200ng), which was required for the DNA microarray.  Genotyping was performed 
using the Illumina HumanOmniExpressExome-8 v1.2 BeadChip Microarray containing 
964,193 single-nucleotide polymorphism (SNP) markers (Kings College, London, 
UK).  The Genome Reference Consortium human genome (build 37) (GRCh37) was used 
for genomic positions.  Three batches were genotyped from 2014-16 (batch1: 2014, 
batch2: 2015, batch3: 2016).  All WTCCC controls were genotyped in batch1 using the 
same Illumina microarray chip as CTEPH cases.   
 
2.1.4  GWAS quality control 
2.1.4.1  GWAS quality control: overview 
Sample and SNP quality control (QC) steps are summarised in Figure 2.2.  This occurred 
in three broad stages: micro-array clustering and genotype calling, sample QC and 
exclusions, SNP marker QC and exclusions.  Samples and SNPs were quality controlled 
in separate micro-array batches and merged together following individual batch QC 
exclusions.  Phasing and imputation were then performed for all remaining samples.  
Following imputation, additional SNP QC was performed prior to statistical association 
testing. 
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Figure 2.2  Flow chart of GWAS analysis steps 
HWE (Hardy-Weinberg equilibrium), IBD (identity by descent), INFO (information score), 
MAF (minor allele frequency), PCA (principal component analysis), QC (quality control), 
sd (standard deviation), 1000G (1000 Genomes phase 3)  
 
 
2.1.4.2  Micro-array intensity data quality control and genotype calling 
Each batch of micro-array intensity data was normalised, clustered and genotypes were 
called independently using Illumina GenomeStudio (v2.0).(206)  Samples containing 
more than 1% missing genotypes (a marker of DNA sample quality) were removed and 
SNPs were re-clustered to remove confounding from differential SNP exclusions between 
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batches.  The rationale for this approach in relation to the study SNP exclusions is 
described in Section 3.2.2.3.2.  SNPs with poor clustering quality scores (GenTrain score 
(<0.7) or clustering separation score (<0.5)) were excluded following re-clustering.(206, 
207)  A higher score (range 0-1; both) reflects better SNP calling quality or separation. 
 
2.1.4.3  Sample quality control 
Sample quality control involved an assessment of administrative exclusions (incorrect 
phenotype), divergent ancestry, relatedness, discordant sex and outlying heterozygosity.  
Sample genotype missingness exclusions were performed at the genotype calling stage 
(Section 2.1.4.2).  The sample and SNP QC steps were performed using PLINK (v1.9 
beta) unless otherwise stated.(208) 
   
Samples with non-Caucasian ancestry could introduce confounding from genotype 
differences between (and within) cases and controls that are related to population 
(ethnicity) differences rather than SNP-trait associations.(147)  Divergent ancestry was 
assessed using principal component analysis (PCA), a statistical dimensionality reduction 
method.  Each batch was merged with the 1000 Genomes phase 3 data using an 
intersecting set of SNPs.(209)  A robust set of independent SNPs (n=30,609) was used 
for PCA using the following criteria: genotype missingness < 5%, SNPs in Hardy-
Weinberg equilibrium (HWE) (p>1x10-5), minor allele frequency (MAF) > 5%, independent 
SNPs (pairwise R2 < 0.2).  Furthermore, SNPs in several regions with long-range linkage 
disequilibrium (LD) were excluded.(210)  PCA against all populations in the 1000 
Genomes data was conducted using the `SNPRelate` R package, and samples not 
clustering with European populations were excluded.(211)  A second PCA was then 
performed with the remaining samples against European 1000 Genome reference 
samples only, and outlying samples were also excluded.  Thresholds were set by visual 
inspection of plots.   
 
Related samples can introduce confounding due to genotype association within families 
rather than SNP-trait associations.  Sample relatedness (including duplicates) was 
assessed by calculating the proportion of shared alleles at genotyped SNPs for sample 
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pairs.  This was achieved by estimating the parameter identity by descent (IBD) from the 
calculated parameter identity by state (IBS) in PLINK.(208)  To generate the pairwise IBD 
matrix an independent set of SNPs (n=228,646) was generated by LD pruning after 
removal of long-distance high LD regions.(210)  LD was calculated for each SNP pair 
within a window of 50 SNPs and one of the pair was removed if high LD was present 
(R2>0.2), before the window was shifted by 5 SNPs and the process repeated.  Samples 
were then excluded if they had a proportion of IBD score (PI_HAT > 0.1875), which 
approximates to a threshold between a 2nd and 3rd degree relative.(212)   
 
Additionally, individual samples were removed due to outlying heterozygosity (3 standard 
deviations from the mean) and missing genotypes (>1%; described in Section 2.1.4.2), 
both markers of DNA sample quality.  Sex discordance between centre-reported sex and 
genotype determined sex was assessed from X-chromosome homozygosity rates but no 
samples were excluded on this basis (see Section 3.2.2.2 for rationale).   
 
2.1.4.4  SNP quality control 
Following sample QC exclusions, SNP markers were removed due to missing genotypes 
(>1%), deviation from HWE (p < 1x10-6), which was only assessed in healthy control 
samples, differential missingness rate between cases and controls (p < 1x10-5) and multi-
allelic SNPs.  Hardy-Weinberg assumptions are used to estimate allele and genotype 
frequencies between generations.  Deviation from HWE can signify population 
stratification, genotyping errors or association with the study trait, and hence its 
application to study controls.(213) 
 
The 3 batches were then merged using an intersecting set of SNPs and further PCA was 
performed using the robust SNP set previously used for divergent ancestry QC, to check 
for batch and recruiting centre effects. 
 
2.1.5  Phasing, genetic imputation and post-imputation SNP QC  
After quality control exclusions there were 1250 CTEPH cases, 1492 healthy controls and 
915,999 SNPs.  Phasing and imputation was performed using EAGLE 2 (v2.0.5) and 
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positional Burrows–Wheeler transform (PBWT) software via the Sanger imputation 
service (https://imputation.sanger.ac.uk, accessed 17/1/17).(214, 215)  The reference 
panel was the Haplotype Reference Consortium (release 1.1), containing ~39 million 
biallelic SNPs from 32,470 individuals.(216)  Following imputation, SNPs were excluded 
if they had a low minor allele frequency (<1%) or if they were poorly imputed (INFO 
(information) score < 0.5), with 7,675,738 SNPs remaining for association testing.   
 
2.1.6  Association testing 
Case-control association testing was performed using the post-imputation allelic dosages 
(scale 0-2).  Logistic regression assuming an additive genetic model was applied to each 
SNP marker using PLINK software.  Models were adjusted for covariates, namely 
ancestry informative principal components described in Section 2.1.4.3.  The final models 
used for case-control association testing in the discovery, validation and joint (discovery 
and validation combined) cohorts used 5 principal components as covariates.  Within-
case CTEPH analyses also included genotyping batch or recruiting centre as covariates 
in addition to 5 principal components to investigate any additional confounding. 
 
Genomic inflation was estimated using the parameter lambda, which was calculated by 
comparing the median of observed and expected test statistics.(145)  Genomic inflation 
values above 1 can indicate population stratification or genotyping errors.(145)  To 
identify independent and secondary signals at associated loci, conditional analysis was 
performed.  Association testing was repeated and conditioned on the allelic dosage of the 
peak (most significant) SNP in that genomic region.  The micro-array intensity clusters for 
the peak SNP (present pre-imputation) in the associated loci were re-examined to confirm 
adequate genotyping. 
 
2.1.7  Linkage disequilibrium 
Linkage disequilibrium was quantified within the study dataset using PLINK and for a 
reference dataset (1000 Genomes project data: all European (non-Finnish) populations) 
using LDlink (https://analysistools.nci.nih.gov/LDlink/, accessed 22/01/2018).(217)  The 
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degree of LD was assessed with the parameters R2 (which takes into account the 
correlation of SNPs and the allele frequency) and D’ (prime).(144) 
 
2.1.8  Genetic ABO groups 
The ABO groups A1, A2, B and O were reconstructed using haplotypes from phased data 
and a described list of tagging ABO SNPs (Table 2.1).  The ABO groups are described 
in Section 1.4.2 and in addition, the A group can be divided into A1 and A2 subgroups 
which have very similar chemical structures, with the A1 group expressing more A 
epitopes (the part of the antigen molecule that the antibody attaches to) and having 
greater antigenicity.(218)  This resulted in 10 groups (A1A1, A1A2, A1B, A1O, A2A2, 
A2B, A2O, BB, BO, OO), from which blood groups A, B, AB and O were inferred.  
 
The tagging SNPs used to reconstruct the genetic ABO groups A1, A2, B and O from 
phased haplotypes were: rs8176746, rs8176704, rs687289 and rs507666.(219)  The 
genetic ABO groups were compared to the available ABO antigen groups measured by 
serology (n=1490 healthy control group) to confirm the accuracy of this method (98% 
concordance).  There were 22 healthy controls and 32 cases that were not able to be 
classified with an ABO group.  The 10 genetic ABO groups were converted into A, B, AB 
and O groups using the following criteria: A = A1A1, A1A2, A2A2, A1O, A2O; B = BB, 
BO; AB = A1B, A2B; O = OO. 
   
Genetic ABO group Haplotype  
 rs8176746  rs8176704  rs687289  rs507666  
A1  C G  A  A  
A2  C A  A  G  
B  A G  A  G  
O  C G  G  G  
 
Table 2.1  Haplotypes used to reconstruct genetic ABO groups 
Haplotypes from 4 “tagging” SNPs from phased genotypes were used to assign genetic 
ABO groups.  Table adapted from Paré et al. (219) 
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2.1.9  Fine mapping 
Fine mapping was performed to narrow down the associated SNPs and identify a causal 
variant or a set of variants.(158)  Statistical analysis and genomic functional annotations 
were used in the fine-mapping process.  
 
2.1.9.1  99% credible set 
Association testing was performed by Bayesian analysis using SNPtest (v2.5.4-beta3) 
assuming an additive model with 5 ancestry informative principal components as 
covariates and using the default priors.(220)  The posterior probabilities were then 
calculated by dividing the Bayes factor for each SNP (within a 200kb region of the peak 
associated SNP) by the sum of all Bayes factors for that region.  Posterior probabilities 
were ranked in descending order and the SNPs included in the 99% cumulative sum 
comprised the 99% credible set.(158)  
 
2.1.9.2 Genomic functional annotations 
Genomic functional annotations for the associated loci were investigated using the 
fumaGWAS (Functional mapping and annotation of GWAS) tool (v1.3.2; 
http://fuma.ctglab.nl/).(221)  Summary statistics from GWAS association testing were 
uploaded to the online platform and SNPs were annotated for biological function.  SNPs 
were then mapped to genes based on genomic proximity, cis-expression quantitative trait 
loci (eQTL) interactions and 3D chromatin interactions.(221)  Data from 18 biological 
repositories was used in these processes including: ANNOVAR (222), Combined 
Annotation Dependent Depletion (CADD) score (223), RegulomeDB (224), 15-core 
chromatin state (225), Genotype-Tissue Expression (GTEx)(165), Roadmap 
Epigenomics Project (164) and Encyclopaedia of DNA Elements (ENCODE) (163).  For 
the fumaGWAS analyses, GTEx (v7) incorporated data from 53 tissue types (including 
systemic arterial and left heart samples) and ENCODE utilised 127 cell/tissue types, but 
no resources included pulmonary vascular endothelial or right heart samples.(221) 
 
Independently associated SNPs and correlated SNPs are linked to the GWAS catalog to 
facilitate interrogation of other trait-SNP associations in the literature.(140)  
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Association testing was also performed at the gene level using MAGMA (Multi-marker 
Analysis of GenoMic Annotation) via fumaGWAS.(226)  Gene-based analysis may 
increase power as less statistical tests are performed than when individual SNP markers 
are tested.(226)  SNPs were mapped to 19,311 protein coding genes and then multiple 
regression (SNP-wise model) was performed with the summary statistics data from the 
combined GWAS analysis using MAGMA.(226)  Gene-set analysis was then performed 
utilising the gene-based p-values for 4728 curated gene sets and 6166 gene ontology 
(GO) terms from the Molecular Signatures Database (MsigDB v5.2).(221, 227)  
 
2.2  ADAMTS13-VWF axis 
 
2.2.1  Study samples and participants 
The study was performed with the same regional ethics committee approval as described 
for the GWAS (REC no. 08/H0304/56 and 08/H0802/32).  All study participants provided 
written informed consent from their respective institutions.  
 
All consecutive CTEPH patients from the national PEA centre (Royal Papworth Hospital, 
United Kingdom (UK)) with available plasma samples (August 2013-December 2016) 
(Figure 2.3) and genotype data were included in the study (n=208).  CTEPH was 
diagnosed using international criteria and healthy volunteers (n=68) without major 
comorbidities were used as a control group (Papworth and Hammersmith Hospital, 
UK).  CTEPH patients were excluded if they had other major contributing factors to their 
pulmonary hypertension.  Additional patient groups were recruited as disease 
comparators including chronic thromboembolic disease (CTED, n=35), idiopathic 
pulmonary arterial hypertension (IPAH, n=30) and pulmonary embolism (PE, 
n=28).  CTED was characterised by persistent pulmonary arterial thromboembolic 
occlusions without pulmonary hypertension (mean pulmonary arterial pressure 
<25mmHg) in symptomatic patients.(10)  The IPAH (Papworth, UK) and PE 
(Hammersmith, UK) groups were also diagnosed using international criteria. 
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The 208 CTEPH patients represented 40% (208/514) of all the patients diagnosed with 
CTEPH during the same period at Royal Papworth Hospital, UK.  Healthy controls and 
disease comparators were selected for the closest possible age- and sex- matching to 
the CTEPH group, and additionally all IPAH patients were matched for anticoagulation 
therapy usage but had not had a venous thromboembolism. 
 
 
 
Figure 2.3  Flow chart of study design and study participant numbers   
PEA (pulmonary endarterectomy), pQTL (protein quantitative trait loci).  The number in 
each group are shown in bold. 
 
 
2.2.2  ADAMTS13 and VWF plasma concentrations 
Plasma ethylenediaminetetraacetic acid (EDTA) samples were used to measure 
ADAMTS13 and VWF antigen (Ag) levels by enzyme-linked immunosorbent assays 
(ELISA).  Samples for the CTEPH, CTED and IPAH groups were obtained closest to the 
time of diagnosis, and pre-operatively for the CTEPH and CTED patients undergoing 
PEA.  Additionally, to assess the effect of PEA, ADAMTS13 and VWF levels were 
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measured in 22 paired post-PEA samples taken at a follow-up time within 1 year of 
surgery.  The PE group were sampled from a specialist PE follow-up service 
(Hammersmith, UK) at a median of 220 days following an acute PE. 
 
2.2.2.1  ADAMTS13 plasma concentration 
ADAMTS13 plasma antigen levels were quantified using a polyclonal rabbit anti-
ADAMTS13 antibody (5μg/mL, anti-TSP2–4 depleted) as previously described.(202, 
212)  The antibody was immobilised in 96-well microplates (Nunc, Rochester, USA) in 
50mM carbonate buffer, pH 9.6 at 4°C overnight.  Washes were performed with 
phosphate buffered saline (PBS) + 0.1% Tween-20 (PBST), and this was repeated 
between each step.  Wells were blocked with 1% bovine serum albumin (BSA) in PBS for 
1 hour.  Plasma samples were diluted 1:20 using 1% BSA in PBS and added to the wells 
in duplicate for 2 hours.  A standard curve of 0-126 ng/mL was made with normal human 
control plasma (NHP) (Technoclone, Vienna, Austria) that had known concentrations of 
ADAMTS13.(202)  Bound ADAMTS13 was detected with biotinylated anti-TSP2–4 
polyclonal antibody for 2 hours followed by incubation of wells with streptavidin-
horseradish peroxidase (HRP) (GE Healthcare, UK) for 1 hour.  Plates were developed 
with a peroxidase substrate (o-phenylenediamine dihydrochloride (OPD); Sigma-Aldrich, 
Darmstadt, Germany) for 5 minutes and the reaction was stopped with 65μL/well of 2.5M 
H2SO.  Absorbance was read at 492nm (FLUOstar Omega plate reader, BMG 
Labtech).  ADAMTS13 concentrations were obtained by interpolating from the standards 
fitted with a four-parameter logistic curve.  The intra- and inter-assay coefficients of 
variation were 8 and 12% respectively. 
 
To enable a comparison with other published thrombotic diseases, each ADAMTS13 
plasma antigen level was divided by the median of the healthy control group and 
expressed as a percentage.  The CTEPH group was then divided into quartiles of the 
ADAMTS13 distribution of the healthy control group.  The quartile thresholds were used 
to stratify CTEPH patients and healthy controls into groups using a combination of 
ADAMTS13 and VWF levels.  Odds ratios for the different groups were then assessed 
using logistic regression adjusted for age, sex, ethnicity and experimental batch. 
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2.2.2.2  VWF plasma concentration 
VWF plasma antigen levels were quantified in a similar well-described manner using a 
polyclonal rabbit anti-VWF antibody (3.1 μg/mL; Dako, Santa Clara, USA).(212)  After 
overnight antibody immobilisation and washes, wells were blocked with 1% BSA in PBST 
for 1 hour.  Plasma samples were diluted 1:400 in PBST 1% BSA and a standard curve 
of 0-125 ng/L was made with NHP that had a known concentration of VWF.(202)  VWF 
was detected with 1.1μg/mL Polyclonal Rabbit Anti-Human VWF/HRP (Dako) followed by 
plate development with OPD for 3 minutes.  The intra- and inter-assay coefficients of 
variation were 5 and 8% respectively. 
 
2.2.2.3  Replicate sample measurements 
The ADAMTS13 and VWF ELISAs were performed for all groups in 2016 
(batch1).  Additional CTEPH samples (n=115) were included in 2017 (batch2) and 
replicates (ADAMTS13: n=24, VWF: n=12) were used to enable the correction of any 
batch effects.  This was achieved by adjusting batch2 values by the median of the 
differences if replicates were significantly different between the two batches.  If batch 
adjustment was applied, the validity of this approach was assessed with a multivariable 
linear model using the uncorrected ADAMTS13 or VWF values.  
 
2.2.3  ADAMTS13 activity, D-dimer and VWF multimeric size 
Additional experiments were performed on a subset of the CTEPH (n=23) and healthy 
control (n=14) groups to identify potential mechanisms for any dysregulation of the 
ADAMTS13-VWF axis.  Plasma lithium heparin samples were used to measure 
ADAMTS13 activity and D-dimer concentrations.  The CTEPH sample subset were those 
with the lowest ADAMTS13 antigen levels (below the first quartile of the CTEPH group) 
and the healthy controls were those with ADAMTS13 antigen levels closest to the median 
of the control group.  An estimate of VWF multimeric size was made by measuring VWF 
collagen binding (VWF:CBA) and comparing this with VWF antigen levels in the CTEPH 
(n=21) samples with the highest VWF antigen concentrations (above the third quartile of 
the CTEPH group) and the same healthy control subset. 
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ADAMTS13 activity was measured with a fluorescence resonance energy transfer 
(FRET) assay.  D-Dimers were quantified by ELISA and VWF multimeric size was 
assessed using a collagen binding assay. 
 
2.2.3.1  ADAMTS13 activity 
ADAMTS13 activity was measured with a fluorescence resonance energy transfer 
(FRET) assay using a short synthetic VWF peptide (VWF73: PeptaNova, Sandhausen, 
Germany) containing the ADAMTS13 cleavage site for VWF.(228)  Plasma samples and 
NHP were diluted to 1:10 in reaction buffer (5 mM Bis-Tris, 25 mM CaCl2 and 0.005% 
Tween-20 at pH 6.0) in 96-well plates (Nunc, Rochester, USA).  FRETS-VWF73 
substrate (an equal volume of 4μM) was added and fluorescence was recorded at 1-
minute intervals for 1 hour (FLUOstar Omega plate reader) to monitor substrate 
proteolysis.  Assays were repeated 3 times to obtain the mean fluorescence and 
ADAMTS13 activity was normalised to NHP, which was defined as 100%. 
 
2.2.3.2  D-Dimer plasma levels 
Plasma D-Dimer levels were quantified using an ELISA kit (ab196269, abcam, 
Cambridge, USA) according to the manufacturer’s instructions.  Plasma lithium heparin 
samples from CTEPH patients and healthy controls were used at a dilution of 1:1000. 
 
2.2.3.3  VWF multimeric size 
VWF multimeric size was evaluated with a collagen binding assay (CBA) which utilises 
the increased collagen binding of higher multimeric VWF.  Human type III placental 
collagen (5μg/mL) was immobilised in 96-well microplates plates (Nunc) in 50mM 
carbonate buffer, pH 9.6 at 4°C overnight.  After washes with PBST, wells were blocked 
with 2% BSA in PBST for 1 hour.  Plasma lithium heparin samples were diluted 1:100 in 
PBST 1% BSA and a standard curve of 0-1000ng/mL was made with NHP.  VWF was 
detected with 1.1μg/mL polyclonal rabbit anti-human VWF/HRP (Dako) followed by plate 
development with OPD for 3 minutes.  Collagen binding is reported as a ratio over the 
total plasma VWF antigen. 
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2.2.4  Immunohistochemistry 
ADAMTS13 is primarily secreted by the liver and is also produced by vascular endothelial 
cells however, its expression in pulmonary arteries in health and disease are 
unclear.(177)  ADAMTS13 expression in the pulmonary arteries and PEA specimens was 
assessed with immunohistochemistry.  Tissue sections from peripheral regions of 
explanted lungs of patients with CTEPH undergoing transplantation (n=6) were compared 
to tumour-free sections from lung cancer patients undergoing surgical lung resection 
(n=6).  Additionally, ADAMTS13 expression was assessed in the chronic thromboembolic 
material removed during PEA surgery (n=5).  Tissue sections used from explanted 
CTEPH lungs, controls (tumour-free lung cancer resections sections) and PEAs were a 
random and representative sample. 
 
Immunohistochemistry is a method for investigating cell or tissue antigens using specific 
antibodies that can be visualised through staining.(229)  The stages of 
immunohistochemistry include specimen preparation and fixation, antigen retrieval, 
antibody incubation and washing and counterstaining.(229, 230)  Antigen-antibody 
interactions are identified by immunostaining (Figure 2.4). 
 
Tissue sections were mounted onto charged adhesive microscope slides (CellPath, UK) 
and dried overnight at 50ºC. Antigen retrieval was performed using a low pH buffer in an 
automated antigen retrieval system (PT-module, DakoCytomation, UK) following the 
manufacturers protocol.  Primary antibodies raised against polyclonal rabbit anti-
ADAMTS13 (1:50 dilution; ab71550, Abcam, USA) and polyclonal rabbit anti-human VWF 
(1:2000 dilution; ab9378, Abcam, USA) were labelled using dextran-coupled peroxidase 
(Envision, DakoCytomation, UK), visualised with 3,3’-diaminobenzidine hydrochloride 
(DAB) to create a brown-coloured reaction product, counterstained with haematoxylin and 
examined by light microscopy. 
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Figure 2.4 Indirect immunohistochemistry using a polymer-based detection system 
Immunohistochemistry can be performed using a number of different methods and this is 
an example of indirect immunohistochemistry that utilises secondary antibodies.  The cell 
(antigen) is exposed to a primary antibody (purple), which binds to a secondary antibody 
(brown) that is coupled to the enzyme horseradish peroxidase (HRP). This catalyses the 
DAB (diaminobenzidine) substrate to produce a colour change. 
Figure from (230) 
 
 
2.2.5  Protein quantitative trait loci 
208 CTEPH patients with ADAMTS13 / VWF antigen levels and 28 patients with CTED 
were also included in the CTEPH GWAS.  Genotypes were available for 207 (185 CTEPH; 
22 CTED) after GWAS quality control exclusions.  These patients were included in the 
analysis comparing ADAMTS13 / VWF protein levels to genetic ABO group and the 
protein quantitative trait loci (pQTL) analysis.  Matched genotypes and ADAMTS13 / VWF 
antigen levels were not available for the healthy control, IPAH or PE groups.  
 
Associations between the post-imputation allelic dosages of SNPs in the ADAMTS13 
gene ± 40kb (n=396 SNPs), and log transformed ADAMTS13 protein levels (the 
   
 
 63 
dependent variable) were evaluated using multivariable linear regression.  The model 
was adjusted for age, sex, ADAMTS13 plasma antigen experimental batch and additional 
models were adjusted for the first 5 ancestry informative principal components used in 
the GWAS analysis and VWF antigen levels.  The ADAMTS13 ± 40kb region included the 
ADAMTS13 cis-pQTLs that have previously been described.(201, 231, 232)  A Bonferroni 
p-value threshold <1.26x10-4 (0.05/396 variants) was used to denote statistical 
significance.  Partitioning of the variance explained by each variable within the models 
was performed by averaging over orders using the R package `relaimpo`.(233) 
 
2.2.6  Clinical phenotype data 
Phenotype data for the CTEPH, CTED and IPAH groups was recorded closest to the time 
of diagnosis and pre-operatively for the CTEPH and CTED patients undergoing 
PEA.  This included demographics, haemodynamics, WHO functional class, 6-minute 
walk distance (6mwd), clinical blood tests, smoking history and anticoagulation therapy 
usage.  Additionally, post-operative haemodynamics were recorded within 1 year of 
surgery for the CTEPH and CTED patients that underwent PEA, as part of routine 
care.  Haemodynamics were evaluated by right heart catherisation according to 
international guidelines and PEA was performed as previously described.(1, 7)  The PE 
group had phenotype data recorded at a follow-up visit (median 220 days) after their acute 
PE, which also included a ventilation perfusion (VQ) scan to assess residual perfusion 
defects. 
 
2.2.7  Statistical analysis 
The differences in categorical variables between groups were assessed using Chi-
squared or Fisher’s exact test, and the Cochran-Armitage test for WHO functional 
class.  The differences in continuous variables were assessed using the Mann-Whitney 
U test and the Kruskal-Wallis test.  Post-hoc pairwise diagnostic group comparisons were 
performed using Dunn’s test with false discovery rate (FDR) adjustment for multiple 
testing.  For matched values pre- and post-PEA Wilcoxon signed-rank test was used.  P-
values are reported to 3 decimal places and experimental data are reported to 3 
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significant figures.  Data averages are described as median ± interquartile range unless 
specified. 
 
Group differences in ADAMTS13 and VWF antigen levels were assessed using 
multivariable linear regression.  ADAMTS13 or VWF plasma levels (dependent variables) 
were log-transformed after assessing log-likelihoods using the Box-Cox power 
transformation.  Log-transformed ADAMTS13 and VWF were used in all multivariable 
linear regression models (Tables 4.4, 4.5, 4.8, 4.9, 4.10, 4.11 and 4.12).  The models 
were adjusted for age, sex, experimental batch (Tables 4.4, 4.5, 4.8, 4.9, 4.10, 4.11 and 
4.12) and additionally ethnicity (Tables 4.4, 4.5, 4.9 and 4.10), VWF (Tables 4.4 and 
4.12) and 5 ancestry informative principal components (Table 4.12).  The β coefficients 
and confidence intervals are presented as percentage change ((expβ-1) x 100) to enable 
clinical interpretation of the log-transformed values.  Models were checked for normality 
of residuals, homoscedasticity and multicollinearity (variance inflation factor), with 
additional checks performed using the R package `gvlma`.(234).  Interacting effects 
between the variables that were used in Tables 4.4 and 4.5 were investigated.  The 
significant (p<0.05) and informative interactions were included in additional multivariable 
linear regression models (Table 4.8). 
  
Spearman's rank correlation coefficients were used to describe associations between 
ADAMTS13 or VWF protein levels and clinical phenotypes associated with disease 
severity (pulmonary vascular resistance (PVR), 6mwd and NT-proBNP) and blood 
markers of inflammation (white cell count (WCC), C-reactive protein (CRP), neutrophil 
and lymphocyte percentages).  P-values from correlation testing were corrected 
for multiple testing using false discovery rate (FDR) adjustment.  
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2.3  CTEPH phenotype–genotype associations 
 
2.3.1  Phenotype data 
A minimal phenotype dataset for CTEPH patients was initially requested from recruiting 
centres that included age, sex and disease distribution in the pulmonary arteries 
(surgically accessible = proximal, surgically inaccessible = distal). 
 
Additional CTEPH phenotype–genotype analyses were performed by utilising deeply 
phenotyped CTEPH datasets from Royal Papworth Hospital and other centres where 
available.  A systematic approach was applied when compiling phenotypes to ensure that 
data within centres and ultimately across centres was harmonised and reproducible. 
 
2.3.1.1  Data extraction and quality control steps 
Exploratory analyses of additional CTEPH phenotype-genotype associations used data 
almost exclusively from Royal Papworth Hospital.  The data extraction and quality control 
steps described will predominately focus on this centre and is summarised in Figure 2.5. 
 
CTEPH phenotypes were extracted from separate clinical NHS databases held locally at 
Royal Papworth Hospital.  At the time of data extraction (mid-2017), the databases were 
not linked and searching directly by disease (CTEPH) was not always possible.  When a 
diagnostic search could not be performed, data was extracted using the consultant codes 
of pulmonary hypertension physicians responsible for CTEPH patient care.  The data was 
then merged with a diagnostic list and filtered to include CTEPH patients (Figure 2.5). 
 
Each dataset was quality controlled separately and an overview of the size of each 
starting dataset prior to filtering, and the number of available variables is summarised in 
Table 2.2. 
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Figure 2.5  Flow chart of phenotype data extraction and quality control 
This flow chart applied to the majority of data used for the additional phenotype-genotype 
analyses from Royal Papworth Hospital.  QC (quality control). 
 
 
Quality control steps were performed in R Markdown annotated documents to facilitate 
reproducibility.(235)  Each dataset had separate QC steps, but generally these involved: 
variable name standardisation, data harmonisation, exclusion of extreme outliers, 
exclusion using physiological rules and QC of dates.  Data harmonisation involved 
standardising variable classes (e.g. continuous, characters, factors, dates), standardising 
data groups within variables, and standardising variable units (of measurement).  Data 
was excluded (set to “NA”) if it was outside a range of biologically/physiologically possible 
values (e.g. height 5cm) or if inconsistent with physiological rules (i.e. cardiac output is 
always higher than cardiac index).  Dates were standardised and anchor dates (i.e. date 
of CTEPH diagnosis) were selected to enable the correct assignment of longitudinal data. 
Data extracted from local 
NHS phenotype datasets
Filtered by CTEPH 
diagnosis
Data 
quality control
Datasets 
merged
By “CTEPH” 
diagnosis
By consultant 
code
• Variable name 
standardization
• Data harmonisation
• Exclusion of extreme
outliers
• Exclusion using
physiological rules
• Date QC
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 N variables N total N individuals 
Pulmonary 
Haemodynamics 
30 3,366 2,329 
Pulmonary Function 
tests 
20 12,677 3,448 
QoL 4 17,896 4,206 
WHO FC 2 28,828 4,724 
6mwt 7 11,156 4,152 
Surgical data 90 1,581 1,578 
Clinical blood tests 26 41,744 4,157 
Survival 3 6,753 6,750 
  
Table 2.2  Summary of extracted datasets 
Summary of a selection of the extracted datasets containing CTEPH phenotypes.  
Datasets for demographics, co-morbidities, echocardiography and radiology not shown.  
The number of variables (N variables) for each dataset does not include identification 
numbers, duplicate variables or multiple dates.  The total (N total) number of tests/rows 
for each dataset is shown together with the number of unique individuals, which differ 
from N total if there are multiple tests per individual.  The surgical dataset primarily 
contained patients with CTEPH however, the other datasets were extracted by consultant 
codes or a wider diagnostic group (pulmonary hypertension).  For those datasets, the N 
total and N individuals do not just represent CTEPH patients.  Following QC, these 
datasets were filtered by CTEPH diagnosis.  Datasets varied in the time periods covered 
but generally contained data from 2007-2017.  QoL (Quality of life), WHO FU (World 
Health Organisation functional class), 6mwt (six-minute walking test).  
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After the QC steps, datasets were merged with a diagnostic list of pulmonary 
hypertension groups / subtypes and filtered for CTEPH patients.  Subsequently, 
phenotype data was filtered by patients that had been genotyped and included in the 
GWAS analysis (Section 3.2.2.2).  This enabled additional phenotype-genotype analyses 
to be performed. 
 
2.3.1.2 Data centralisation 
Data centralisation allows disparate datasets from separate tests within a centre (Table 
2.2) and from different centres to be standardised and secured for future use.  
OpenClinica is an open source clinical data capture and management platform 
(https://www.openclinica.com/) utilised for CTEPH data capture.  Electronic case report 
forms (eCRFs) were designed using OpenClinica templates (Figure 2.6).  The content of 
the eCRFs was determined by the data availability from extracted CTEPH datasets.  
Additional parameters were decided by a pulmonary hypertension expert clinical panel 
that comprised 5 pulmonary hypertension physicians and additional researchers (Table 
2.3).  The ultimate aim was to import the extracted CTEPH datasets into OpenClinica and 
have additional functionality for manual data entry that could be shared between centres. 
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Figure 2.6  Electronic case report form for right heart catheterisation data 
A section of an eCRF for right heart catheterisation (RHC) data is displayed.  The eCRF 
is dynamic with certain sections being hidden/displayed dependent on the question 
answers.  Multiple eCRFs were designed for different phenotype data (Table 2.3) 
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Phenotype domain Example eCRF 
ID Centre ID, Research ID, Genotype ID 
Demographics Sex and ethnicity 
Symptoms and risk 
factors 
CTEPH symptoms, co-morbidities, VTE risk factors, VTE 
management, CTEPH risk factors 
Diagnosis MDT diagnosis 
Investigations 6mwt, clinical blood tests, RHC, PFTs,  
Management Medications, PEA, BPA 
Outcome Mortality, longitudinal outcome data (RHC, WHO FC, QoL, 
6mwt) 
 
Table 2.3  Phenotype domains and example eCRFs for OpenClinica data capture 
The CTEPH phenotype groups and example eCRFs for each domain. 
ID (identification), VTE (venous thromboembolism), MDT (multi-disciplinary team), 6mwt 
(six-minute walking test) RHC (right heart catheterisation), PFTs (pulmonary function 
tests), PEA (pulmonary endarterectomy), BPA (balloon pulmonary angioplasty), WHO FC 
(World Health Organisation functional class), QoL (quality of life).  
 
 
2.3.2  GWAS associations 
2.3.2.1  Additional case-control analysis 
Case-control analysis was performed as described in Section 2.1.6.  The loci associated 
with VTE were examined in the CTEPH case-control GWAS to identify differential 
associations.(70)   
 
Abnormalities in haemostasis and fibrinolysis are implicated in the pathobiology of 
CTEPH.  Patients with VTE and CTEPH are treated with anticoagulation, which is 
predominantly the drug warfarin.  GWASs have identified loci associated with warfarin 
metabolism.(236)  In the CTEPH GWAS, these loci were examined to establish whether 
inadequate anticoagulation due to genetic variants related to warfarin metabolism were 
associated.  
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Post-imputation allelic dosages were converted to alleles (A, T, C, G) using PLINK. 
Genotypes for the significant case-control GWAS associations (p<5x10-8) were used in a 
logistic regression model with case/control as the dependent variable.  Genotypes for the 
lead SNP associations were also used in an analysis of CTEPH disease severity.  
Disease severity at baseline (closest to diagnosis) was assessed by right heart catheter 
haemodynamics (mPAP, CI, PVR) for the CTEPH group.  Haemodynamics were also 
stratified by genetic ABO groups (Section 2.1.8) and additional CTEPH severity 
measures (6mwd and WHO FC) were stratified by ABO group. 
 
Survival was investigated in CTEPH patients from Royal Papworth Hospital following PEA 
as this represented the largest group that received the same intervention.  Survival from 
the time of PEA was recorded until April 2018 using a centralised national resource.  Post-
PEA survival differences between genetically inferred ABO groups were assessed using 
Kaplan-Meier plots.  As multiple variables can influence post-PEA survival in CTEPH, a 
cox proportional hazards model was constructed with age, sex and pre-operative disease 
severity (mPAP) as covariables.  The cox models were checked for proportional hazards 
assumptions, influential observations and non-linearity. 
 
2.3.2.2  Additional phenotype-genotype associations 
CTEPH can occur in different pulmonary artery distributions from the central, proximal 
pulmonary arteries to the distal vasculature.  Different risk factors have been associated 
with distal and proximal CTEPH and this may reflect differing pathobiological 
mechanisms.(11, 78)  Disease distribution (proximal (operable) or distal (surgically 
inaccessible) disease) was used as the dependent variable in a logistic regression 
analysis within CTEPH cases.  SNP allelic dosages, 5 ancestry informative principal 
components (Section 2.1.4.3), age, sex and recruiting centre were included in the model 
as independent variables. 
 
Distal CTEPH and post-PEA persistent or recurrent PH have been grouped together for 
clinical drug trials.(24)  The rationale is that post-PEA PH may be due to residual distal 
disease, as the more proximal chronic thromboembolic material has been removed.  A 
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separate logistic regression analysis was performed comparing proximal CTEPH with 
distal CTEPH and post-PEA residual PH. 
 
Patients can have a comparable amount of chronic thromboembolic obstruction but 
differing degrees of pulmonary hypertension and right ventricular adaptation.(237)  
Pulmonary and right ventricular adaptation may be associated with different genetic 
associations within CTEPH.  Linear regression was performed with either mPAP, CI or 
PVR as the dependent variable and the independent variables included SNP allelic 
dosages, 5 ancestry informative principal components, age, sex and recruiting centre. 
 
2.4  Software and online tools 
 
The analyses were performed using the following software and online tools: GAS online 
power calculator(203), Genomestudio (version(v)2.0)(206), PLINK (v1.90beta)(208), 
bcftools (v1.4.1)(238), LDLink(217), Snptest (v2.5.4-beta3)(220), fumaGWAS 
(v1.3.2)(221), LocusZoom (v0.4.8)(239), gnomAD(240), Ensembl 37 (241), R 
(v3.4.3)(235) and RStudio (v1.1.414)(242).  The R packages used included: MASS(243), 
coin(244), gvlma(234), PMCMR(245), SNPRelate(211), relaimpo(233), jtools(246), 
forestmodel(247), forestplot(248), survival(249), survminer(250) and the tidyverse 
suite(251). 
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3  GWAS 
 
3.1  Introduction 
 
Investigating CTEPH aetiology and pathobiology has been challenging for several 
reasons.  Firstly, no small animal model exists that adequately recapitulates failure of 
thrombus resolution or the chronic pulmonary artery and right ventricular changes 
observed in CTEPH.  Secondly, investigating biological pathways related to 
haemostasis and fibrinolysis is confounded by anticoagulation treatment that all 
CTEPH patients receive.  Finally, CTEPH is an uncommon complication of PE 
affecting ~3% of PE survivors.  Therefore, very large cohorts of extensively 
phenotyped individuals post-PE would be required to establish the genetic and 
environmental drivers of CTEPH development. 
 
GWAS has the potential to circumvent some of the challenges to investigating the 
aetiology of CTEPH (Section 1.2.2.7).  A case-control GWAS was performed to 
compare SNP allele frequencies between CTEPH patients and healthy controls.  The 
statistically significant associations will guide subsequent investigation of CTEPH 
pathobiology.  As three-quarters of CTEPH patients have had a preceding pulmonary 
embolism the ultimate aim is to identify unique and differential genetic associations 
from resolved PE.  This may also inform and enhance clinical risk prediction post-PE. 
 
Royal Papworth Hospital and the University of Cambridge are optimally positioned to 
perform and co-ordinate this multi-centre international study.  Royal Papworth Hospital 
is the National referral centre for pulmonary endarterectomy, the surgical operation to 
remove chronic scarred blood clots from the proximal pulmonary arteries of CTEPH 
patients.  An extensive biobank of CTEPH samples has been established that have 
been utilised in the CTEPH GWAS. 
 
The aim of this Chapter was to perform a GWAS in CTEPH to identify genetic 
associations with disease susceptibility. 
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3.2  Results 
 
3.2.1  Study samples and participants 
1555 CTEPH cases and 1536 healthy control samples were recruited and genotyped 
from 6 international centres (Figure 3.1A).  CTEPH samples were genotyped in 3 
batches from 2014-2016 (Figure 3.1B).  All healthy controls samples (WTCCC) were 
genotyped in batch1 (Figure 3.1C).  Royal Papworth Hospital was the largest 
recruiting centre (n=747) and together with Hammersmith Hospital, Imperial 
Healthcare NHS trust, made up the discovery cohort (n=841).  The remaining 
European and US centres comprised the validation cohort (n=714). 
 
 
 
Figure 3.1  GWAS sample numbers prior to exclusions 
A Starting sample numbers for CTEPH cases by centre and B genotyping batch 
(batch1: 2014, batch2: 2015, batch3: 2016).  
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C Starting sample numbers for CTEPH cases and healthy controls (WTCCC) by 
centre and batch. 
n displayed at the top of each count bar.  Bad Nauheim (Kerckhoff Heart and Lung 
Centre, Bad Nauheim, Germany); Papworth (Royal Papworth Hospital, Cambridge, 
UK), Imperial (Hammersmith Hospital, Imperial College Healthcare NHS Trust, 
London, UK), Leuven (KU Leuven - University of Leuven, Leuven, Belgium), San 
Diego (University of California, San Diego, USA), Vienna (Medical University, Vienna, 
Austria), WTCCC (Wellcome Trust Case Control Consortium, UK). 
 
 
3.2.2  Study exclusions and GWAS quality control 
3.2.2.1  Sample exclusions: overview 
A total of 349 samples (CTEPH cases = 305 (20%), healthy controls = 44 (3%)) were 
excluded from the study (Figure 3.2).  Samples were excluded on the basis of 
thresholds and criteria defined in the methods (Section 2.1.4.3) for ancestry, 
heterozygosity, relatedness, sample genotype missingness and administrative (i.e. 
incorrect disease phenotype) (Figure 3.2).  The relatively high CTEPH case 
exclusions of 28% (n = 134) for batch1 and  31% (n=140) for batch2, improved to 11% 
(n = 69) for batch3 (Figure 3.2B). 
 
The number of exclusions from the healthy control WTCCC group (n=44) was similar 
to other studies which have used the same healthy control cohort.(204) 
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Figure 3.2  GWAS sample exclusions 
A Sample exclusion numbers for CTEPH cases and healthy controls (WTCCC) by 
centre and batch  
B Sample exclusions for CTEPH cases by genotyping batch and C centre. 
The "Total (unique)” row in B and C represents the distinct individual sample 
exclusions.  As samples could be excluded on more than one criterion, the individual 
exclusions do not equal the "Total (unique)" values.  Administrative reasons were due 
to either the incorrect disease phenotype (non-CTEPH) or non-Caucasian (self-
reported) samples that were identified after micro-arraying.  There were no exclusions 
for the San Diego centre (not shown).   
n displayed at the top of each count bar.  n=343 exclusions (unique) in Figure 3.2A-
C There was an additional n=6 exclusions when batch1, batch2 and batch3 were 
merged due to relatedness, resulting in n=349 total GWAS exclusions. 
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3.2.2.2  Sample exclusions: GWAS quality control 
Samples for exclusion from the study were identified by quality control steps outlined 
in Figure 2.2 (Materials and Methods).  Following genotype calling, samples with a 
genotype missingness of >1% were excluded (n: batch1=20, batch2=41, 
batch3=5).  The rationale for this approach is described in Section 
3.2.2.3.2.  Subsequently, each sample quality control step was performed on all the 
remaining samples prior to further sample removal.   
 
Firstly, samples were identified and excluded due to administrative reasons (incorrect 
phenotype or self-reported ethnicity) (n: batch1=6, batch2=81, batch3=2).   
 
Principal component analysis using a robust set of independent SNPs was used to 
identify samples with outlying ancestry (n: batch1=51, batch2=19, batch3=60) (Figure 
3.3).  Samples were initially excluded if they did not cluster with super-populations 
from 1000 genomes data (Figure 3.3A, D and G).  PCA was then repeated, and 
samples that did not cluster with 1000 genomes European populations were excluded 
(Figure 3.3B, E and H).  The remaining CTEPH cases and healthy controls cluster 
with the 1000 genomes European populations (Figure 3.3C, F and I). 
 
Sample relatedness (including duplicates) was assessed by estimating identity by 
descent in PLINK.  Samples were excluded if they had a proportion of IBD score 
(PI_HAT) > 0.1875, which approximates to a threshold between a 2nd and 3rd degree 
relative (n: batch1=54, batch2=2, batch3=7) (Figure 3.4).  In the WTCCC healthy 
control group there were 23 individual samples with IBD scores above the QC 
threshold (only half of which would have been excluded), which is similar to other 
studies that have used the same healthy control cohort.(204) 
 
DNA quality was assessed by excluding samples with outlying genotype missingness 
(>1%) and outlying heterozygosity (Figure 3.5).  The genotype missingness exclusion 
step was previously described and is performed after genotype calling.  Samples with 
high or low heterozygosity rates can represent contamination or inbreeding 
respectively and were excluded if they were ± 3 standard deviations from the mean of 
the batch group (n: batch1=30, batch2=10, batch3=12).(142) 
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Figure 3.3  Divergent ancestry assessed by principal component analysis 
Batch1 (A-C) contains both CTEPH cases and healthy control samples, and Batch2 (D-F) and Batch3 (G-I) contain CTEPH cases 
only. 
The first column of plots (A, D and G) are PCAs including the 1000 genomes super-populations (AFR, AMR, EAS, EUR and 
SAS).  The second column of plots (B, E and H) are PCAs including the 1000 genomes European (EUR) populations (CEU, FIN, 
GBR, IBS and TSI).  The third column of plots (C, F and I) are the PCAs after samples with divergent ancestry have been 
excluded.  The horizontal and vertical black lines in A, B, D, E, G and H are the clustering exclusion thresholds, set by visual 
inspection.  Group colours vary across plots and are defined in the individual legends. 
Study samples: CASE (CTEPH cases), CON (WTCCC healthy controls) 
Super populations: AFR (African), AMR (Admixed American), EAS (East Asian), EUR (European), SAS (South Asian). 
Populations: CEU (Utah Residents (CEPH) with Northern and Western European Ancestry), FIN (Finnish in Finland), GBR (British in 
England and Scotland), IBS (Iberian Population in Spain), TSI (Toscani in Italia). 
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Figure 3.4  Sample relatedness assessed by identity by descent 
The proportion of identity by descent (IBD) between pair-wise samples was 
determined in PLINK using the PI_HAT parameter.  PI_HAT ranges from 0 (unrelated) 
to 1 (duplicate or monozygotic twins).  PI_HAT is calculated by: P(IBD=2) + 0.5 
x P(IBD=1), where P(IBD=2) and P(IBD=1) are the probabilities that at a given locus 
2 or 1 alleles respectively are identical by descent.(207)  Sample pairs are plotted on 
the x-axis (Batch1=1,983,036, Batch2=55,955, Batch3=190,036).  The dotted red 
horizontal line represents a PI_HAT threshold of 0.1875 with excluded samples shown 
by red triangles.  For a pair of samples with high PI_HAT values, the sample with the 
lowest sample genotype rate was excluded.  
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Figure 3.5  Outlying sample heterozygosity plotted against sample genotype 
missingness 
The autosomal heterozygosity rate and genotype missingness were calculated using 
PLINK.  The dotted red horizontal and vertical lines represent thresholds of a 
heterozygosity rate ± 3 standard deviations from the mean and a genotype 
missingness of 1% respectively.  No sample outliers for genotype missingness are 
displayed as they were removed during an earlier QC step.  Missingness values were 
converted to log10 to improve visualisation. 
 
 
Sex discordance between centre-reported sex and genotype determined sex was 
assessed from X-chromosome homozygosity rates using PLINK (Figure 3.6).  PLINK 
assigns a male or female genotype if the X-chromosome homozygosity estimate is 
>0.8 and <0.2 respectively.(208)  There were 19, 1 and 8 samples that had discordant 
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sex in batches 1,2 and 3.  Sex discordance may arise for legitimate reasons in addition 
to sample handling and identification problems.  Patients with a self-reported gender 
different to that assigned at birth may be receiving oestrogen therapy and at increased 
risk of venous thromboembolism and potentially CTEPH.  To retain sample numbers, 
disease phenotypes were confirmed separately with centres and no exclusions were 
made due to discordant sex. 
 
 
 
Figure 3.6  Discordant sex for individual samples 
Discordant sex was assessed using X-chromosome homozygosity calculated in 
PLINK.  The dotted horizontal grey lines represent thresholds of 0.8 and 0.2 for male 
and female genotype assignment respectively.  The red triangles represent individual 
samples with discordant sex.  An X-chromosome homozygosity score of between 0.2-
0.8 was called as missing genotype sex. 
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Following quality control exclusions, 1250 CTEPH cases and 1492 healthy controls 
remained for genetic imputation and statistical association testing.  The number of 
individual samples for each centre and genotyping batch are summarised in Figure 
3.7.   
 
 
Figure 3.7  Total sample numbers following QC exclusions 
Sample numbers for CTEPH cases by A centre and B batch.  C Sample numbers for 
CTEPH cases and healthy controls by batch and centre. 
n displayed at the top of each count bar. 
 
 
3.2.2.3  SNP exclusions: GWAS quality control 
3.2.2.3.1  SNP exclusions: overview 
A total of 31,344 (3% of total), 27,692 (3%) and 35,648 (4%) SNPs were excluded 
from batches1, 2 and 3 respectively during quality control steps prior to genetic 
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imputation (Table 3.1).  SNPs were excluded on the basis of thresholds and criteria 
defined in Section 2.1.4.4 for micro-array intensity clustering and genotype calling 
quality, genotype missingness and deviation from Hardy-Weinberg equilibrium.  A 
minor allele frequency threshold was not applied until post-imputation. 
 
 
Batch1  Batch2  Batch3  
Starting SNPs 964193  964193  964193  
SNPs excluded 31344 27692 35648 
SNPs after QC removals 932849  936501   928545  
 
Table 3.1  Total number of SNP exclusions per batch prior to imputation 
 
 
3.2.2.3.2  Micro-array clustering, genotype calling and exclusions 
After the initial micro-array clustering and genotype calling using GenomeStudio(252), 
there were a disproportionate number of samples that were removed by applying 
clustering quality scores (GenTrain score < 0.7 and clustering separation score < 0.5) 
between batches (Table 3.2).  There were 30,289 and 35,648 removed from batches1 
and 3 respectively however, 468,806 were removed from batch2.  Failure to apply 
clustering quality scores resulted in false positive associations (Figure 3.8).  Manual 
inspection of micro-array data intensity plots for isolated significant SNPs confirmed 
that many were due to poor quality clustering (Figure 3.9). 
 
 
Batch1  Batch2  Batch3  
Starting SNPs 964193  964193  964193  
SNPs excluded 
GeneTrain score < 0.7 
Clustering separation score < 0.5 
30289  468806  35648  
SNPs after clustering QC removal 933904  495387  92854 
 
Table 3.2  SNP exclusions from micro-array clustering quality thresholds that 
were applied without a re-clustering step 
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The number of SNPs that were excluded when clustering quality thresholds were 
applied after micro-array clustering and genotype calling without the sample 
missingness exclusions and re-clustering steps. 
 
 
 
Figure 3.8  Manhattan plot of all associations including incorrect genotype 
clustering and calling 
This was an interim analysis of batch1 and batch2 data (CTEPH cases = 900, healthy 
controls = 1495) with similar quality control steps for samples and SNPs as described 
in the methods.  An additive model of association was applied using logistic regression 
and adjusted for 1 principal component prior to genetic imputation.  Manual inspection 
of micro-array intensity plots for isolated significant SNPs confirmed that many were 
due to poor quality micro-array intensity clustering. 
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Figure 3.9  Micro-array intensity clustering and false positive associations 
Micro-array intensity clustering for two biallelic SNPs with A good and B poor 
clustering, which fails to adequately separate the AB and BB genotypes.  Intensities 
for Allele A and B are plotted for each SNP, which generates 3 genotypes (coloured 
blue, purple and red).  A GenomeStudio algorithm was used for micro-array clustering 
and genotype calling.  SNPs with poor quality clustering that are not adequately 
removed by quality control steps can result in false positive associations. 
 
 
High missingness in a few individual samples has the potential to skew the SNP 
genotype calling algorithms.  To address the discordant number of SNPs removed 
from each batch when only a clustering quality score was applied, the micro-array 
intensity clustering and genotype calling methodology was refined.  First, micro-array 
clustering and genotype calling were performed, then samples with a missingness of 
greater than 1% were removed, followed by genotype re-clustering (cases and 
controls) and finally, SNPs were excluded using genotype clustering quality 
scores.  This resulted in a marked improvement in batch2 SNP exclusions (n=26,198) 
(Table 3.3) and similar exclusions from batches 1 (n=28,124) and 3 (n=33,212) 
respectively.  Applying a more stringent sample missingness threshold of 1% resulted 
in increased sample exclusions (1% sample missingness threshold: batch1=20, 
batch2=41, batch3=15 vs. 5% sample missingness threshold: batch1=6, batch2=15, 
batch3=5).  This was acceptable given the marked improvement in SNP retention.   
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3.2.2.3.3  SNP genotype missingness, deviations from Hardy-Weinberg 
distribution and pre-imputation minor allele frequency 
Low quality individual SNPs were excluded if their genotype missingness was greater 
than 1% (n: batch1=1746, batch2=1283, batch3=2180) (Figure 3.10).  SNPs with a 
differential missingness (p < 1x10-5) between cases and controls were also 
excluded.  This was only applied to batch 1 (n=1113 SNPs) as this was the only batch 
containing both cases and controls.  As batches were subsequently merged on 
intersecting SNPs, then these SNP removals applied to all batches. 
 
 
Figure 3.10  Genotype missingness SNP exclusions 
The red dotted vertical line in A, B and C represents a missingness of 1%.  The red 
dotted vertical line in D presents a p-value of 1x10-5 for differential missingness 
between CTEPH cases and healthy controls.  The axes are plotted on a log1p (e.g. 
log(x+1)) scale to allow visualisation of zero values for A-D.  P-values have been 
transformed to -log10 values in D. 
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If SNPs are in Hardy-Weinberg equilibrium their allele and genotype frequencies can 
be estimated between generations.  Deviation from HWE can occur due to genotyping 
errors, population stratification or a genuine disease association.(213)  There were 
only a modest number of SNPs excluded due to HWE (batch1=1094, batch2=291, 
batch3=425) (Figure 3.11) potentially due to the stringent genotype clustering 
exclusion QC step. 
 
 
 
Figure 3.11  SNP Hardy-Weinberg equilibrium exclusions 
The red dotted vertical line in A-C represents a p-value of 1x10-6, below which SNPs 
were considered to have deviated from HWE and were excluded.  The axes are plotted 
on a log1p scale to allow visualisation of zero values and p-values have been 
transformed to a -log10 value. 
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SNPs were not excluded due to a minor allele frequency prior to imputation.  The 
distribution of the minor allele frequency for each batch pre-imputation is shown in 
Figure 3.12. 
 
 
 
Figure 3.12  SNP minor allele frequency distribution prior to imputation 
The axes are plotted on a log1p scale to allow visualisation of zero values. 
 
 
A summary of the QC SNP exclusions prior to imputation is shown in Table 
3.3.  Batches 1, 2 and 3 were merged on an intersecting set of SNPs (n=915,999) and 
between-batch related samples were excluded as described in Section 3.2.2.2.  The 
data was then submitted for genetic imputation as described in the methods. 
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Exclusion 
threshold  
Batch1  Batch2  Batch3  
Starting SNPs 
 
964193  964193  964193  
Genotype clustering 
exclusions 
GenTrain < 0.7 
Clustering 
separation < 0.5 
28124  26198  33212 
SNP missingness exclusions > 1%   1746   1283   2180   
SNP differential missingness 
exclusions 
p < 1x10-5   1113   NA   NA   
Divergent Hardy-
Weinberg equilibrium 
p < 1x10-6   1094   291   425   
Total (unique) SNPs 
excluded   
 
31344 27692 35648 
SNPS after QC removals 
 
932849  936501   928545  
 
Table 3.3  SNP exclusions for each quality control step 
SNPs could be excluded on more than one criterion therefore, the individual SNP 
exclusions do not equal the "Total (unique)" values.  
 
 
3.2.2.3.4  Post GWAS QC: minor allele frequency and imputation quality 
Following genetic imputation there were ~40 million variants.  Imputation quality was 
assessed using an information (INFO) score parameter.  This ranged on a scale of 0-
1 from poor to high quality imputation (Figure 3.13).  Variants with an INFO score 
below 0.5 were excluded.  SNPs with low minor allele frequencies can be challenging 
for genotype clustering algorithms to call and are also more difficult to impute, which 
can result in false positive associations.(142)  SNPs were excluded if they had a low 
minor allele frequency (<1%) (Figure 3.14). 
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Figure 3.13  SNP imputation quality 
The information (INFO) score was a parameter supplied following genetic imputation 
to assess the imputation quality.  The dashed vertical red line represents an 
information score threshold of 0.5 below which, SNPs were excluded (n=18,043,895). 
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Figure 3.14  Minor allele frequency post imputation 
The dashed red vertical line represents a MAF threshold of 1% below which, variants 
were excluded (n=32,676,650).  The axes are plotted on a log1p scale to allow 
visualisation of zero values. 
 
 
After removal of SNPs with low imputation quality, low minor allele frequency and 
multi-allelic SNPs there were 7,675,738 remaining for association testing. 
 
3.2.2.4  Residual population structure 
Residual population structure was assessed after QC exclusions and prior to 
imputation for each batch and after merging batches 1, 2 and 3 on a common 
intersecting SNP set.  PCAs were performed and principal components were 
visualised using up to 20 eigenvector pairs to detect outlying clusters (Figures 3.15 
and 3.16; the first 5 eigenvector pairs are shown).  These principal components were 
used for to adjust for residual population structure in subsequent association testing. 
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Figure 3.15  Principal component analysis to detect residual population 
structure for each batch 
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PCAs were performed on individual batches prior to merging on a common SNP 
set.  The first two eigenvectors are displayed in A, C and E, and the first 5 pairs of 
eigenvectors are shown in B, D and F including the percentage of variation that is 
explained by the pair.  Up to 20 eigenvector pairs were visualised (not 
shown).  Colours used to represent centres vary between plots. 
BN (Bad Nauheim), IMP (Imperial), LEU (Leuven), PAP (Papworth), SD (San 
Diego), VIE (Vienna), WTCCC (Wellcome Trust Case Control Consortium). 
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Figure 3.16  Principal component analysis to detect residual population 
structure for combined batches 
PCAs were performed for all CTEPH cases and healthy controls following QC 
exclusions and merging batches, but prior to genetic imputation.  PCA plots have been 
coloured by A, B centre and C, D batch.  The first two eigenvectors are displayed in 
A, C, and the first 5 pairs of eigenvectors are shown in B, D including the percentage 
of variation that is explained by the pair.  Up to 20 eigenvector pairs were visualised 
(not shown). 
BN (Bad Nauheim), IMP (Imperial), LEU (Leuven), PAP (Papworth), SD (San 
Diego), VIE (Vienna), WTCCC (Wellcome Trust Case Control Consortium). 
 
 
3.2.2.5  Study participant characteristics post-QC 
The baseline characteristics of the case-control groups following QC exclusions are 
summarised in Table 3.4.  There was no difference in sex however, CTEPH cases 
were older than healthy controls (median ± IQR: 65 ± 22 vs. 45 ± 18; p < 0.001).  It 
was not necessary to adjust for age in the GWAS statistical association testing as the 
prevalence of CTEPH in the general population (< 1/30,000) is low and any 
confounding due to the presence of CTEPH in the healthy control group (unidentified 
or new incident cases with increasing age) was unlikely.  
 
 
Healthy Controls CTEPH cases p 
Study participants, n 1492 1250 
 
Sex: Female, n (%) 795 (52) 712 (49) 0.164 
Age, median ± IQR 45 ± 18 65 ± 22 < 0.001 
 
Table 3.4  Baseline characteristics for the case-control groups included in 
association testing 
Group differences in sex and age assessed by Chi-squared test and Mann-Whitney U 
test respectively. 
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3.2.3  GWAS statistical association testing 
Following genetic imputation, the data for the discovery and validation cohorts were 
combined in one dataset.  A joint analysis was initially performed prior to dividing the 
data into discovery and validation cohorts.  This also enabled selection of the most 
appropriate number of principal components to adjust for residual population structure 
that were then applied to the discovery and validation groups.  The composition of the 
discovery and validation cohorts was determined a priori.  The discovery cohort was 
comprised of UK centres and the remaining European and US centres made up the 
validation cohort.   
 
3.2.3.1  Joint analysis: discovery and validation cohorts combined 
3.2.3.1.1  Association testing without covariates 
Imputed genotype dosages were used to test for an association between the CTEPH 
and healthy control groups.  Logistic regression assuming an additive genetic model 
was applied to each SNP marker.  When no covariates were used to adjust the models 
there are at least 4 associated loci, however the genomic inflation factor is elevated 
(lambda = 1.22) (Figure 3.17).  The inflation factor is estimated by comparing the 
median of observed and expected test statistics.(145)  Genomic inflation values above 
1 can indicate population stratification or genotyping errors.(145)  When the data is 
divided into discovery and validation cohorts (Sections 3.2.3.2 and 3.2.3.3) and 
association testing repeated without additional covariates, the genomic inflation is 
higher in the validation cohort (lambda = 1.03 vs. 1.47) (Figure 3.18).  As samples 
comprising the discovery and validation groups were genotyped across batches, the 
elevated genomic inflation values are a likely consequence of population 
stratification.  This can result in false positive associations due to differences in 
ancestry rather than a genuine disease association.(213)  To adjust for confounding 
from population stratification, eigenvectors from the pre-imputation PCAs (Section 
3.2.2.4) were included as covariates in the logistic regression models. 
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Figure 3.17  Case-control association testing without additional covariates: joint 
analysis 
Analysis of 1250 CTEPH cases (discovery and validation cohorts combined), 1492 
healthy controls and 7,675,738 SNPs.  The same healthy control group was used for 
the discovery and validation cohorts.  Statistical testing of individual SNPs using allelic 
dosage (range 0-2) for an association with CTEPH diagnosis was performed using 
logistic regression assuming an additive genetic model without additional 
covariates.  A p-value of <5x10-8 was considered genome-wide significant (dotted grey 
line B).  Genomic inflation factor (lambda)=1.22.   
A Quantile-quantile (QQ) plot of the observed and expected p-values. 
B Manhattan plot of p-values plotted against genomic position. 
P-values are transformed to a -log10 scale. 
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Figure 3.18  Case-control association testing without covariates: discovery and 
validation cohorts 
Manhattan plots of A Discovery and B Validation cohorts. 
Statistical testing without additional covariates was performed as described in Figure 
3.17.  The genomic inflation factor (lambda) for the discovery and validation cohorts 
are 1.03 and 1.47 respectively. 
 
 
3.2.3.1.2  Association testing adjusted for population stratification 
The first 2 eigenvectors were most significantly associated (p=1.48x10-57 and 
p=2.35x10-30) with the case-control group when logistic regression was performed 
(Table 3.5).  As the fifth eigenvector was nominally associated, the first 5 ancestry 
informative principal components were used to adjust for residual population 
stratification.  This markedly improved the genomic inflation (lambda = 1.04) and 
confirmed that the elevation was due to residual population substructure (Figure 
3.19).  As other eigenvectors were nominally associated (EV11 and EV16) with case-
control status, up to 20 were included as covariates in GWAS association 
testing.  These did not improve the genomic inflation further (lambda: EV1-10 = 1.05, 
EV1-20 = 1.05) and therefore, only the first 5 ancestry informative principal 
components were used for subsequent association testing.  
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β SE  p  
EV1  -43.0  2.69  1.48e-57  
EV2  30.0 2.62  2.35e-30  
EV3  -1.20 2.32  0.604  
EV4  0.884  2.22  0.690  
EV5  3.82 2.21  0.084  
EV6  1.32 2.21  0.550  
EV7  -0.376 2.20  0.864  
EV8  0.705 2.20  0.748  
EV9  2.71 2.21  0.220  
EV10  -1.86 2.19  0.396  
EV11  -6.51  2.22  0.003  
EV12  0.306  2.20  0.889  
EV13  2.78  2.21  0.209  
EV14  0.74  2.20  0.737  
EV15  -0.0785  2.20  0.972  
EV16  -3.98  2.20  0.071  
EV17  -0.0619  2.20  0.978  
EV18  0.237 2.19  0.914  
EV19  2.79 2.20  0.205  
EV20  3.40  2.20  0.122 
 
Table 3.5  Ancestry informative eigenvectors and case-control status 
Logistic regression of eigenvectors (EV) 1-20 on case-control status (case/control 
group ~ EV1 + EV2 + … + EV20).  The most significant eigenvectors are EV1 and 
EV2.  β (beta coefficient), SE (standard error), p (p-value). 
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Figure 3.19  Case-control association testing with 5 ancestry informative 
principal components: joint analysis 
Case-control association testing of 1250 CTEPH cases and 1492 controls using allelic 
dosages and assuming an additive genetic model adjusted for the first 5 ancestry 
informative principal components. 
A QQ plot and B Manhattan plot 
Genomic inflation factor (lambda)=1.04 
 
 
There were 87 significantly associated SNPs (p<5x10-8) (Table 3.6) that were all 
located in chromosome 9.  The lead SNP (rs2519093, OR (95% CI) = 2.4 (2.3-2.5), 
p=3.42x10-31) is an intronic variant in the ABO gene.  Rs2519093 was well imputed 
(INFO=0.951) with an effect allele (T) frequency of 0.165 in healthy controls and 0.316 
in CTEPH cases.  This compared with effect allele frequencies in reference 
populations of 0.182 (European (non-Finnish) in 1000 genomes phase 3) and 0.198 
(European (non-Finnish) in gnomAD).(240) 
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rsID  CHR:POS_EA/NEA  GENE  FUNC  EAF_A  EAF_U  EAF_REF  INFO  OR (95% CI)  p  
rs2519093  9:136141870_T/C  ABO  intronic  0.316  0.165  0.182  0.951  2.4 (2.25-2.55)  3.42e-31  
rs532436  9:136149830_A/G  ABO  intronic  0.316  0.165  0.185  0.965  2.39 (2.24-2.53)  7.01e-31  
rs507666  9:136149399_A/G  ABO  intronic  0.316  0.166  0.185  0.965  2.38 (2.23-2.53)  8.89e-31  
rs635634*  9:136155000_T/C  ABO  intergenic  0.321  0.174  0.185  0.977  2.31 (2.16-2.46)  2.87e-29  
rs600038  9:136151806_C/T  ABO  intergenic  0.331  0.189  0.218  0.965  2.16 (2.02-2.3)  2.61e-26  
rs651007*  9:136153875_T/C  ABO  intergenic  0.330  0.189  0.215  0.971  2.13 (1.99-2.27)  7.1e-26  
rs579459*  9:136154168_C/T  ABO  intergenic  0.330  0.189  0.215  1.000  2.12 (1.98-2.26)  9.08e-26  
rs649129  9:136154304_T/C  ABO  intergenic  0.330  0.189  0.215  0.988  2.12 (1.98-2.27)  1.44e-25  
rs495828  9:136154867_T/G  ABO  intergenic  0.330  0.189  0.215  0.964  2.13 (1.99-2.27)  2e-25  
rs550057  9:136146597_T/C  ABO  intronic  0.386  0.241  0.280  0.972  2.03 (1.9-2.17)  5.88e-25  
rs9411378  9:136145425_A/C  ABO  intronic  0.380  0.236  0.290  0.887  2.09 (1.95-2.23)  6.5e-24  
rs529565  9:136149500_C/T  ABO  intronic  0.463  0.313  0.345  0.976  1.9 (1.77-2.02)  4.42e-23  
rs505922*  9:136149229_C/T  ABO  intronic  0.463  0.313  0.345  1.000  1.88 (1.75-2)  6.75e-23  
rs582094  9:136145484_T/A  ABO  intronic  0.463  0.315  0.350  0.990  1.89 (1.76-2.01)  7.08e-23  
rs2769071  9:136145974_G/A  ABO  intronic  0.463  0.315  0.350  0.971  1.9 (1.77-2.03)  7.81e-23  
rs582118  9:136145471_G/A  ABO  intronic  0.463  0.315  0.350  0.991  1.88 (1.76-2.01)  7.89e-23  
rs676996  9:136146077_G/T  ABO  intronic  0.463  0.315  0.353  0.991  1.88 (1.76-2.01)  8.1e-23  
rs597988  9:136144284_A/T  ABO  intronic  0.463  0.315  0.348  0.992  1.88 (1.76-2.01)  8.11e-23  
rs677355  9:136146046_A/G  ABO  intronic  0.463  0.315  0.353  0.971  1.9 (1.77-2.03)  8.12e-23  
rs492488  9:136144960_A/G  ABO  intronic  0.463  0.315  0.350  0.989  1.88 (1.76-2.01)  8.74e-23  
rs676457  9:136146227_T/A  ABO  intronic  0.463  0.315  0.350  0.991  1.88 (1.75-2.01)  1.05e-22  
rs687289*  9:136137106_A/G  ABO  intronic  0.463  0.315  0.353  0.989  1.88 (1.76-2.01)  1.1e-22  
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rs493246  9:136144994_A/G  ABO  intronic  0.463  0.315  0.350  0.999  1.87 (1.74-1.99)  1.79e-22  
rs495203  9:136145240_T/C  ABO  intronic  0.463  0.315  0.350  0.999  1.86 (1.74-1.99)  1.8e-22  
rs514659*  9:136142203_C/A  ABO  intronic  0.463  0.315  0.350  1.000  1.86 (1.74-1.99)  1.92e-22  
rs8176663  9:136144427_C/T  ABO  intronic  0.463  0.315  0.350  1.000  1.86 (1.74-1.99)  1.93e-22  
rs491626  9:136144873_T/C  ABO  intronic  0.463  0.315  0.350  1.000  1.86 (1.74-1.99)  1.93e-22  
rs545971  9:136143372_T/C  ABO  intronic  0.463  0.315  0.350  1.000  1.86 (1.74-1.99)  1.94e-22  
rs612169  9:136143442_G/A  ABO  intronic  0.463  0.315  0.348  1.000  1.86 (1.74-1.99)  1.94e-22  
rs687621*  9:136137065_G/A  ABO  intronic  0.463  0.315  0.350  1.000  1.86 (1.74-1.99)  2.27e-22  
rs527210  9:136146431_T/C  ABO  intronic  0.462  0.315  0.350  0.977  1.88 (1.75-2.01)  2.33e-22  
rs674302  9:136146664_A/T  ABO  intronic  0.463  0.315  0.350  0.999  1.86 (1.74-1.99)  2.41e-22  
rs554833  9:136147160_T/C  ABO  intronic  0.463  0.315  0.350  0.997  1.86 (1.74-1.99)  2.46e-22  
rs494242  9:136145118_T/C  ABO  intronic  0.478  0.339  0.377  0.985  1.79 (1.67-1.91)  4.19e-20  
rs644234  9:136142217_G/T  ABO  intronic  0.478  0.339  0.377  0.994  1.78 (1.65-1.9)  7.08e-20  
rs8176645  9:136149098_A/T  ABO  intronic  0.463  0.322  0.375  0.735  2.02 (1.86-2.17)  7.23e-20  
rs613534  9:136143120_G/A  ABO  intronic  0.478  0.339  0.377  0.995  1.78 (1.65-1.9)  7.42e-20  
rs543968  9:136143121_C/T  ABO  intronic  0.478  0.339  0.377  0.995  1.78 (1.65-1.9)  7.42e-20  
rs544873  9:136143212_A/G  ABO  intronic  0.478  0.339  0.377  0.995  1.78 (1.65-1.9)  7.42e-20  
rs643434  9:136142355_A/G  ABO  intronic  0.478  0.339  0.377  0.996  1.77 (1.65-1.9)  8.2e-20  
rs657152*  9:136139265_A/C  ABO  intronic  0.478  0.339  0.377  1.000  1.76 (1.63-1.88)  2.54e-19  
rs11244061  9:136153981_T/C  ABO  intergenic  0.187  0.102  0.120  0.947  2.1 (1.93-2.28)  7.95e-17  
rs11244084  9:136191010_T/C  LCN1P2  intergenic  0.165  0.091  0.075  0.850  2.03 (1.84-2.22)  1.38e-13  
rs142956930  9:136143330_G/A  ABO  intronic  0.131  0.066  0.017  0.513  3.31 (2.99-3.63)  3.57e-13  
rs8176681  9:136139754_T/C  ABO  intronic  0.654  0.548  0.592  0.990  1.54 (1.42-1.66)  3.36e-12  
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rs2073827  9:136137133_G/C  ABO  intronic  0.653  0.548  0.592  0.989  1.54 (1.42-1.66)  3.58e-12  
rs2073828  9:136137140_G/A  ABO  intronic  0.653  0.548  0.595  0.989  1.54 (1.41-1.66)  4.34e-12  
rs559723  9:136150484_A/G  ABO  intronic  0.382  0.490  0.498  0.988  1.53 (1.41-1.65)  4.67e-12  
rs616154  9:136150466_C/T  ABO  intronic  0.382  0.491  0.500  0.976  1.53 (1.41-1.65)  7.16e-12  
rs630014*  9:136149722_A/G  ABO  intronic  0.381  0.489  0.495  1.000  1.52 (1.4-1.64)  8.23e-12  
rs630510  9:136149581_A/G  ABO  intronic  0.381  0.489  0.495  0.998  1.52 (1.4-1.64)  8.39e-12  
rs8176690  9:136138317_A/G  ABO  intronic  0.653  0.548  0.592  0.980  1.53 (1.41-1.65)  8.97e-12  
rs2073826  9:136136963_G/T  ABO  intronic  0.652  0.548  0.595  0.977  1.52 (1.4-1.65)  1.22e-11  
rs8176715  9:136133148_T/C  ABO  intronic  0.379  0.481  0.410  0.917  1.52 (1.4-1.65)  5.19e-11  
rs8176668  9:136144059_A/T  ABO  intronic  0.669  0.572  0.617  0.977  1.5 (1.38-1.63)  7.19e-11  
rs7873635  9:136132012_T/C  ABO  intronic  0.333  0.428  0.383  0.831  1.58 (1.45-1.72)  7.56e-11  
rs7046674  9:136147012_C/T  ABO  intronic  0.669  0.571  0.620  0.991  1.5 (1.38-1.62)  7.87e-11  
rs8176649  9:136147295_G/A  ABO  intronic  0.669  0.571  0.620  0.992  1.5 (1.38-1.62)  7.95e-11  
rs7036642  9:136144626_G/A  ABO  intronic  0.669  0.572  0.620  0.985  1.5 (1.38-1.62)  9.6e-11  
rs3124761  9:136339755_C/T  SLC2A6  intronic  0.799  0.877  0.838  0.876  1.76 (1.59-1.93)  9.77e-11  
rs3094379  9:136334910_C/T  CACFD1  UTR3  0.798  0.876  0.838  0.887  1.75 (1.58-1.92)  1.25e-10  
rs8176691  9:136138229_C/T  ABO  intronic  0.668  0.572  0.620  0.989  1.49 (1.37-1.61)  1.78e-10  
rs8176682*  9:136139297_C/T  ABO  intronic  0.668  0.572  0.620  0.990  1.49 (1.37-1.61)  1.86e-10  
rs3124764  9:136329954_C/T  CACFD1  intronic  0.800  0.877  0.840  0.892  1.74 (1.57-1.91)  1.91e-10  
rs3124765  9:136328657_C/T  CACFD1  exonic  0.800  0.877  0.892   0.892  1.74 (1.57-1.91)  2.13e-10  
rs4962153*  9:136323754_G/A  ADAMTS13  intronic  0.800  0.877  0.838  0.900  1.72 (1.55-1.89)  3.01e-10  
rs3124766  9:136316942_A/G  ADAMTS13  intronic  0.200  0.124  0.162  0.906  1.71 (1.54-1.88)  3.4e-10  
rs28645493*  9:136305738_G/C  ADAMTS13  intronic  0.140  0.076  0.098  1.000  1.86 (1.66-2.05)  3.44e-10  
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rs739468  9:136326248_G/T  CACFD1  intronic  0.799  0.875  0.838  0.897  1.71 (1.54-1.88)  4.07e-10  
rs8176702  9:136136146_G/A  ABO  intronic  0.667  0.572  0.620  0.976  1.48 (1.36-1.6)  4.19e-10  
rs4962040  9:136133531_A/G  ABO  intronic  0.666  0.571  0.617  0.973  1.47 (1.35-1.6)  6.55e-10  
rs500499  9:136148648_G/C  ABO  intronic  0.362  0.454  0.432  0.959  1.47 (1.35-1.6)  8.6e-10  
rs500498  9:136148647_T/C  ABO  intronic  0.362  0.454  0.432  0.959  1.47 (1.35-1.6)  8.71e-10  
rs36222279  9:136315974_C/G  ADAMTS13  intronic  0.139  0.076  0.098  0.926  1.86 (1.66-2.06)  9.92e-10  
rs476410  9:136148368_G/C  ABO  intronic  0.362  0.454  0.432  0.961  1.47 (1.35-1.59)  1.01e-09  
rs41302667  9:136330428_A/G  CACFD1  intronic  0.138  0.076  0.098  0.911  1.87 (1.67-2.07)  1.18e-09  
rs645982  9:136148409_A/G  ABO  intronic  0.362  0.453  0.432  0.961  1.47 (1.34-1.59)  1.24e-09  
rs28602660  9:136312071_A/G  ADAMTS13  intronic  0.140  0.077  0.100  0.938  1.85 (1.65-2.04)  1.41e-09  
rs475419  9:136148231_C/T  ABO  intronic  0.362  0.453  0.432  0.979  1.45 (1.33-1.58)  2.17e-09  
rs660340  9:136147553_A/G  ABO  intronic  0.362  0.453  0.432  0.979  1.45 (1.33-1.58)  2.2e-09  
rs581107  9:136147702_C/T  ABO  intronic  0.362  0.453  0.432  0.979  1.45 (1.33-1.57)  2.24e-09  
rs28446901  9:136308796_G/C  ADAMTS13  intronic  0.234  0.149  0.180  0.920  1.62 (1.46-1.78)  2.34e-09  
rs473533  9:136148035_T/C  ABO  intronic  0.362  0.453  0.432  0.962  1.45 (1.33-1.58)  2.88e-09  
rs659104  9:136147823_T/G  ABO  intronic  0.362  0.453  0.432  0.970  1.45 (1.32-1.57)  4.1e-09  
rs633862  9:136155444_C/T  ABO  intergenic  0.367  0.455  0.448  0.971  1.43 (1.31-1.55)  6e-09  
rs558240*  9:136157133_A/G  ABO  intergenic  0.492  0.402  0.405  1.000  1.4 (1.29-1.52)  7.44e-09  
rs647800  9:136148000_A/G  ABO  intronic  0.347  0.429  0.405  0.975  1.41 (1.29-1.54)  3.48e-08 
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Table 3.6  Significant SNPs in the joint analysis 
 
Association testing for 1250 CTEPH cases, 1492 healthy controls and 7,675,738 SNPs post-imputation were included in the 
analysis.  Statistical testing of individual SNPs using allelic dosage (range 0-2) for an association with CTEPH diagnosis was 
performed using logistic regression assuming an additive genetic model.  5 principal components were used to adjust for any residual 
population structure.  A p-value of <5x10-8 was considered genome-wide significant and SNPs are ordered by significance.  The 
Genome Reference Consortium human genome (build 37) (GRCh37) was used for genomic positions.  The allele frequencies and 
the odds ratios are for the effect alleles.  P-values are displayed using exponential notation.  * SNPs with an asterisk were present 
on the micro-array chip pre-imputation and those without have been imputed.  rsID (reference SNP cluster ID), CHR (chromosome), 
POS (base position), EF (effect allele), NEA (non-effect allele), GENE (nearest gene for the SNP, from ANNOVAR), FUNC (functional 
consequence of the SNP on the gene, from ANNOVAR), EAF_A (effect allele frequency of CTEPH patients), EAF_U (effect allele 
frequency of healthy controls), EAF_REF (effect allele frequency of reference, 1000 genomes phase 3 European (non-Finnish) 
populations), INFO (information score, imputation quality), OR (odds ratio), p (p-value). 
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To ensure that the disease associations for CTEPH were not being confounded by 
recruiting centre or genotyping batch, separate within case analyses that included only 
CTEPH patients were undertaken.  Linear regression was performed with batch or 
centre as the dependent variable and the SNP allelic dosage as the independent 
variable, additionally adjusted for 5 ancestry informative principal components.  This 
confirmed that centre and batch were not major sources of confounding (Figure 
3.20).   
 
 
Figure 3.20  Batch and centre association testing with CTEPH 
Linear regression was performed with batch or centre as the dependent variable with 
the CTEPH group (n=1250): Batch or centre ~ SNP allelic dosage + EV1 + … + EV5. 
 
 
3.2.3.1.3  Independent associations 
The majority of the associated SNPs in the chromosome 9 locus were in close 
proximity to the ABO gene (Figure 3.21).  There was an additional cluster of significant 
SNPs around the ADAMTS13 gene that were in moderate to low linkage disequilibrium 
with the significant ABO SNPs (Figures 3.21 and 3.22).  These ADAMTS13 SNPs 
were not significant when the analysis was conditioned on the lead SNP in the ABO 
locus (rs2519093), indicating that they are not independently associated (Figure 
3.23).  There were no secondary associations in the ABO locus when conditioned on 
the lead ABO SNP (Figure 3.23).  
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Figure 3.21  Regional association plot of the associated locus in chromosome 9 
SNP p-values are plotted against genomic position and were generated with the 
association testing described in Figure 3.19.  The most statistically significant SNP 
(9:136141870=rs2519093) is plotted in purple with the correlation (linkage 
disequilibrium, from 1000 Genomes and HapMap) with respect to it, shown on a colour 
scale from red (high) to dark blue (low).  Gene positions are shown on the bottom 
panel of each plot.  The recombination rates (from HapMap) are plotted on the right 
axis.  The regional association plot was generated using Locuszoom.(239)  Some 
gene track annotations have been omitted to improve visualisation. 
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Figure 3.22  Linkage disequilibrium heat maps of significant SNPs in the ABO 
and ADAMTS13 loci 
   
 
 109 
Pairwise SNP correlations for the significant SNPs in chromosome 9 were used to 
calculate LD using PLINK for the parameters R2 .  SNPs were assigned to the ABO or 
the ADAMTS13 locus depending on their proximity to the nearest gene.  Each axis 
tick mark represents a SNP (displayed as CHR:POS).  The LD range is from low LD 
(0; no correlation) to high LD (1; perfect correlation).   
 
 
 
 
 
Figure 3.23  Conditional analysis at the associated chromosome 9 locus 
A Regional association plot of the significant locus from the analysis described in 
Figure 3.19 and shown in Figure 3.21. 
B The analysis was repeated and conditioned on the lead SNP in ABO to identify 
independent associations (case/control group ~ SNP allelic dosage + lead ABO SNP 
(rs2519093) + EV1+ … + EV5).  The dotted horizontal lines represent a p-value 
threshold of 5x10-8. 
 
 
3.2.3.2  Discovery cohort analysis 
The discovery cohort included 678 CTEPH cases from UK centres (Papworth and 
Imperial) and 1492 healthy controls following quality control and imputation.  The data 
was divided into discovery and validation cohorts from the combined datasets using a 
priori group definitions.  Association testing was performed as described for the joint 
analysis using logistic regression with post-imputation SNP dosages (n=7,675,738) 
assuming an additive model and adjusted for 5 principal components.  There were 68 
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associated SNPs in chromosomes 4 and 9 (Figure 3.24 and Table 3.7).  The lead 
SNP in chromosome 4 (rs2036914, OR (95% CI) = 1.43 (1.30-1.56), p =4.79x10-8) was 
an intronic variant in the F11 gene.  The associated locus in chromosome 9 was the 
same as for the joint analysis, with the same lead intronic SNP (rs2519093) in ABO. 
 
 
 
Figure 3.24  Associated loci in the discovery cohort 
Association testing for 678 CTEPH cases and 1492 healthy controls.  Logistic 
regression was performed using post-imputation SNP dosages (n=7,675,738) 
assuming an additive model and adjusted for 5 ancestry informative principal 
components. 
A Manhattan plot of the discovery cohort associations 
B Regional association plot of the chromosome 4 locus in proximity to the F11 gene 
C Regional association plot of the chromosome 9 locus in proximity to the ABO gene 
Some gene tracks are omitted to improve visualisation 
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rsID  CHR:POS_EA/NEA  GENE  FUNC  EAF_A  EAF_U  EAF_REF  INFO  OR (95% CI)  p  
rs2519093  9:136141870_T/C  ABO  intronic  0.298  0.165  0.182  0.951  2.22 (2.06-2.38)  1.42e-22  
rs532436  9:136149830_A/G  ABO  intronic  0.297  0.165  0.185  0.965  2.21 (2.05-2.37)  2.89e-22  
rs507666  9:136149399_A/G  ABO  intronic  0.297  0.166  0.185  0.965  2.2 (2.04-2.36)  3.77e-22  
rs635634*  9:136155000_T/C  ABO  intergenic  0.302  0.174  0.185  0.977  2.14 (1.98-2.29)  4.47e-21  
rs600038*  9:136151806_C/T  ABO  intergenic  0.316  0.189  0.218  0.965  2.04 (1.88-2.19)  1.57e-19  
rs651007*  9:136153875_T/C  ABO  intergenic  0.316  0.189  0.215  0.971  2 (1.85-2.15)  3.86e-19  
rs579459*  9:136154168_C/T  ABO  intergenic  0.316  0.189  0.215  1.000  1.99 (1.84-2.14)  4.47e-19  
rs649129  9:136154304_T/C  ABO  intergenic  0.316  0.189  0.215  0.988  2 (1.85-2.15)  5.61e-19  
rs495828  9:136154867_T/G  ABO  intergenic  0.316  0.189  0.215  0.964  2 (1.85-2.16)  7.95e-19  
rs550057  9:136146597_T/C  ABO  intronic  0.370  0.241  0.280  0.972  1.93 (1.79-2.08)  2e-18  
rs9411378  9:136145425_A/C  ABO  intronic  0.364  0.236  0.290  0.887  1.99 (1.83-2.14)  7.19e-18  
rs529565  9:136149500_C/T  ABO  intronic  0.448  0.313  0.345  0.976  1.82 (1.68-1.96)  2.67e-17  
rs687289*  9:136137106_A/G  ABO  intronic  0.448  0.315  0.353  0.989  1.81 (1.67-1.95)  4.53e-17  
rs2769071  9:136145974_G/A  ABO  intronic  0.448  0.315  0.350  0.971  1.82 (1.68-1.96)  4.77e-17  
rs505922*  9:136149229_C/T  ABO  intronic  0.447  0.313  0.345  1.000  1.8 (1.66-1.93)  4.82e-17  
rs677355  9:136146046_A/G  ABO  intronic  0.448  0.315  0.353  0.971  1.82 (1.68-1.96)  5e-17  
rs597988  9:136144284_A/T  ABO  intronic  0.448  0.315  0.348  0.992  1.8 (1.67-1.94)  5.1e-17  
rs492488  9:136144960_A/G  ABO  intronic  0.448  0.315  0.350  0.989  1.81 (1.67-1.94)  5.15e-17  
rs582118  9:136145471_G/A  ABO  intronic  0.448  0.315  0.350  0.991  1.8 (1.67-1.94)  5.21e-17  
rs582094  9:136145484_T/A  ABO  intronic  0.448  0.315  0.350  0.990  1.8 (1.67-1.94)  5.27e-17  
rs676996  9:136146077_G/T  ABO  intronic  0.448  0.315  0.353  0.991  1.8 (1.67-1.94)  5.38e-17  
rs676457  9:136146227_T/A  ABO  intronic  0.447  0.315  0.350  0.991  1.8 (1.66-1.94)  6.59e-17  
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rs687621*  9:136137065_G/A  ABO  intronic  0.448  0.315  0.350  1.000  1.79 (1.65-1.93)  7.91e-17  
rs493246  9:136144994_A/G  ABO  intronic  0.448  0.315  0.350  0.999  1.79 (1.65-1.93)  9.06e-17  
rs495203  9:136145240_T/C  ABO  intronic  0.448  0.315  0.350  0.999  1.79 (1.65-1.93)  9.14e-17  
rs514659*  9:136142203_C/A  ABO  intronic  0.448  0.315  0.350  1.000  1.79 (1.65-1.92)  9.26e-17  
rs545971  9:136143372_T/C  ABO  intronic  0.448  0.315  0.350  1.000  1.79 (1.65-1.92)  9.32e-17  
rs612169  9:136143442_G/A  ABO  intronic  0.448  0.315  0.348  1.000  1.79 (1.65-1.92)  9.32e-17  
rs8176663  9:136144427_C/T  ABO  intronic  0.448  0.315  0.350  1.000  1.79 (1.65-1.92)  9.32e-17  
rs491626  9:136144873_T/C  ABO  intronic  0.448  0.315  0.350  1.000  1.79 (1.65-1.92)  9.32e-17  
rs527210  9:136146431_T/C  ABO  intronic  0.446  0.315  0.350  0.977  1.8 (1.66-1.94)  1.06e-16  
rs674302  9:136146664_A/T  ABO  intronic  0.447  0.315  0.350  0.999  1.79 (1.65-1.92)  1.17e-16  
rs554833  9:136147160_T/C  ABO  intronic  0.447  0.315  0.350  0.997  1.79 (1.65-1.92)  1.17e-16  
rs494242  9:136145118_T/C  ABO  intronic  0.466  0.339  0.377  0.985  1.74 (1.6-1.88)  1.48e-15  
rs644234  9:136142217_G/T  ABO  intronic  0.466  0.339  0.377  0.994  1.73 (1.59-1.86)  2.11e-15  
rs8176645  9:136149098_A/T  ABO  intronic  0.451  0.322  0.375  0.735  1.95 (1.78-2.11)  2.23e-15  
rs613534  9:136143120_G/A  ABO  intronic  0.466  0.339  0.377  0.995  1.73 (1.59-1.86)  2.29e-15  
rs543968  9:136143121_C/T  ABO  intronic  0.466  0.339  0.377  0.995  1.73 (1.59-1.86)  2.29e-15  
rs544873  9:136143212_A/G  ABO  intronic  0.466  0.339  0.377  0.995  1.73 (1.59-1.86)  2.29e-15  
rs643434  9:136142355_A/G  ABO  intronic  0.466  0.339  0.377  0.996  1.72 (1.59-1.86)  2.47e-15  
rs657152*  9:136139265_A/C  ABO  intronic  0.466  0.339  0.377  1.000  1.71 (1.58-1.85)  4.92e-15  
rs11244061  9:136153981_T/C  ABO  intergenic  0.176  0.102  0.120  0.947  1.97 (1.78-2.16)  2.44e-12  
rs11244084  9:136191010_T/C  LCN1P2  intergenic  0.159  0.091  0.075  0.850  1.92 (1.72-2.13)  2.5e-10  
rs142956930  9:136143330_G/A  ABO  intronic  0.125  0.066  0.017  0.513  2.99 (2.65-3.34)  5.83e-10  
rs559723  9:136150484_A/G  ABO  intronic  0.392  0.490  0.498  0.988  1.51 (1.37-1.64)  2.03e-09  
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rs616154  9:136150466_C/T  ABO  intronic  0.392  0.491  0.500  0.976  1.51 (1.37-1.64)  2.64e-09  
rs630014*  9:136149722_A/G  ABO  intronic  0.391  0.489  0.495  1.000  1.5 (1.36-1.63)  2.69e-09  
rs630510  9:136149581_A/G  ABO  intronic  0.391  0.489  0.495  0.998  1.5 (1.36-1.63)  2.86e-09  
rs8176681  9:136139754_T/C  ABO  intronic  0.642  0.548  0.592  0.990  1.49 (1.35-1.62)  6.94e-09  
rs2073827  9:136137133_G/C  ABO  intronic  0.642  0.548  0.592  0.989  1.49 (1.35-1.62)  7.75e-09  
rs2073828  9:136137140_G/A  ABO  intronic  0.642  0.548  0.595  0.989  1.49 (1.35-1.62)  8.7e-09  
rs7873635  9:136132012_T/C  ABO  intronic  0.340  0.428  0.383  0.831  1.57 (1.41-1.72)  1.18e-08  
rs8176690  9:136138317_A/G  ABO  intronic  0.642  0.548  0.592  0.980  1.48 (1.34-1.61)  1.34e-08  
rs2073826  9:136136963_G/T  ABO  intronic  0.642  0.548  0.595  0.977  1.48 (1.34-1.61)  1.59e-08  
rs8176715  9:136133148_T/C  ABO  intronic  0.387  0.481  0.410  0.917  1.49 (1.35-1.63)  2.25e-08  
rs8176649  9:136147295_G/A  ABO  intronic  0.661  0.571  0.620  0.992  1.47 (1.34-1.61)  2.31e-08  
rs3124761  9:136339755_C/T  SLC2A6  intronic  0.808  0.877  0.838  0.876  1.7 (1.52-1.89)  2.33e-08  
rs7046674  9:136147012_C/T  ABO  intronic  0.661  0.571  0.620  0.991  1.47 (1.34-1.61)  2.34e-08  
rs8176668  9:136144059_A/T  ABO  intronic  0.661  0.572  0.617  0.977  1.47 (1.34-1.61)  2.41e-08  
rs3124765  9:136328657_C/T  CACFD1  exonic  0.808  0.877  0.839   0.892  1.7 (1.51-1.88)  2.59e-08  
rs3124764  9:136329954_C/T  CACFD1  intronic  0.808  0.877  0.840  0.892  1.7 (1.51-1.88)  2.75e-08  
rs3094379  9:136334910_C/T  CACFD1  UTR3  0.808  0.876  0.838  0.887  1.69 (1.51-1.88)  2.75e-08  
rs7036642  9:136144626_G/A  ABO  intronic  0.661  0.572  0.620  0.985  1.47 (1.33-1.61)  2.78e-08  
rs28645493*  9:136305738_G/C  ADAMTS13  intronic  0.131  0.076  0.098  1.000  1.81 (1.6-2.02)  3.27e-08  
rs4962153*  9:136323754_G/A  ADAMTS13  intronic  0.808  0.877  0.838  0.900  1.68 (1.5-1.87)  3.54e-08  
rs8176682*  9:136139297_C/T  ABO  intronic  0.660  0.572  0.620  0.990  1.46 (1.32-1.6)  4.52e-08  
rs8176691*  9:136138229_C/T  ABO  intronic  0.660  0.572  0.620  0.989  1.46 (1.32-1.6)  4.77e-08  
rs2036914  4:187192481_T/C  F11  intronic  0.386  0.479  0.485  1.000  1.43 (1.3-1.56)  4.79e-08 
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Table 3.7  Significant SNPs in the discovery cohort 
Association testing for 678 CTEPH cases and 1492 healthy controls.  Logistic regression was performed using post-imputation SNP 
dosages (n=7,675,738) assuming an additive model and adjusted for 5 ancestry informative principal components.  * SNPs with an 
asterisk were present on the micro-array chip pre-imputation and those without have been imputed.  The column headings and 
additional details are described in Table 3.6. 
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3.2.3.3  Validation cohort analysis 
The validation cohort included 572 CTEPH cases from other European and US centres 
and the same 1492 healthy controls following quality control and 
imputation.  Association testing was performed as described for the joint analysis and 
discovery cohort.  There were 37 associated SNPs in chromosome 9 (Figure 3.25 and 
Table 3.8).  The associated locus in chromosome 9 was the same as for the joint 
analysis and discovery cohort, with the same lead intronic SNP (rs2519093) in 
ABO.  The odds ratio for the lead SNP is higher in the validation cohort than in the 
discovery cohort (OR: 2.2 vs. 2.7) and there is a corresponding higher effect allele 
frequency in the CTEPH group (EAF: 0.337 vs. 0.298).  The significant chromosome 
4 locus identified in the discovery cohort was not replicated in the validation cohort. 
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Figure 3.25  Associated loci in the validation cohort 
Association testing for 572 CTEPH cases and 1492 healthy controls.  Logistic 
regression was performed using post-imputation SNP dosages (n=7,675,738) 
assuming an additive model and adjusted for 5 ancestry informative principal 
components. 
A Manhattan plot of the discovery cohort associations 
B Regional association plot of the chromosome 9 locus in proximity to the ABO gene 
Some gene tracks are omitted to improve visualisation. 
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rsID  CHR:POS_EA/NEA  GENE  FUNC  EAF_A  EAF_U  EAF_REF  INFO  OR (95% CI)  p  
rs2519093  9:136141870_T/C  ABO  intronic  0.337  0.165  0.182  0.951  2.72 (2.48-2.96)  2.92e-16  
rs532436  9:136149830_A/G  ABO  intronic  0.338  0.165  0.185  0.965  2.72 (2.48-2.96)  2.95e-16  
rs507666  9:136149399_A/G  ABO  intronic  0.338  0.166  0.185  0.965  2.72 (2.48-2.96)  2.98e-16  
rs635634*  9:136155000_T/C  ABO  intergenic  0.343  0.174  0.185  0.977  2.65 (2.41-2.89)  1.64e-15  
rs600038  9:136151806_C/T  ABO  intergenic  0.348  0.189  0.218  0.965  2.37 (2.14-2.61)  7.18e-13  
rs651007*  9:136153875_T/C  ABO  intergenic  0.348  0.189  0.215  0.971  2.34 (2.1-2.57)  1.07e-12  
rs579459*  9:136154168_C/T  ABO  intergenic  0.348  0.189  0.215  1.000  2.32 (2.09-2.55)  1.11e-12  
rs495828  9:136154867_T/G  ABO  intergenic  0.348  0.189  0.215  0.964  2.34 (2.11-2.58)  1.43e-12  
rs649129  9:136154304_T/C  ABO  intergenic  0.347  0.189  0.215  0.988  2.33 (2.09-2.56)  1.51e-12  
rs550057  9:136146597_T/C  ABO  intronic  0.405  0.241  0.280  0.972  2.22 (2-2.45)  4.19e-12  
rs9411378  9:136145425_A/C  ABO  intronic  0.398  0.236  0.290  0.887  2.28 (2.04-2.52)  2.02e-11  
rs582094  9:136145484_T/A  ABO  intronic  0.482  0.315  0.350  0.990  1.95 (1.74-2.16)  5.44e-10  
rs505922*  9:136149229_C/T  ABO  intronic  0.482  0.313  0.345  1.000  1.94 (1.73-2.15)  5.45e-10  
rs2769071  9:136145974_G/A  ABO  intronic  0.482  0.315  0.350  0.971  1.96 (1.75-2.18)  5.82e-10  
rs677355  9:136146046_A/G  ABO  intronic  0.482  0.315  0.353  0.971  1.96 (1.75-2.18)  5.83e-10  
rs676996  9:136146077_G/T  ABO  intronic  0.482  0.315  0.353  0.991  1.95 (1.73-2.16)  5.84e-10  
rs676457  9:136146227_T/A  ABO  intronic  0.482  0.315  0.350  0.991  1.95 (1.73-2.16)  5.84e-10  
rs582118  9:136145471_G/A  ABO  intronic  0.482  0.315  0.350  0.991  1.94 (1.73-2.16)  5.88e-10  
rs529565  9:136149500_C/T  ABO  intronic  0.481  0.313  0.345  0.976  1.95 (1.74-2.16)  5.99e-10  
rs597988  9:136144284_A/T  ABO  intronic  0.482  0.315  0.348  0.992  1.94 (1.73-2.15)  6.37e-10  
rs492488  9:136144960_A/G  ABO  intronic  0.482  0.315  0.350  0.989  1.94 (1.73-2.15)  6.81e-10  
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rs687289*  9:136137106_A/G  ABO  intronic  0.482  0.315  0.353  0.989  1.94 (1.73-2.15)  8.56e-10  
rs674302  9:136146664_A/T  ABO  intronic  0.482  0.315  0.350  0.999  1.92 (1.71-2.13)  9.11e-10  
rs493246  9:136144994_A/G  ABO  intronic  0.482  0.315  0.350  0.999  1.92 (1.71-2.13)  9.16e-10  
rs495203  9:136145240_T/C  ABO  intronic  0.482  0.315  0.350  0.999  1.92 (1.71-2.13)  9.17e-10  
rs554833  9:136147160_T/C  ABO  intronic  0.482  0.315  0.350  0.997  1.92 (1.71-2.13)  9.53e-10  
rs514659*  9:136142203_C/A  ABO  intronic  0.482  0.315  0.350  1.000  1.92 (1.71-2.13)  9.97e-10  
rs545971  9:136143372_T/C  ABO  intronic  0.482  0.315  0.350  1.000  1.92 (1.71-2.13)  1e-09  
rs612169  9:136143442_G/A  ABO  intronic  0.482  0.315  0.348  1.000  1.92 (1.71-2.13)  1e-09  
rs8176663  9:136144427_C/T  ABO  intronic  0.482  0.315  0.350  1.000  1.92 (1.71-2.13)  1e-09  
rs491626  9:136144873_T/C  ABO  intronic  0.482  0.315  0.350  1.000  1.92 (1.71-2.13)  1e-09  
rs11244061  9:136153981_T/C  ABO  intergenic  0.199  0.102  0.120  0.947  2.43 (2.15-2.72)  1.04e-09  
rs527210  9:136146431_T/C  ABO  intronic  0.481  0.315  0.350  0.977  1.93 (1.72-2.15)  1.08e-09  
rs687621*  9:136137065_G/A  ABO  intronic  0.482  0.315  0.350  1.000  1.92 (1.71-2.13)  1.16e-09  
rs558240*  9:136157133_A/G  ABO  intergenic  0.511  0.402  0.405  1.000  1.77 (1.58-1.97)  1.54e-08  
rs8176645  9:136149098_A/T  ABO  intronic  0.478  0.322  0.375  0.735  2.05 (1.8-2.3)  2.98e-08  
rs142956930  9:136143330_G/A  ABO  intronic  0.139  0.066  0.017  0.513  4.35 (3.82-4.87)  4.18e-08 
 
Table 3.8  Significant SNPs in the validation cohort 
Association testing for 572 CTEPH cases and 1492 healthy controls.  Logistic regression was performed using post-imputation 
SNP dosages (n=7,675,738) assuming an additive model and adjusted for 5 ancestry informative principal components.  * SNPs 
with an asterisk were present on the micro-array chip pre-imputation and those without have been imputed.  The column headings 
and additional details are described in Table 3.6. 
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3.2.3.4  Genotyping quality of the significant GWAS associations 
To confirm that the significant associations described in the ABO locus and the F11 
locus (for the discovery cohort analysis) were adequately genotyped, the micro-array 
clustering plots were examined.  Prior to imputation, association testing was 
performed in a joint analysis of all samples (CTEPH cases=1250, Healthy 
controls=1492) and 640,744 SNPs (275,255 SNPs were excluded by a MAF threshold 
of <1%).  Logistic regression adjusted for 5 ancestry informative principal components 
identified the lead SNP in these two regions as rs635634 (9:136155000_T/C, OR 2.34, 
p=5.71x10-30) and rs2289252 (4:187207381_T/C, OR=1.34, p=7.97x10-7) (Table 3.9 
and Figure 3.26).  Micro-array clustering was adequate for these two SNPs, which 
confirmed that the associations were not due to genotyping errors (Figure 3.27). 
 
rsID CHR:POS_EA/NEA GENE FUNC OR (95% CI) P 
rs635634  9:136155000_T/C ABO intergenic 2.34 (2.19-2.48) 5.71e-30 
rs651007  9:136153875_T/C ABO intergenic 2.12 (1.98-2.25) 9.08e-26 
rs579459  9:136154168_C/T ABO intergenic 2.12 (1.98-2.25) 9.08e-26 
rs505922  9:136149229_C/T ABO intronic 1.88 (1.75-2) 6.75e-23 
rs687289  9:136137106_A/G ABO intronic 1.86 (1.73-1.98) 3.31e-22 
rs514659  9:136142203_C/A ABO intronic 1.86 (1.74-1.99) 1.92e-22 
rs687621  9:136137065_G/A ABO intronic 1.86 (1.74-1.99) 2.27e-22 
rs657152  9:136139265_A/C ABO intronic 1.76 (1.63-1.88) 2.54e-19 
rs630014  9:136149722_A/G ABO intronic 1.52 (1.4-1.64) 8.23e-12 
rs8176682  9:136139297_C/T ABO intronic 1.48 (1.36-1.6) 2.18e-10 
rs4962153  9:136323754_G/A ADAMTS13 intronic 1.66 (1.5-1.82) 5.44e-10 
rs28645493  9:136305738_G/C ADAMTS13 intronic 1.86 (1.66-2.05) 3.44e-10 
rs558240  9:136157133_A/G ABO intergenic 1.4 (1.29-1.52) 8.74e-09 
 
Table 3.9  Significant SNPs in the pre-imputation GWAS analysis 
Association testing for 1250 CTEPH cases and 1492 healthy controls prior to 
imputation using the SNPs available on the original micro-array chip (n=640,744 SNPs 
following QC).  Logistic regression was performed using pre-imputation SNPs 
assuming an additive model and adjusted for 5 ancestry informative principal 
components.  The column headings and additional details are described in Table 3.6. 
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Figure 3.26  Case-control association testing pre-imputation 
Analysis of 1250 CTEPH cases (discovery and validation cohorts combined), 1492 
healthy controls and 640,744 SNPs.  Logistic regression was performed using pre-
imputation SNPs assuming an additive model and adjusted for 5 ancestry informative 
principal components.  A p-value of <5x10-8 was considered genome-wide significant 
(dotted grey line B).  Genomic inflation factor (lambda)=1.05.   
A Quantile-quantile (QQ) plot of the observed and expected p-values. 
B Manhattan plot of p-values plotted against genomic position. 
P-values are transformed to a -log10 scale. 
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Figure 3.27  Micro-array clustering plots for the lead SNP associations 
A, B and C micro-array cluster plots for the lead SNP association rs635634 in 
chromosome 9 prior to imputation from a joint analysis. 
D, E and F micro-array cluster plots for the lead SNP association rs2289252 in 
chromosome 9 prior to imputation from a joint analysis. 
Micro-array plot interpretation is described in Figure 3.9.  
 
 
3.2.4  The ABO association 
The ABO locus was associated with CTEPH in the discovery, validation and joint 
analysis.  ABO groups have been associated with CTEPH in international 
observational studies with an over-representation of non-O blood groups.(68)  There 
are different risk associations within the non-O blood groups for venous 
thromboembolism.  The A1 subtype has a higher VTE risk association than the A2 
subgroup, however both would be classified as blood group A on serological 
testing.(253)  Reconstructing genetic ABO groups enabled investigation of CTEPH 
associations with comprehensive ABO subgroups. 
 
A B C
D E F
Batch1 Batch2 Batch3
rs635634 rs635634 rs635634
rs2289252 rs2289252 rs2289252
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The allele frequencies of the 4 “tagging" SNPs used to reconstruct the ABO subgroups 
are shown in Table 3.10.  The SNP associated with the A1 ABO group (rs507666) is 
over-represented in CTEPH compared with study healthy controls and a European 
(non-Finnish) reference population (EAF: 0.316 vs. 0.166 vs. 0.185 respectively) 
(Table 3.10).  This SNP is also the third most significant association in the joint 
analysis (OR (95% CI): 2.38 (2.23-2.53), p=8.89x10-31) and highly correlated with the 
lead SNP (LDlink: R2 = 0.991, p<0.001, European (non-Finnish)).  Conversely, the 
SNP that tags the O ABO group is under-represented in CTEPH compared with 
healthy controls and a reference population (EAF: 0.537 vs. 0.685 vs. 0.647 
respectively) (Table 3.10).  The SNPs tagging the A2 and B subgroups have similar 
allele frequencies in CTEPH and healthy controls. 
 
Reconstructing ABO subgroups resulted in 10 genotype groups (A1A1, A1A2, A1B, 
A1O, A2A2, A2B, A2O, BB, BO, OO), from which blood groups A, B, AB and O were 
inferred.  The A1 group was enriched in CTEPH compared with healthy controls 
(Figure 3.28A).  The inferred A blood group occurred in 719 (59%) CTEPH cases and 
567 (38%) healthy controls (Figure 3.28B).  The inferred O blood group was under-
represented in CTEPH (317 (26%)) compared with healthy controls (697 (47%)). 
 
The risk of CTEPH differed within the comprehensive genetic non-O groups with the 
highest risk in the A1A1 group (OR (95% CI) 4.39 (2.92-6.69), p<0.001) and the 
subgroups enriched by A1 (Figure 3.29A).  Interestingly, the risk of CTEPH was not 
increased in the largest A2 enriched group (A2O: OR (95% CI) 1.11 (0.80-1.53), 
p=0.544) but was increased in the equivalent A1 group (A1O: 3.04 (2.46-3.75), 
p<0.001).  The risk of CTEPH was increased in the largest B enriched subgroup (BO: 
1.66 (1.22-2.27), p<0.001) but the magnitude was less than the A1 enriched groups.  
The risk of CTEPH was increased in the A, B and AB groups when they were inferred 
from the 10 comprehensive genetic ABO genotypic groups (Figure 3.29B).  The 
differential effects of A1 and A2 on CTEPH risk results in a lower odds ratio for the A 
groups (containing A1 and A2) than described for A1 enriched subgroups in Figure 
3.29A. 
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Genetic ABO group rsID CHR:POS_EA/NEA EAF_A EAF_U EAF_REF OR (95% CI) p  
O rs687289 9:136137106_G/A 0.537 0.685 0.647 0.53 (0.50-0.57)  1.10e-22 
A1 rs507666 9:136149399_A/G  0.316  0.166 0.185 2.38 (2.23-2.53)  8.89e-31 
A2 rs8176704 9:136135552_A/G  0.062 0.072 0.090 0.88 (0.64-1.13)  0.324 
B rs8176746 9:136131322_T/G 0.077  0.073 0.066 1.04 (0.82-1.27)  0.711 
 
Table 3.10  Effect allele frequencies for the tagging SNPs used to reconstruct ABO subgroups  
The odds ratios and allele frequencies are for the effect allele which tags the ABO subgroup (see Table 2.1 Material and Methods).  
Consequently, for rs687289 the effect and non-effect alleles are reversed compared to those reported in Tables 3.6 - 3.8.  The 
column headings and additional details are described in Table 3.6. 
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Figure 3.28  Genetic ABO groups in CTEPH and healthy controls 
A The percentages of the comprehensive genotypic ABO groups 
B The percentages of the inferred A, AB, B and O ABO groups 
The numbers in each group are shown in Figure 3.29. 
 
 
ABO group frequencies can vary by populations and subpopulations.(254)  To 
investigate whether the ABO association was being driven by allele frequency 
differences in certain subpopulations, the genetic ABO group frequencies were 
subdivided by centre (Figure 3.30).  In CTEPH, the over representation of the A group 
and the under representation of the O ABO group was consistent across all centres. 
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Figure 3.29  Genetic ABO groups and CTEPH risk 
Odds ratios for CTEPH (with respect to healthy controls) in different genetic ABO 
groups were calculated using logistic regression and adjusted for 5 ancestry 
informative principal components. 
A Comprehensive genetic ABO groups 
B 4 inferred genetic ABO groups (O, A, AB and B) 
Of 1492 healthy controls and 1250 CTEPH cases, genetic ABO groups could not be 
inferred for n=22 and n=32 respectively. 
 
 
A
B
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Figure 3.30  The percentage of genetic ABO groups in recruiting study centres 
WTCCC (Wellcome Trust Case Control Consortium, the healthy control group) 
 
 
3.2.5  Fine mapping 
3.2.5.1  Credible set analysis 
A Bayesian analysis was performed for the combined cohort (discovery and validation) 
and used to calculate a 99% credible SNP set (Section 2.1.9.1) (Table 3.11 and 
Figure 3.31).  This comprised the lead SNP (rs2519093) (in the frequentist association 
testing) and the next two most significant SNPs (rs532436 and rs507666).  Rs507666 
is the SNP used to tag the A1 genetic ABO group described in Section 3.2.4.   
 
There is a high degree of correlation between rs2519093, rs532436 and rs507666 
(R2=1.00-0.992, European (non-Finnish) 1000Genomes phase 3 data). 
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rsID  CHR:POS_EA/NEA BF PP CumPP Rank  
rs2519093  9:136141870_T/C  2.59e+26  4.60e-01  0.460  1  
rs532436  9:136149830_A/G  2.03e+26  3.60e-01  0.820  2  
rs507666  9:136149399_A/G  1.01e+26  1.79e-01  0.999  3  
rs635634  9:136155000_T/C  6.15e+23  1.09e-03  1.000  4  
rs600038  9:136151806_C/T  8.52e+21  1.51e-05  1.000  5 
 
Table 3.11  Fine mapping: 99% credible SNP set for the chromosome 9 
association 
Bayesian analysis was performed in SNPtest as described in Section 2.1.9.1.  The 
posterior probabilities were then calculated by dividing the Bayes factor for each SNP 
(within a 200kb region of the peak associated SNP) by the sum of all Bayes factors for 
that region (5.64e+26).  Posterior probabilities were ranked in descending order and 
the SNPs included in the 99% cumulative sum comprised the 99% credible set.  Bayes 
factors and posterior probabilities are displayed using exponential notation.  BF 
(Bayes factor), PP (posterior probability), CumPP (cumulative posterior probability). 
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Figure 3.31  Regional association plot of 99% credible SNP set for the 
chromosome 9 association 
The 3 SNPs that comprise the 99% credible set are named and highlighted with the 
blue rectangle.   
 
 
3.2.5.2  Genomic functional annotation 
The fumaGWAS tool was used to visualise functional annotations for associated loci, 
using a range of data resources that are described in Section 2.1.9.2.  The lead SNP 
(rs2519093) had a CADD score of 6.85 (unlikely to be highly deleterious), no available 
evidence of regulatory elements (regulomeDB score=7) and is an eQTL for the SURF1 
gene in the atrial appendage of the heart (p = 7.02x10-8, normalised effect size (NES) 
= -0.380, GTEx v7 data) (Figure 3.32).  rs532436 and rs507666 have CADD scores 
suggesting low deleteriousness (3.11 and 4.11 respectively) and regulomeDB scores 
suggesting minimal evidence of regulatory elements (3a and 4 respectively, see 
Figure 3.32 for explanation).  Both rs532436 (p = 6.95x10-8, NES = -0.371) and 
rs507666 (p = 6.95x10-8, NES=-0.371) are also eQTLs for the SURF1 gene in the 
atrial appendage of the heart. 
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Figure 3.32  Fine mapping: functional annotations for the 99% credible SNP set 
in chromosome 9 
The top panel shows the ABO associated locus with correlated SNPs (LD calculated 
from 1000 Genomes phase 3 data). 
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The CADD score is shown in the second track with a higher score indicating increased 
likelihood of deleteriousness.   
The third track displays the regulomeDB score (range 1-7) for SNPs, with a lower 
score indicating greater evidence of regulatory elements. 
Cis-expression quantitative trait loci (eQTL) are shown in the fourth panel for selected 
tissues (GTEx v7: lymphocytes, whole blood, aorta, coronary artery, tibial artery, heart 
(atrial appendage, left ventricle), liver, lung, spleen).  Different colours represent 
different tissue/cell types.  P-values on the y-axis are -log10 scale. 
There are no chromatin interactions present for genomic region in the selected tissues 
(aorta, left ventricle, liver, lung, right ventricle, spleen), displayed in the final, empty 
track (Hi-C data). 
SNPs coloured grey are those not in LD (R2 < 0.1) with lead SNP (top panel) or those 
than were not used for the mapping of the respective tracks.  
 
 
Additionally, rs507666 was associated with the expression of SURF1 in left ventricle 
and lung tissues (p = 1.56x10-5, NES = -0.288 and p = 2.09 x10-5, NES = -0.190, 
respectively).  
 
There were no chromatin interactions present for the genomic region containing the 
99% credible SNP set (Figure 3.32) in selected tissues (aorta, left ventricle, liver, lung, 
right ventricle, spleen) using Hi-C (a chromosome conformation capture method) data 
via fumaGWAS.(255) 
 
There were no additional effects when visualising chromatin interactions and the cis-
eQTLs over a wider genomic range (by chromosome) (Figure 3.33A and 3.33C).  The 
lead SNP (rs2036914) in the chromosome 4 locus (discovery cohort) was an eQTL for 
the F11 gene (p = 3.74, NES = -0.247).  Rs4253409 is moderately correlated 
(R2=0.615) with the lead chromosome 4 SNP and is an eQTL for the KLKB1 gene in 
aortic and tibial artery tissues (Figure 3.33B and 3.33D). 
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Figure 3.33  Circos plots of chromatin interactions and eQTLs for the 
associations in chromosome 9 (combined analysis) and chromosome 4 
(discovery cohort) 
The outer layer displays a Manhattan plot of SNPs and the associated loci in A 
chromosome 9 (combined analysis) and B chromosome 4 (discovery cohort).  The 
next layer (yellow or red) is the chromosome co-ordinates with the risk locus in blue.  
The inner circle displays the eQTLs (green) and chromatin interactions (orange) for 
the mapped genes.  When a gene is mapped to both, it is coloured red.  Zoomed in 
C D
A B
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views of A and B are shown in C and D respectively.  The chromatin interactions use 
Hi-C data and the eQTLs are from GTEx v7.(255, 256)   
 
 
3.2.6  Gene-based and gene-set analysis 
Genome-wide association testing was repeated with genes rather than individual SNP 
markers using MAGMA via fumaGWAS.(226)  SNPs were mapped to 19,311 protein 
coding genes and association testing was performed to assess the joint effect of 
multiple SNP markers across genes.  The FGG and CACFD1 genes were statistically 
significant across the genome when adjusting for multiple testing (Figure 3.34).  
Importantly, ABO was not included in the genes that were tested as it was unavailable 
on the panel of genes used by fumaGWAS.  The CACFD1 gene is ~200kb 
downstream of ABO and in close proximity to ADAMTS13, which was shown to be in 
moderate-low LD with ABO (Section 3.2.3.1.3).  Furthermore, SNPs in the CACFD1 
are associated with CTEPH in the joint analysis (Table 3.6), but this association is not 
independent when a conditional analysis is performed (Figure 3.23).  Consequently, 
the CACFD1 gene association is likely to be a proxy association of ABO. 
 
 
Figure 3.34  Gene-based association testing: combined group (discovery and 
validation cohort) 
Gene-based association was performed using MAGMA via fumaGWAS for 1250 
CTEPH patients and 1492 healthy controls.  SNPs (n=7,675,738) were mapped to 
19,311 protein coding genes.  MAGMA performed multiple regression (SNP-wise 
model) using the summary statistics data from the combined GWAS analysis 
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described in Section 3.2.3.1.2.  The horizontal red line represents a genome-wide 
significance threshold of p=2.59x10-6 (0.05/19,311). 
 
 
Gene-set analysis was then performed utilising the gene-based p-values for 4,728 
curated gene sets and 6,166 gene ontology terms.(221)  The most significantly 
associated gene-set was for cardiac muscle contraction however, this was not 
statistically significant when adjusted for multiple testing (Table 3.12).  The most 
associated tissue in the MAGMA tissue expression analysis was whole blood, followed 
by atrial appendage and left ventricle of the heart (Figure 3.35).  No tissue was 
significantly associated after adjustment for multiple testing. 
 
Gene Set N 
genes 
Beta P Pbon 
Curated_gene_sets: 
kegg_cardiac_muscle_contraction  
72 0.364 6.08e-5 0.647 
GO_bp: 
go_cytoplasmic_translation  
39 0.452 1.12e-4 1.000 
Curated_gene_sets: 
korkola_embryonal_carcinoma_dn  
12 0.877 1.78e-4 1.000 
Curated_gene_sets: 
biocarta_intrinsic_pathway  
23 0.581 2.18e-4 1.000 
GO_bp: 
go_regulation_of_amine_transport  
71 0.339 2.34e-4 1.000 
Curated_gene_sets: 
creighton_endocrine_therapy_resistance_5  
460 0.135 3.04e-4 1.000 
Curated_gene_sets: 
missiaglia_regulated_by_methylation_up  
117 0.256 4.33e-4 1.000 
Curated_gene_sets: 
korkola_seminoma_dn  
11 0.827 4.73e-4 1.000 
Curated_gene_sets: 
kondo_colon_cancer_hcp_with_h3k27me1  
26 0.53 5.24e-4 1.000 
Curated_gene_sets: 
matzuk_meiotic_and_dna_repair  
38 0.386 6.21e-4 1.000 
 
Table 3.12  MAGMA gene-set analysis 
MAGMA gene-set analysis was performed via fumaGWAS.  P-values from the gene-
based analysis were utilised for an analysis with curated gene sets and GO terms 
obtained from MsigDB.  Only the top 10 most significant gene-sets are displayed.  No 
gene-set was significantly associated when adjusted for multiple testing.  N genes 
(number of genes in the gene-set), Pbon (p-value adjusted for Bonferroni correction). 
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Figure 3.35  MAGMA tissue expression analysis 
MAGMA tissue expression analysis was performed using the p-values from the gene-
based analysis and tissue specific gene expression values from GTEx v7 for 53 
general tissue types.  Average gene expression values are log2 transformed.(221)  No 
tissues were significantly associated when adjusted for false discovery rate.  
 
 
3.2.7 GWAS putative associations 
To assess putative associations, loci with a higher p-value threshold (p<1x10-5) are 
summarised in Table 3.13.  These regions may contain genuine SNP-trait 
associations that are currently under-powered with current sample numbers.  Care 
should be taken in interpreting the putative associations, as lowering the p-value 
threshold also increases false positive associations.  
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rsID CHR:POS_EA/NEA GENE FUNC EAF_A EAF_U EAF_REF INFO OR (95% CI) p 
rs7594443 2:206668450_C/T NRP2 intergenic 0.027       0.047 0.037 0.766 2.33 (1.97-2.69) 3.71e-06 
rs6794945 3:133518463_C/T SRPRB intronic 0.504        0.550 0.666 0.695 1.68 (1.47-1.89) 1.25e-06 
rs13130318 4:155538470_G/T FGG intergenic 0.318        0.241 0.219 0.935 1.41 (1.28-1.54) 4.45e-07 
rs264994 5:79165176_T/C CMYA5 / MTX3 intergenic 0.026       0.046 0.067 0.730 2.43 (2.06-2.80) 2.49e-06 
rs678409 6:74299575_C/T SLC17A5 intergenic 0.601        0.655 0.624 0.928 1.34 (1.22-1.46) 3.79e-06 
rs117853706 9:6972010_G/A KDM4C intronic 0.989       0.980 0.968 0.809 3.62 (3.05-4.19) 9.80e-06 
rs72784778 10:31961058_T/A RP11-472N13.3 intergenic 0.970      0.953 0.975 0.916 2.17 (1.83-2.50) 5.79e-06 
rs12413249 10:6714659_C/T RP11-554I8.1 intergenic 0.783        0.831 0.801 0.992 1.41 (1.25-1.56) 9.59e-06 
rs7297105 12:127495362_C/T RP11-575F12.1 intronic 0.411        0.468 0.430 0.719 1.42 (1.28-1.56) 1.02e-06 
rs73324509 14:90404239_T/G EFCAB11 intronic 0.014       0.031 0.026 0.944 2.72 (2.27-3.17) 9.71e-06 
rs142103720 18:33140192_G/A GALNT1 intergenic 0.984       0.969 0.975 0.780 2.74 (2.30-3.18) 8.45e-06 
 
Table 3.13  Putative GWAS associations: joint analysis group 
Putative associations (p<1x10-5) from the analysis described in Section 3.2.3.1.2 (1250 CTEPH patients, 1492 healthy controls and 
7,675,738 SNPs).  The associations previously described in chromosome 9 (ABO) and 4 (F11) are not included in the table.  Only 
the lead (most significant) SNP is shown.  The column headings and additional details are described in Table 3.6.  Gene names 
starting with “RP11” are long non-coding RNAs. 
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3.3  Discussion 
 
3.3.1  Overview 
This multi-centre international GWAS is the largest study undertaken in CTEPH.  The 
ABO locus was identified as the most significant common variant genetic association 
in CTEPH in both a discovery and validation cohort.  There was a putative association 
in the discovery cohort in the F11 gene locus.  The A1 subgroup of ABO was enriched 
in CTEPH and this may result in multiple functional consequences given the pleiotropy 
displayed by ABO.  
 
3.3.2  Associated Loci 
3.3.2.1  The ABO association 
The most significant SNP associated with CTEPH is an intronic variant in the ABO 
gene (rs2519093, OR (95% CI) = 2.4 (2.3-2.5), p=3.42x10-31).  The effect allele is over-
represented in CTEPH cases compared with healthy controls in the current study and 
a reference European population (0.316, 0.165 and 0.182 respectively).  A conditional 
analysis did not identify any additional variants that were independently associated 
with CTEPH at the chromosome 9 locus.  Fine mapping using a Bayesian analysis 
identified a 99% credible set of 3 SNPs (rs2519093, rs507666 and rs532436), which 
are most likely to contain the causative variant.  The limitation of this analysis is that it 
assumes the causative SNP is present in the region tested and that only one variant 
is causative.(257)  One of these SNPs (rs507666) is the variant used to “tag” the A1 
genetic ABO group.  
 
When genetic ABO subgroups were reconstructed, the risk of CTEPH was increased 
for the A1 enriched groups, which was most marked in the A1A1 group (OR (95% CI) 
4.39 (2.92-6.69), p<0.001). CTEPH risk was also increased to a lesser degree in group 
B individuals but the A2 group was not associated.  This is consistent with VTE, which 
also exhibits an association with A1 enriched ABO subtypes but not with the A2 group. 
(253)  Individuals possessing A1 enriched ABO groups have higher plasma levels of 
VWF and factor VIII compared with the O and A2 enriched groups.(253)  This 
functional consequence of ABO may be an aetiological mechanism in CTEPH. 
 
   
 
 137 
The ABO groups vary by the ABH(O) antigens (oligosaccharide residues) and are 
found on red blood cells, platelets and VWF, a protein involved in haemostasis.(80)  
Genetic variation in ABO has been associated with ischaemic stroke, coronary artery 
disease and venous thromboembolism.(70, 258)  Whilst the exact mechanism linking 
ABO antigen groups to thrombotic risk has not been defined, it may be mediated by 
VWF levels, which are 25% lower in O group individuals.(121)  The relationship 
between ABO groups and the ADAMTS13-VWF axis is discussed further in Chapter 
4. 
 
ABO is likely to have additional functional effects as it is a pleiotropic locus that is 
associated with a large number of diseases and traits.  There are 99 studies, 236 
associations and 78 traits related to the ABO locus recorded in the GWAS Catalog 
(accessed March 2019).(140)  The ABO-disease associations include: VTE (259), 
CAD (260), ischaemic stroke (261), allergy (262) and type 2 diabetes mellitus (263).  
Additional traits associated with ABO include: coagulation factor levels (VWF and 
factor VIII) (264), alkaline phosphatase (265), blood cell trait variation (266), P- and E-
selectins (267, 268), lipid traits (269), endothelial growth factors (270) and Intercellular 
Adhesion Molecule 1 (ICAM-1) (271).  The GWAS Catalog traits associated with the 
3 SNPs comprising the CTEPH GWAS 99% credible set (rs2519093, rs507666 
and rs532436) include VTE, CAD, ICAM-1, and lipid levels.(140)   
 
A recent study charting the human plasma proteome identified 64 plasma protein 
levels that were associated with ABO variants. (272)  Of these associations, there 
were 12 in the 3 SNPs (rs2519093, rs532436 and rs507666) that comprised the 99% 
credible set in the CTEPH GWAS.  The protein levels influenced by these ABO 
variants included: P- and E-selectins, Interleukin-3 receptor subunit alpha (IL3RA), 
Vascular endothelial growth factor receptor 3 (FLT4), Protein FAM3B (FAM3B), 
Thrombospondin type-1 domain-containing protein 1 (THSD1), Insulin receptor (INSR) 
and ICAM-1.(272)  ABO is a pleiotropic locus that may have a wide range of functional 
consequences that result in thrombotic disease including CTEPH. 
 
3.3.2.2  The F11 putative association 
There was a significant association in the discovery cohort with a F11 gene intronic 
variant (rs2036914, OR (95% CI) = 1.43 (1.30-1.56), p = 4.79x10-8) that was not 
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replicated in the validation cohort.  This SNP has also been associated with venous 
thromboembolism and activated partial thromboplastin time.(70, 273)  
 
Coagulation factor XI (FXI) is a component of the blood coagulation pathway that acts 
downstream of factor XII, and is able to activate factors FX, FV and FVIII.(274)  FXI 
has a significant role in promoting thrombosis and is associated with ischaemic stroke 
and myocardial infarction in addition to VTE.(274) 
 
3.3.3  Genomic functional annotations, gene-set and gene-based analyses 
Genomic functional annotations were utilised to investigate the lead ABO SNP 
(rs2519093).  This variant is an expression quantitative trait locus (eQTL) for the 
Surfeit locus protein 1 (SURF1)  gene on chromosome 9 particularly in the atrial 
appendage of the heart.  SURF1 is associated with oxidative phosphorylation, which 
has been implicated in the pathobiology of other forms of PH.(275)  Right ventricular 
adaptation is important in CTEPH and therefore alterations in the oxidative 
phosphorylation pathways of the heart is a plausible pathobiological mechanism in 
CTEPH.(276) 
 
Exploratory gene-set and gene-based analysis was performed as an alternative to 
single variant association testing due to the studies small sample size and relative lack 
of power.  Gene-based analysis identified significant associations in the Fibrinogen 
Gamma (FGG) and calcium channel flower domain containing 1 (CACFD1) genes.  
The CACFD1 association was unlikely to have been independent from ABO and 
therefore not unique.  FGG has been associated with venous thromboembolism and 
is discussed in Section 3.3.4.1.  There were no significant associations for the gene-
set and tissue expression analyses. 
 
3.3.4  Absence of genetic associations 
As well as the presence of genetic associations, the absence of associations in the 
CTEPH GWAS may be also informative.  SNPs in FGG and genetic variants that occur 
in other types of pulmonary hypertension which have previously been investigated in 
CTEPH are discussed in Sections 3.3.4.1 and 3.3.4.2.  Genetic variants in the CTEPH 
GWAS that relate to previously described VTE associated variants and warfarin 
metabolism associations are investigated in Chapter 5.   
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3.3.4.1  The FGA-FGB-FGG locus 
No single variant in the FGA-FGB-FGG locus was associated with CTEPH in the 
GWAS.  A SNP in the FGA gene (rs6050; missense variant) encoding the fibrinogen 
Aα chain protein has previously been associated with CTEPH.(42, 66)  
Suntharalingam et al, described that the rs6050 polymorphism was over-represented 
in 214 CTEPH cases compared with 200 healthy controls.(66)  A subsequent study by 
Li et al in 101 patients with CTEPH, 102 with pulmonary embolism and 108 healthy 
controls confirmed that rs6050 was overrepresented in CTEPH compared with healthy 
controls but not in PE.(42)  Furthermore, fibrin resistance has been demonstrated to 
vary in CTEPH patients with rs6050 genotype and this SNP variant is associated with 
clot structure that may predispose to embolisation.(42, 277)  These CTEPH studies 
were limited by small sample sizes (for genetic studies) and an inability to adjust for 
important potential confounding factors including population structure. 
 
Rs6050 was poorly imputed in the current study and therefore not included in the 
CTEPH GWAS analysis.  However, rs6050 is highly correlated (LDlink: R2 = 0.872, 
p<0.001, European (non-Finnish)) with rs13130318 (OR (95% CI) = 1.41 (1.28-1.54), 
p=4.45x10-7) a putative CTEPH association (Table 3.13).  Furthermore, rs6050 is 
highly correlated with rs2066865 (R2 = 0.879) which is associated with VTE in a GWAS 
meta-analysis (Chapter 5, Table 5.2).  The absence of an FGA-FGB-FGG locus 
association using single variant GWAS statistical testing may reflect a lack of study 
power.  There is putative evidence of an association between CTEPH and the FGA-
FGB-FGG locus when a higher p-value threshold (p<1x10-5) is applied or when 
utilising gene-based analysis.  Gene-based analysis has the advantage that less 
statistical tests are performed by grouping variants into genes which can increase 
power to detect associations compared with single-variant analysis.(226)  They are 
limited by assigning non-coding variants to adjacent genes, which may not be the 
causal variant/gene is some circumstances.(278)  Nevertheless, the putative 
association in the single-variant GWAS analysis and the gene-based significance of 
the FGA-FGB-FGG suggest that this is a likely association that may become 
significant as sample size increases.  
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3.3.4.2  Pulmonary hypertension related genes in CTEPH 
Genetic variants that occur in other types of pulmonary hypertension have been 
previously investigated in CTEPH and are summarised in Section 1.3.3.  In the 
CTEPH GWAS, there is no association with common variants in these PH related 
genes.  However, many of the PH associated variants are rare / very rare and would 
not be included in this GWAS analysis.  Previous CTEPH studies that have reported 
genetic variant associations have used a candidate gene / variant approach and 
methodologies that may have resulted in false positive associations.(131)  
Alternatively, some genetic variants associated with CTEPH may be specific to the 
population being studied and their absence in the current study may be a consequence 
of the Caucasian composition. 
 
3.3.5  Strengths and limitations 
This multi-centre international GWAS is the largest study undertaken in CTEPH, an 
uncommon disease that occurs following acute pulmonary embolism.  CTEPH patients 
included in the study had a robust diagnosis that is defined at expert PH centres using 
a range of investigations and international guidelines.  The significant ABO locus 
occurs in VTE and is therefore likely to represent a genuine association. 
 
Separate studies from Bonderman et al have shown a prevalence of non-O ABO blood 
groups of 77% in CTEPH patients compared with 58% in non-CTEPH and an odds 
ratio 2.1 (95% CI 1.1-3.9) for the non-O blood group.(12, 35)  In an international 
CTEPH registry of 679 patients, the prevalence of non-O blood groups was 76% and 
this compares with 55% in a UK biobank cohort.(68, 279)  In the current GWAS, 
inferred non-O blood groups occurred in 74% of CTEPH patients compared with 43% 
in healthy controls.  The current GWAS finding of an association between ABO and 
CTEPH is more robust than previous observational studies that had not adjusted 
adequately for confounding factors particularly population structure, which is important 
as ABO frequencies vary widely with ethnicity.(280) 
 
Whilst ABO is definitively associated with CTEPH in this study, a limitation of the 
GWAS methodology is that it does not necessarily prove aetiological causality or 
provide a mechanism by which genetic ABO association predisposes to CTEPH.  
Alternatively, patients with CTEPH may have ABO associations due to another 
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“hidden” confounder that causes CTEPH rather than directly via ABO, or ABO may 
interact with other genes/variants predisposing to CTEPH, which is possible given the 
pleiotropic nature of the ABO locus.  The GWAS study cohort is biased towards 
containing patients with more severe CTEPH that are being assessed for PEA.  
Therefore, ABO may be associated with CTEPH disease severity and progression 
rather than disease aetiology, which is addressed in Chapter 5. 
 
The current study sample size limits the ability to identify genetic variants associated 
with CTEPH with more modest effect sizes.  This may account for the absence of 
previously reported VTE genetic associations that may be expected given that three-
quarters of CTEPH patients have had a preceding VTE.  This is investigated in 
Chapter 5.  There were a large number of samples (CTEPH 305, health controls 44) 
that were removed during the quality control steps.  This was necessary to account for 
variable genotyping quality between batches and to adhere to robust GWAS 
methodology.  Alternative statistical approaches such as linear mixed modelling could 
be utilising to retain some samples (e.g. those removed due to ethnicity), although this 
is likely to have minimal impact on the overall study power.(281)  Shared control 
samples were used between the discovery and validation cohort and whilst this is an 
accepted methodology, power could have been increased by having separate control 
groups.(204, 282)  Furthermore, comparing allele frequencies from the validation 
cohort that contained European and American patients to a UK based control group 
required additional statistical correction for population structure and it is possible a 
degree of residual confounding remains.  Ideally a population matched control group 
should be used for the discovery and validation cohorts, although this can be 
challenging in modern international GWAS consortia. 
   
The fine mapping using genomic functional annotations was limited by the tissue types 
available in the reference datasets.  Non-coding variants can affect transcriptional 
regulation differently dependent upon the tissue and cell type.(156)  Therefore, 
annotations should ideally be interrogated in the tissues implicated in disease 
pathobiology, which for CTEPH would primarily be pulmonary vascular endothelial 
cells, right heart samples and blood cells.  The most complete set of tissue types that 
were available were analysed from annotation datasets, including 53 from GTEx and 
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127 from ENCODE, however neither contained pulmonary vascular endothelial cells 
or right heart tissue which limited the analysis.(221)   
 
 
In summary, the ABO locus is associated with CTEPH in a GWAS and this is driven 
by an over-representation of the A1 subtype.  The genetic ABO association may result 
in functional consequences related to CTEPH pathobiology. 
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4  The ADAMTS13-VWF axis 
 
4.1  Introduction 
 
The ABO gene locus was the most signification association in the CTEPH GWAS 
(Chapter 3).  The ADAMTS13 gene locus is situated ~200kb distal of ABO and in low-
moderate linkage disequilibrium with ABO.  Whilst the ADAMTS13 locus was initially 
associated in the GWAS, this was not independent of the ABO association. 
 
The ABO gene is linked to the ADAMTS13-VWF axis, as ABO groups determine a large 
proportion of the variation in VWF.(200)  ADAMTS13 has only one known substrate, VWF 
and therefore, it regulates VWF activity by cleaving the more procoagulant ultra-large 
VWF multimers. 
 
Increased VWF and reduced ADAMTS13 are associated with thrombotic diseases 
including coronary artery disease, ischaemic stroke and venous thromboembolism.(191-
193)  Moreover, micro-vessel thrombosis occurs when ADAMTS13 activity levels are 
severely decreased by autoantibodies in thrombotic thrombocytopenic purpura.(188) 
 
Abnormalities in haemostasis including elevated VWF and an association with non-O 
blood groups have been described in CTEPH.(35, 68)  The role of ADAMTS13 in CTEPH 
has not been investigated to date. 
 
The aim of this Chapter was to investigate the ADAMTS13-VWF axis in CTEPH patients 
including its relationship to ABO groups and ADAMTS13 genetic variants. 
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4.2  Results 
 
4.2.1  Study samples and participants 
ADAMTS13 and VWF plasma concentrations were measured in 208 CTEPH patients and 
68 healthy controls.  Additional disease groups comprised: 35 patients with CTED, 30 
with IPAH and 28 following PE.  Baseline group characteristics are summarised in Table 
4.1 and Table 4.2.  Age and sex differed across the groups (p<0.001 and p=0.014) with 
CTEPH patients being older (median ± IQR: 64 ± 19 years) than healthy controls (49 ± 
24 years).  As ADAMTS13 levels can vary with age and sex, multivariable linear 
regression was used to adjust for these variables (Section 4.2.2.1).(201)  Ethnicity also 
differed (p<0.001) with more non-Caucasians in the PE group.  In the whole CTEPH 
group, 176 (87%) had a proximal distribution of pulmonary arterial obstruction deemed to 
be surgically accessible and 150 (72%) underwent PEA.  
 
 
 Healthy 
control 
CTEPH CTED IPAH PE p 
Subjects  68 208 35 30 28 <0.001 
Age, Years 49 ± 24 64 ±19 58 ± 27 64 ± 27 52 ± 26 0.013 
Sex, Female 32 (47) 90 (43) 9 (26) 21 (70) 15 (54) <0.001 
Ethnicity, Caucasian 53 (78) 180 (95) 28 (88) 26 (90) 13 (54) <0.001 
WHO functional class 
   1 
   2 
   3 
   4 
  
4 (2) 
42 (21) 
151 (74) 
7 (3) 
 
6 (18) 
17 (50) 
11 (32) 
0 (0) 
 
5 (17) 
4 (13) 
21 (70) 
0 (0) 
  
<0.001 
6mwd, Metres  318 ± 176 366 ± 180 342 ± 244  0.204 
Pulmonary 
haemodynamics 
   mPAP, mmHg 
   CI, L/min/m2 
   PVR, dynes.s.cm-5 
  
 
42 ± 18 
2 ± 0.6 
639 ± 476 
 
 
21 ± 4 
2.4 ± 0.6 
151 ± 71 
 
 
42 ± 17 
1.7 ± 0.8 
808 ± 642 
  
 
<0.001 
<0.001 
<0.001 
Clinical blood tests 
   Haemoglobin, g/dL 
  
140 ± 27 
 
138 ± 16 
 
142 ± 22 
  
0.848 
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   Platelet count, x109 
   WCC, x109 
   Lymphocyte, % 
   Neutrophil, % 
   CRP, mg/L 
   NT-proBNP, pg/mL 
246 ± 82 
7 ± 3 
25 ± 10 
64 ± 14 
5 ± 10 
592 ± 1576 
200 ± 56 
6.6 ± 2.1 
28 ± 13 
59 ± 14 
3 ± 3 
113 ± 194 
222 ± 77 
6.9 ± 2.4 
18 ± 13 
72 ± 14 
3 ± 4 
334 ± 695 
0.014 
0.273 
0.025 
0.007 
0.035 
0.006 
Smoking status 
   Never 
   Ex-smoker 
   Current smoker 
  
91 (47) 
87 (45) 
15 (8) 
 
16 (50) 
13 (41) 
3 (9) 
 
15 (52) 
11 (38) 
3 (10) 
  
0.943 
Anticoagulation 
medication 
 137 (94) 15 (94) 30 (100)  0.004 
 
Table 4.1  Baseline group characteristics 
Data is presented as median ± interquartile range or number of patients (%).  
Percentages were calculated using the number of patients that data was available for as 
the denominator.  The differences in categorical variables between groups were assessed 
using Chi-squared or Fisher’s exact test, and the Cochran-Armitage test for WHO 
functional class.  The difference across groups in continuous variables was assessed 
using the Kruskal-Wallis test; the non-parametric equivalent of a one way analysis of 
variance (ANOVA).  P-values adjusted for the number of statistical tests performed using 
FDR correction.  6mwd (6-minute walk distance), CI (cardiac index), CRP (C-reactive 
protein) mPAP (mean pulmonary artery pressure), NT-proBNP (N-terminal pro b-type 
natriuretic peptide), PVR (pulmonary vascular resistance), WCC (white cell count). 
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 n (%) 
CTEPH  
   Disease distribution 
      Proximal 
      Distal 
 
176 (87) 
25 (13) 
   PEA 
      Residual PH (>25mmHg) 
150 (72) 
83 (63) 
   Co-morbidities 
      IHD 
      DM 
      Malignancy 
      Thrombophilia 
      Splenectomy 
      Systemic hypertension 
      Atrial fibrillation / flutter 
      COPD 
 
20 (14) 
19 (13) 
19 (13) 
9 (6) 
9 (6) 
48 (34) 
14 (10) 
8 (6) 
PE  
   VQ defects post PE 
      None 
      Present 
 
8 (40) 
12 (60) 
   Idiopathic PE 8 (40) 
  
Table 4.2  Additional clinical phenotype data for the CTEPH and PE groups 
COPD (chronic obstructive pulmonary disease), IHD (ischaemic heart disease), DM 
(diabetes mellitus), PH (pulmonary hypertension), VQ (ventilation-perfusion). 
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4.2.2  ADAMTS13 and VWF plasma concentrations 
4.2.2.1  ADAMTS13 plasma concentrations 
ADAMTS13 antigen levels were decreased in CTEPH patients (0.889 ± 0.397 μg/mL; 
p<0.001) compared to healthy controls (1.15 ± 0.300 μg/mL) (Figure 4.1A).  Furthermore, 
ADAMTS13 was reduced in CTED cases (0.831 ± 0.224 μg/ml, p<0.001) but levels were 
similar to CTEPH (p=0.205) (Table 4.3).  There was no difference in ADAMTS13 levels 
between IPAH (1.12 ± 0.413 μg/mL; p=0.373) and healthy controls, though the PE group 
did exhibit slightly lower levels (0.969 ± 0.704; p=0.049) (Table 4.3). 
 
Since ADAMTS13 levels can vary with age and sex, group associations were assessed 
with multivariable linear regression adjusted for age, sex and additionally batch and 
ethnicity (Table 4.4).(201)  This confirmed that ADAMTS13 was lowest in the CTEPH (β 
(% change) = -23.4%, p<0.001) and CTED groups (β = -25.9%, p<0.001).  These 
observations should be interpreted together with the additional models that utilise 
interaction terms presented in Section 4.2.2.3.  Furthermore, increasing age was also 
associated with lower ADAMTS13 (β = -5% per 10 years, p<0.001).  ADAMTS13 antigen 
levels were not significantly associated with the PE group (β = -12%, p=0.089), nor were 
they associated with IPAH, sex or ethnicity. 
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Figure 4.1  ADAMTS13 and VWF antigen (Ag) levels by diagnostic groups 
Dunn’s test with FDR adjustment was used to calculate p-values. ****: p <=0.0001, ***: 
p<=0.001, **: p<=0.01, *: p<=0.05, ns (not significant): p>0.05. Healthy control (n=68), 
CTEPH (chronic thromboembolic pulmonary hypertension, n=208), CTED (chronic 
thromboembolic disease, n=35), IPAH (idiopathic pulmonary arterial hypertension, n=28), 
PE (pulmonary embolism, n=28). 
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ADAMTS13 
 
Healthy 
control 
CTEPH CTED IPAH 
CTEPH 3.00x10-08 - - - 
CTED 9.70x10-07 0.205 - - 
IPAH 0.373 0.003 0.001 - 
PE 0.049 0.131 0.038 0.294 
VWF 
 
Healthy 
control 
CTEPH CTED IPAH 
CTEPH 4.00x10-12 - - - 
CTED 2.20x10-06 0.834 - - 
IPAH 0.071 0.006 0.021 - 
PE 0.433 1.90x10-04 0.002 0.433 
 
Table 4.3  ADAMTS13 and VWF antigen level pair-wise diagnostic group 
comparisons 
Dunn’s test with FDR adjustment was used to calculate p-values. 
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 Model1 Model2* 
 β (%) 95% CI (%) p β (%) 95% CI (%) p 
Healthy Control Reference 
CTEPH -23.4 -30.9, -15.1 5.91x10-07 -17.6 -27.9, -5.78 0.005 
CTED -25.9 -35.1, -15.4 1.18x10-05 -23.1 -35.1, -8.75 0.003 
IPAH -2.18 -14.7, 12.2 0.752 1.17 -14.7, 20.0 0.894 
PE -12.0 -24.0, 1.97 0.089 -7.84 -23.3, 10.7 0.381 
Female Reference 
Male -1.07 -7.57, 5.89 0.756 -1.98 -9.92, 6.65 0.641 
Age -0.518 
-0.732, -
0.303 
3.30x10-06 -0.541 
-0.810,  
-0.271 
9.99x10-5 
Batch1 Reference 
Batch2 -2.16 -10.5, 6.95 0.630 13.5 1.71, 26.8 0.024 
Caucasian Reference 
Non-Caucasian -5.58 -15.2, 5.10 0.293 -6.7 -18.4, 6.59 0.306 
 
Table 4.4  Multivariable linear regression model of ADAMTS13 antigen levels 
Beta (β) coefficients and 95% confidence intervals (95% CI) are presented as percentage 
change with respect to healthy controls.  The reference diagnostic group is healthy 
control, the reference sex is female, the reference batch is batch1 and the reference 
ethnicity is Caucasian.  n=343 individuals included in the models.   
*Model2 additionally adjusted for VWF antigen levels. 
 
 
4.2.2.2  VWF plasma concentrations 
VWF antigen levels were confirmed to be increased in CTEPH (16.7 ± 15.2 μg/mL; 
p<0.001) compared to healthy controls (8.45 ± 8.77 μg/mL) and PE (9.23 ± 9.82 μg/mL; 
p<0.001) (Figure 4.1B).  Furthermore, VWF was increased in CTED (17.0 ± 10.1 μg/mL, 
p<0.001) compared to healthy controls, but were no different to CTEPH (p=0.834) (Table 
4.3).  There was no difference in VWF antigen levels between IPAH (11.6 ± 12.3 μg/mL; 
p=0.071) or PE (p=0.433) and healthy controls. 
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Multivariable linear regression was also used for VWF plasma concentrations as 
described for ADAMTS13.  This confirmed that VWF was significantly increased in the 
CTEPH (β=+75.5%, p<0.001) and CTED groups (β=+89.5%, p<0.001) (Table 
4.5).  Furthermore, increasing age was also associated with increased VWF (β=+6% per 
10 years, p=0.005).  VWF plasma concentrations were not significantly associated with 
the IPAH or PE groups, sex or ethnicity. 
 
 β (%) 95% CI (%) p 
CTEPH 75.5 44.8, 113 2.00x10-8 
CTED 89.5 48.0, 143 6.19x10-7 
IPAH 26.7 -1.93, 63.7 0.070 
PE 19.4 -9.26, 57.2 0.205 
Male 7.11 -5.65, 21.6 0.288 
Age 0.584 0.180, 0.990 0.005 
Batch 7.33 -9.10, 26.7 0.403 
Non-Caucasian -14.5 -30.0, 4.42 0.124 
 
Table 4.5  Multivariable linear regression model of VWF antigen levels 
Reference groups are the same as described in Table 4.4.  n=343 individuals included 
in the model.  
 
 
There was a modest negative correlation between ADAMTS13 and VWF plasma levels 
in CTEPH (rho = -0.164, p=0.018) but they were not correlated in healthy controls (rho = 
-0.0622, p=0.614) (Figure 4.2).  Furthermore, adjusting the multivariable linear 
regression model of ADAMTS13 antigen levels (Table 4.4) by VWF had minimal effect 
(on the β value), suggesting that the associations are not mediated by VWF antigen 
levels. 
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Figure 4.2.  Correlation of ADAMTS13 with VWF antigen levels in CTEPH (n=208) 
and healthy controls (n=68) 
Spearman's rank correlation in other diagnostic groups: CTED (rho = -0.161, p = 0.354), 
IPAH (rho = 0.329, p = 0.076), PE (rho = -0.0504, p = 0.799). 
 
 
Converting ADAMTS13 antigen levels to a percentage of the median value of the healthy 
control group (set at 100%) allowed comparisons with thrombotic diseases in other 
studies.  The majority of the CTEPH group (n=136, 65%) were in the lowest quartile 
(Q1<88% ADAMTS13) (Table 4.6). 
 
The combination of low ADAMTS13 and high VWF antigen levels has a synergistic effect 
on the odds of CTEPH (Odds ratio (OR) = 14.5, p<0.001) compared with healthy controls 
(Figure 4.3 and Table 4.7). 
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 CTEPH (n=208) Healthy control (n=68) 
Q1 (<88%) 136 (65) 16 (24) 
Q2 (88-100%) 24 (12) 18 (26) 
Q3 (100-114%) 12 (6) 17 (25) 
Q4 (>114%) 36 (17) 17 (25) 
 
Table 4.6  ADAMTS13 antigen level quartiles for CTEPH and healthy controls 
ADAMTS13 levels were divided by the median of the healthy control group and expressed 
as a percentage.  The CTEPH group was then divided into quartiles (Q1-Q4) of the 
ADAMTS13 distribution of the healthy control group.   
 
 
  
Figure 4.3  The odds ratios of CTEPH in relation to healthy controls for combined 
ADAMTS13 and VWF groups 
The ADAMTS13 and VWF group ORs are adjusted for age, sex, ethnicity and batch in a 
logistic regression model. N represents the total for both the CTEPH and healthy control 
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groups.  Threshold criteria and n (%) within the CTEPH and healthy control groups are 
shown in Table 4.7.  Forest plot generated with the R package `forestmodel`.(247) 
 
 
Groups Thresholds 
Healthy 
Control 
CTEPH 
low VWF &  
high ADAMTS13 
VWF: < 165% (Q1-Q3) 
ADAMTS13 > 88% (Q2-Q4) 
38 (56) 33 (16) 
low VWF &  
low ADAMTS13 
VWF: < 165% (Q1-Q3) 
ADAMTS13: <= 88% (Q1) 
13 (19) 45 (22) 
high VWF &  
high ADAMTS13 
VWF: >= 165% (Q4) 
ADAMTS13: > 88% (Q2-4) 
12 (18) 39 (19) 
high VWF &  
low ADAMTS13 
VWF: >= 165% (Q4) 
ADAMTS13: <=88% (Q1) 
5 (7) 91 (44) 
 
Table 4.7  Summary table for combined ADAMTS13 and VWF groups 
Threshold criteria are described in the table with the n (%) for CTEPH and healthy 
controls.  ADAMTS13 and VWF antigen levels were converted to a percentage (the 
median of the healthy control group) and the quartile thresholds were then determined 
(healthy control group).  The lowest quartile (Q1) was used to represent “low ADAMTS13” 
and the other quartiles (Q2-4) were used for “high ADAMTS13”. The highest quartile (Q4) 
was used to represent “high VWF” and the other quartiles (Q1-3) were used for “low 
VWF”. These cut points were used (as opposed to the median) due to the skewed 
distribution of ADAMTS13-VWF (Table 4.6) and to enable a comparison with other 
published thrombotic diseases that used a similar methodology.(212)  The odds ratios for 
each group are shown in Figure 4.3.  The combined numbers in each group vary from 
Figure 4.3, which used additional variables in a logistic regression model, some of which 
were missing. 
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4.2.2.3  Interaction effects  
Interaction effects for the variables used in Tables 4.4 and 4.5 were investigated.  For 
ADAMTS13 antigen levels, there was a significant interaction between age and CTEPH 
(p=0.007) and additionally between age and sex (Age:Sex) (p=0.019) (Table 4.8 and 
Figure 4.4).  There was insufficient sample size to investigate 3-way interactions, 
including what was driving the interaction effect of age and sex.  This suggests that the 
reduction in ADAMTS13 levels with increasing age is of more relevance within the CTEPH 
group.  Consideration of the interaction terms is most relevant for the extreme values.  
For example, there is less difference between a 30-year-old Caucasian female with 
CTEPH and a 30-year-old Caucasian male healthy control (predicted ADAMTS13: 1.07 
vs. 1.28 μg/mL, 16% reduction) than an 80-year-old Caucasian male with CTEPH and an 
80-year-old Caucasian female healthy control (0.688 vs. 1.18 μg/mL, 42% reduction).  
There were no significant interaction effects for a separate model of VWF antigen levels 
using the variables in Table 4.5. 
 
 
β 95% CI p 
(Intercept) 0.827 -0.194, 0.359 0.557 
CTEPH 0.192 -0.135, 0.519 0.249 
CTED  -0.325 -0.785, 0.136 0.167 
IPAH 0.218 -0.236, 0.672 0.345 
PE -0.0728 -0.499, 0.353 0.737 
Male 0.286 0.0305, 0.541 0.028 
Age 0.00101 -0.00386, 0.00587 0.684 
Batch  -0.0237 -0.111, 0.0638 0.594 
Non-Caucasian -0.0535 -0.16, 0.0527 0.322 
CTEPH:Age  -0.00768 -0.0133, -0.00207 0.007 
CTED:Age  0.000386 -0.00766, 0.00844 0.925 
IPAH:Age  -0.00420 -0.012, 0.00358 0.289 
PE:Age  -0.000410 -0.00825, 0.00743 0.918 
Age:Sex  -0.00500 -0.00917, -0.000817 0.019 
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Table 4.8  Multivariable linear regression of ADAMTS13 plasma levels and 
interaction effects 
The reference groups for diagnostic group, batch and ethnicity are the same as described 
in Table 4.4.  The interaction terms included in the model are those that were significant 
(p<0.05) and informative from the combination of variables in Table 4.4.  The beta 
coefficients should be interpreted with consideration of the interaction effects.  For 
example, the predicted ADAMTS13 antigen level in an 80 year old male Caucasian with 
CTEPH from experimental batch1 would be: exp(0.0827 + 0.192 + (80 x 0.00100) + 
(0.286) + (80 x -0.00768) + (80 x -0.00500)) =  0.688 μg/mL.  This is 34% lower than an 
80 year old male Caucasian healthy control from experimental batch1: exp(0.827 + (80 x 
0.00100) + 0.286 + (80 x -0.00500)) = 1.04 μg/mL.  n=343 included in the model. 
 
 
 
 
Figure 4.4  ADAMTS13 multivariable linear model interaction effects 
Interaction effects for the model described in Table 4.8.  The predicted ADAMTS13 
values are plotted with the interaction terms:  
A.  Age:Diagnostic group. 
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The ADAMTS13 difference between CTEPH patients and healthy controls is more 
pronounced for older patients than for younger patients.  ADAMTS13 levels remain lower 
in CTEPH patients across all ages compared with healthy controls.  The rate of 
ADAMTS13 reduction in the CTED group is similar to healthy controls and is also lower 
than healthy controls across all ages. 
B. Sex:Age. n=343 individuals (from all groups) included in models 
The rate of ADAMTS13 reduction with age is more pronounced for males than for 
females. 
 
 
4.2.2.4  Replicates and ADAMTS13 batch adjustment 
The median of the differences in ADAMTS13 protein levels between the replicates (n=24) 
of batch1 and batch2 (0.19 μg/mL; p<0.001) was used to adjust each batch2 ADAMTS13 
value.  This batch correction resulted in a larger CTEPH group size for subsequent 
genotype analyses.  It was consistent with the ADAMTS13 antigen concentrations that 
have been previously reported with the same methodology.(212)  As batch2 only 
contained CTEPH patients, no adjustment was applied to the other diagnostic 
groups.  The validity of this approach was assessed with a multivariable linear model 
using the uncorrected ADAMTS13 values from batch2 together with values from batch1 
(the dependent variable) and including the covariates batch, age, sex, ethnicity and 
diagnostic group (Table 4.9).  This confirmed that the β coefficients and p-values were 
similar to the previous ADAMTS13 (corrected) multivariable linear model (Table 4.4) with 
the expected addition of a difference with batch (β=+35.1% (for batch2 with respect to 
batch1); p<0.001).  Furthermore, the findings are maintained when limiting the analysis 
to the data from batch1 (Figure 4.5).   
 
The median of differences in VWF protein levels between the replicates (n=12) of batch1 
and batch2 was not significantly different (-0.98 μg/mL; p=0.970) and therefore a 
correction factor was not applied.  
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β (%) 95% CI (%) p 
CTEPH -23.4 -30.9, -15.1 5.91x10-7 
CTED -25.9 -35.1, -15.4 1.18x10-5 
IPAH -2.20 -14.7, 12.2 0.752 
PE -12.0 -24.0, 2.00 0.089 
Batch 35.1 23.6, 47.7 1.20x10-10 
Age -0.500 -0.700, -0.300 3.30x10-6 
Male -1.10 -7.60, 5.90 0.756 
Non-Caucasian -5.60 -15.2, 5.10 0.293 
 
Table 4.9  Multivariable linear regression model of uncorrected (batch2) ADAMTS13 
antigen levels 
Reference groups are the same as described in Table 4.4.  n=343 individuals included in 
the model. 
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Figure 4.5  ADAMTS13 antigen levels by diagnostic groups for batch1  
ADAMTS13 plasma levels for batch1 study participants without batch2 adjusted values 
for the CTEPH group (n=93).  n: Healthy control=68, CTED=35, IPAH=28, PE=28. 
 
 
4.2.2.5  ADAMTS13 and VWF: pre- and post-pulmonary endarterectomy 
In 22 CTEPH patients matched samples were taken post-PEA, after a median of 343 
days.  There were no differences in ADAMTS13 (median of differences ± IQR: -0.0328 ± 
0.250 μg/mL, p=0.777) or VWF protein levels (-3.05 ± 10.7 μg/mL, p=0.777) following 
removal of proximal organised thrombus material by PEA (Figure 4.6). 
 
ADAMTS13 and VWF levels did not change pre- and post-PEA and this also applied 
when limited to patients with normal post-operative haemodynamics (mPAP <25mmHg) 
(n=7, ADAMTS13: p=0.742, VWF: p=0.195). 
 
 
 
Figure 4.6  ADAMTS13 and VWF antigen levels pre- and post-pulmonary 
endarterectomy 
A. ADAMTS13 and B. VWF antigen levels (n=22).  Wilcoxon signed-rank test was used 
to calculate p-values. 
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4.2.3  ADAMTS13 activity, D-dimer and VWF multimers 
ADAMTS13 activity and D-dimer concentrations were measured in a subset of patients 
with CTEPH (n=23) with the lowest ADAMTS13 protein concentrations (below the 1st 
Quartile of the CTEPH group) (0.556 ± 0.130 μg/mL) and compared to a subset of healthy 
controls (n=14, ADAMTS13: 1.03 ± 0.284 μg/mL).   
 
VWF multimeric size was assessed in a subset of CTEPH (n=21) with the highest VWF 
protein concentration (above the 3rd quartile) (32.5 ± 6.80 μg/mL) and compared to the 
same subset of healthy controls (n=14, VWF: 9.97 ± 4.99 μg/mL).   
 
4.2.3.1  ADAMTS13 activity 
ADAMTS13 activity was reduced in CTEPH (84 ± 15%) compared with healthy controls 
(107 ± 14%; p<0.001) (Figure 4.7A).  
 
The ADAMTS13 FRET assay is influenced by ADAMTS13 antigen levels, with apparently 
low ADAMTS13 activity, if antigen levels are reduced.  Therefore, the ADAMTS13 activity 
was adjusted for the ADAMTS13 antigen levels in each individual sample.  Specific 
ADAMTS13 activity (Activity:antigen (Act:Ag) ratio) was increased in CTEPH (Act:Ag 1.57 
± 0.32) compared with healthy controls (1.05 ± 0.190; p<0.001) (Figure 4.7B).  Specific 
ADAMTS13 activity (Act:Ag) is not correlated with VWF:Ag in either CTEPH or healthy 
controls (Figure 4.8A).   
 
4.2.3.2  D-dimers 
Plasmin and thrombin are able to inactivate ADAMTS13 proteolytically in vitro and 
plasmin mediated ADAMTS13 cleavage has been observed in TTP.(283, 
284)  Furthermore, abnormalities in the fibrinolysis pathway have been implicated in 
CTEPH.(39)  Therefore, fibrinogen degradation products measured by D-dimer were 
used as a potential surrogate marker of plasmin and thrombin activity.  D-dimer was 
increased in CTEPH (1.24 ±1.25 μg/mL) compared to healthy controls (0.538 ± 0.344 
μg/mL; p=0.030) (Figure 4.7C).  Specific ADAMTS13 activity was not correlated with D-
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dimer in the CTEPH (rho=0.0938, p=0.761) or healthy control groups (rho=-0.220, 
p=0.313) (Figure 4.7D). 
 
4.2.3.3  VWF multimeric size   
It was hypothesised that a decrease in ADAMTS13 antigen levels would result in reduced 
VWF cleavage and an increase in high multimeric VWF as occurs in TTP.(285)  There 
was no difference in VWF multimeric size between CTEPH (VWF CBA:Ag ratio, 0.659 ± 
0.537) and healthy controls (0.866 ± 0.494; p=0.160) (Figure 4.7E).  VWF:CBA was not 
correlated with ADAMTS13:Ag in CTEPH or healthy controls (Figure 4.8B).  VWF:CBA 
was correlated with VWF:Ag in healthy controls but not in CTEPH (Figure 4.8C). 
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Figure 4.7  ADAMTS13 activity, D-dimer and VWF multimeric size in CTEPH and 
healthy controls 
A subset of CTEPH patients (n=23) with the lowest ADAMTS13 antigen levels (below the 
first quartile of the CTEPH group) and healthy controls (n=14) were used for A-D.  VWF 
multimeric size was measured in CTEPH (n=21) samples with the highest VWF antigen 
concentrations (above the third quartile of the CTEPH group) using the same healthy 
control subset and displayed in E.  The Mann-Whitney U test was used to calculate group 
differences (A, B, C, E) and correlation was assessed with Spearman’s rank correlation 
coefficients (D).  A. ADAMTS13 activity (%)  B. Specific ADAMTS13 activity (Act:Ag ratio). 
C. D-dimer antigen levels. D. Specific ADAMTS13 activity and D-dimer antigen 
correlation.  Healthy control correlation: rho=0.0938, p=0.761; CTEPH correlation:  
rho=-0.220, p=0.313.  E. VWF multimeric size (VWF Collagen binding assay:Antigen 
ratio).  
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Figure 4.8  ADAMTS13 activity, D-dimer and VWF multimeric size correlation in 
CTEPH and healthy controls 
Correlation was assessed with Spearman’s rank correlation coefficients for both the 
healthy control (green circles) and the CTEPH (red triangles) groups.  Additional analysis 
from the data shown in Figure 4.7 (See Figure 4.7 for group details). 
A. ADAMTS13 Act:Ag ratio vs. VWF:Ag.  Healthy control correlation: rho=0.36, p=0.210; 
CTEPH correlation: rho=0.24, p=0.270. 
B. ADAMTS13:Ag ratio vs. VWF:CBA.  Healthy control correlation: rho=-0.61, p=0.022; 
CTEPH correlation: rho=-0.02, p=0.930. 
C. VWF:Ag vs. VWF:CBA.  Healthy control correlation: rho=0.670, p=0.008; CTEPH 
correlation: rho=-0.088, p=0.700. 
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4.2.4  Clinical phenotype associations with ADAMTS13 and VWF 
The association between clinical phenotypes and ADAMTS13 or VWF antigen levels was 
assessed in all patients with CTEPH (n=208).  ADAMTS13 and VWF did not significantly 
correlate with pulmonary vascular resistance, 6-minute walk distance or N-terminal pro b-
type natriuretic peptide (NT-proBNP), which are markers of disease severity (Figure 
4.9).  Since inflammation has been associated with both CTEPH and abnormalities in the 
ADAMTS13-VWF axis, correlation between the ADAMTS13-VWF axis and inflammatory 
markers was investigated.(46, 286)  There were no correlations with blood markers of 
inflammation (CRP, WCC, neutrophil and lymphocyte %) (Figure 4.10), including 
when confining the analysis to samples that were taken on the same day as ADAMTS13 
and VWF sampling (n=81, for WCC, neutrophil and lymphocyte %; n= 77 for CRP). 
 
As proximal operable CTEPH has different risk associations to distal inoperable CTEPH 
and thus potentially different pathophysiological mechanisms, the disease sub-types 
were investigated.(78)  There was no difference in ADAMTS13 (p=0.070) or VWF 
(p=0.253) between the different sub-diagnostic categories of CTEPH (Figure 4.11A and 
4.11B).  Furthermore, there was no difference in ADAMTS13 (p=0.366) or VWF (p=0.078) 
in those with and without post-operative residual pulmonary hypertension (mPAP ³ 
25mmHg) (n=83, 63%), which is a potential marker of distal vasculopathy (Figure 4.11C 
and 4.11D).(15) 
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Figure 4.9  Correlation of ADAMTS13 and VWF antigen levels with markers of 
disease severity in CTEPH at baseline 
Correlation was assessed by Spearman’s rank test.  Baseline was defined as the value 
closest to diagnosis.  P-values adjusted for the number of statistical tests performed using 
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FDR correction.  6mwd (6-minute walk distance), NT-proBNP (N-terminal pro b-type 
natriuretic peptide), PVR (pulmonary vascular resistance).  NT-proBNP log-transformed 
to improve visualisation. Numbers per group: PVR = 169, 6mwd = 165, NT-proBNP = 
144. 
 
 
CTEPH is a potential severe consequence of acute PE, however there are a spectrum of 
changes following PE (post-PE syndrome) that may have differing pathobiology.(9) 
ADAMTS13 and VWF antigen levels were evaluated in groups with varying degrees of 
post-PE perfusion defects on available VQ scans (n=20).  There was no difference in 
ADAMTS13 (p=0.812) or VWF (p=0.678) levels in those that had residual perfusion 
defects post-PE (n=12) compared with those with no perfusion defects (n=8) (Figure 
4.12A and 4.12B).  Furthermore, there was no difference in ADAMTS13 (p=0.938) or 
VWF (p=0.427) levels when the PE group was stratified into provoked PE (n=8) and 
idiopathic PE (n=12) (Figure 4.12C and 4.12D). 
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Figure 4.10  Correlation of ADAMTS13 and VWF antigen levels with blood markers 
of inflammation at baseline 
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Correlation was assessed by Spearman’s rank test.  P-values adjusted for the number of 
statistical tests performed using FDR correction.  CRP log-transformed to improve 
visualisation.  CRP (C-reactive protein), WCC (white cell count).  Numbers in each group: 
WCC = 169, Neutrophils = 169, Lymphocytes = 168, CRP = 95. 
 
 
 
 
Figure 4.11  ADAMTS13 and VWF antigen levels in CTEPH sub-diagnostic and post-
PEA residual pulmonary hypertension groups 
A, B. ADAMTS13 and VWF antigen levels in CTEPH diagnostic sub-groups.  Numbers 
in each group: proximal PEA = 150, proximal no PEA = 25, distal (surgically inaccessible) 
= 24, insufficient clinical data in 9 patients to classify them. 
   
 
 170 
C, D. ADAMTS13 and VWF antigen levels in CTEPH post-PEA residual pulmonary 
hypertension (mPAP ³ 25mmHg) groups.  Numbers in each group: no residual PH = 49, 
residual PH = 83, insufficient clinical data in 18 patients to classify them.  The group 
differences were assessed using the Kruskal-Wallis test (A, B) and the Mann-Whitney U 
test (C, D). 
 
 
 
 
 
Figure 4.12  ADAMTS13 and VWF antigen levels in PE stratified by residual 
perfusion defects and provoked PE 
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The group differences were assessed using the Mann-Whitney U test.  Numbers in each 
group: no perfusion defect on VQ scan = 8, residual perfusion defect on VQ scan = 12, 
unprovoked (no VTE risk factors) = 12, provoked (VTE risk factors) = 8.  Of those with 
residual perfusion defects, the majority were minor (n=10). 
 
 
4.2.5  ADAMTS13-VWF and genotype analyses 
Imputed genotype dosages were available from the CTEPH GWAS described in Section 
2.1.6.  All individuals were genotyped on commercially available Illumina assays and 
imputed to the Haplotype Reference Consortium Build 1.1. 
  
208 CTEPH patients with ADAMTS13 / VWF antigen levels and 28 patients with CTED 
were also included in the CTEPH GWAS (CTED patients were not included in the final 
GWAS analysis and were removed due to incorrect phenotype, see Section 
3.2.2.2).  Genotypes were available for 207 (187 CTEPH; 23 CTED) after GWAS quality 
control exclusions.  These patients were included in the genetic ABO group and protein 
quantitative trait loci (pQTL) analyses.  Matched genotypes and ADAMTS13 / VWF 
antigen levels were not available for the healthy control, IPAH or PE groups.  
 
4.2.5.1  Genetic ABO groups and ADAMTS13-VWF 
Reconstructing genetic ABO groups allowed us to explore more complex 
associations within the ABO subgroups.  Whilst the A1 and A2 groups would be classified 
as non-O on serological testing, they have been associated with different effects on VWF 
levels and VTE risk.(253)  There was no difference in ADAMTS13 antigen levels when 
stratified by simple genetic ABO groups (O, A, B, AB) (Figure 4.13A) (p=0.443) or more 
comprehensive genetic ABO groups (Figure 4.14A) (p=0.616). 
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Figure 4.13  ADAMTS13 and VWF antigen levels by ABO genetic groups 
CTEPH (n=182) and CTED (n=22) patients with genotypes and protein levels available 
(in n=3 a genetic ABO group could not be inferred) were included.  Dunn’s test with FDR 
adjustment was used to calculate p-values.  Numbers in each group: O = 51, A = 128, B 
= 12, AB = 13.   
 
   
 
 173 
 
Figure 4.14  ADAMTS13 and VWF antigen levels by comprehensive ABO genetic 
groups 
The group differences were assessed using the Kruskal-Wallis test.  Numbers in each 
group: OO = 51, A1A1 = 18, A1A2 = 11, A1B = 11, A1O = 81, A2A2 = 2, A2B = 2, A2O = 
16, BB = 1, BO = 11 (in n=3 a genetic ABO group could not be inferred). 
 
 
VWF levels did not vary by ABO groups (Figure 4.13B and Figure 4.14B) however, when 
accounting for covariates (Table 4.10), ABO group B had a higher VWF level (β=+51.3%, 
p=0.025) compared to group O.  ABO group A also had a higher VWF level, although this 
was not statistically significant (β=+19.8%, p=0.073).  Patients with ABO group O had the 
lowest VWF levels within the CTEPH group (14.5 ± 13.0 μg/mL), however this was still 
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significantly higher than healthy controls (8.45 ± 8.77 μg/mL, p<0.001) (Figure 4.1).  This 
implies that the increase in VWF observed in the CTEPH group is not only driven by ABO. 
 
 
β (%) 95% CI (%) p 
ABO group - O Reference 
ABO group - A  19.8 -1.75, 46.1 0.074 
ABO group - B  51.3 5.30, 117 0.025 
ABO group - AB  4.41 -26.9, 49.1 0.811 
CTEPH Reference 
CTED 7.43 -18.5, 41.6 0.609 
Male  4.40 -11.9, 23.7 0.617 
Age  0.921 0.341, 1.50 0.002 
Batch  11.8 -5.88, 32.8 0.203 
Non-Caucasian -1.71 -51.7, 100 0.962 
 
Table 4.10  Multivariable linear regression model of VWF antigen levels and genetic 
ABO groups in CTEPH 
The reference ABO group is O and the reference diagnostic group is CTEPH.  Otherwise, 
reference groups are the same as described in Table 4.4.  n=204 included in the model. 
 
 
There was no difference in ADAMTS13 antigen levels between ABO groups, when 
accounting for covariates with multivariable linear regression.   
 
4.2.5.2  Protein quantitative trait loci for ADAMTS13 
There were 5 SNPs in the ADAMTS13 ± 40kb region that were significantly associated 
with ADAMTS13 protein in a linear regression model (Table 4.11).  The most significant 
SNP (rs3739893, risk allele C, information score=0.960, β = -37.1%, p=3.78x10-06) is a 5' 
untranslated region (UTR) variant in the C9orf96 gene, which is ~8kb 5' of the ADAMTS13 
gene.  In a model adjusted for age, sex and batch, the lead SNP (rs3739893) explained 
7.7% of the variance in ADAMTS13 levels within the CTEPH group (Table 
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4.12).  However, as only 10 CTEPH patients had the rs3739893 effect allele, this 
accounts for a small proportion of the ADAMTS13 antigen level reduction observed in 
CTEPH.  In the whole CTEPH GWAS cohort, the effect allele frequency for rs3739893 in 
CTEPH cases (0.0128) and healthy controls (0.0158) was not significantly different, which 
suggests that it is not associated with CTEPH disease risk.  The effect allele frequency 
of the study healthy controls was similar to a European (non-Finnish) reference population 
(0.0160) (http://gnomad.broadinstitute.org/, accessed Feb 2018). 
 
The most variance in ADAMTS13 antigen levels was attributable to age (16%) (Table 
4.12), which is higher than reported in healthy cohorts.(231)  The 4 other significant SNPs 
were highly correlated with the lead SNP (R2=0.91-1.00, p<0.001).  Additional analysis 
correcting for the first 5 ancestry informative principal components and VWF antigen 
levels did not alter the results.  Furthermore, the results were unchanged when the 
analysis was confined to the CTEPH group. 
 
rsID CHR Position β (%) 95% CI (%) p 
rs3739893 9 136243324 -37.1 -48.1, -23.8 3.78x10-6 
rs28407036 9 136252654 -39.0 -51.3, -23.5 2.42x10-5 
rs8181039 9 136253927 -37.4 -49.5, -22.5 2.42x10-5 
rs78883179 9 136241818 -41.0 -54.1, -24.1 5.05x10-5 
rs77533110 9 136286789 -43.0 -56.4, -25.5 5.20x10-5 
 
Table 4.11  Protein quantitative trait loci for ADAMTS13 antigen levels in CTEPH 
Associations were assessed using multivariable linear regression and the SNPs included 
were those in the ADAMTS13 gene ± 40 Kilobases (n=396).  The model was adjusted for 
age, sex and batch.  A Bonferroni p-value threshold <1.26x10-4 (0.05/396 variants) was 
used to denote statistical significance. rsID (reference SNP identification), CHR 
(chromosome), position (base position).  GRCh37 was used for the genomic positions of 
the SNPs.  n=207 individuals included in the model.  
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 β (%) 95% CI (%) p Variance (%) 
rs3739893 -37.1 -48.1, -23.8 3.78x10-6 7.70  
Age -0.935 -1.21, -0.660 2.23x10-10 16.3  
Male -4.55 -11.7, 3.34 0.253 0.651  
Batch -2.40 -9.67, 5.47 0.537 0.0748 
  
Table 4.12  Multivariable linear regression with the percentage of variance of 
ADAMTS13 antigen levels explained by SNPs and other characteristics 
Reference groups are the same as described in Table 4.4.  Partitioning of the variance 
explained by each variable within the models was performed by averaging over orders 
using the R package `relaimpo`.(233)  n=207 individuals included in the model.  
 
 
4.2.6  Immunohistochemistry 
Immunohistochemistry was assessed to determine if ADAMTS13 is expressed in vascular 
endothelial cells, which is a major site of disease pathogenesis.  ADAMTS13 was 
expressed in the vascular endothelium of CTEPH and control lungs with no clear 
differences (Figure 4.15).  Furthermore, ADAMTS13 was expressed in the endothelial 
neovessels of chronic thromboembolic material.  
 
   
 
 177 
 
 
Figure 4.15  Expression of ADAMTS13 in lung tissue evaluated by 
immunohistochemistry 
Serialised sections of lung tissue from controls, explanted lungs from patients with chronic 
thromboembolic pulmonary hypertension (CTEPH) and chronic thromboembolic material 
removed during pulmonary endarterectomy (PEA).  Scale bars = 50 µm.  Negative (Neg) 
control (A-C) H&E staining (D-F); VWF (G-I); ADAMTS13 (J-L); ADAMTS13 high power 
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field views (M-O).  The negative control images are from the same tissue but a different 
location (as images from the same location were unavailable) and are representative.   
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4.3  Discussion 
 
4.3.1  Overview 
This is the first study demonstrating a marked reduction in levels of ADAMTS13 in 
CTEPH. This is independent of pulmonary hypertension, disease severity or systemic 
inflammation.  VWF was confirmed to be increased in CTEPH and this implicates 
dysregulation of the ADAMTS13-VWF axis in CTEPH pathobiology.  
 
4.3.2  ADAMTS13-VWF plasma levels and other diseases 
The ADAMTS13-VWF axis is dysregulated in other thrombotic diseases including 
coronary artery disease and ischaemic stroke.(191, 193)  However, the magnitude of 
ADAMTS13 reduction and VWF increase in CTEPH is greater than observed in studies 
of ischaemic stroke using the same methodology.(212)  Furthermore, levels are lower in 
CTEPH than CAD when considering the proportion of patients in the lowest ADAMTS13 
quartile (65% versus 28% respectively), although direct comparison is precluded by 
differing thresholds.(193)  Additionally, the combination of decreased ADAMTS13 and 
increased VWF has a synergistic effect on the odds of CTEPH that is greater than 
observed in CAD or ischaemic stroke.(212)  The more pronounced ADAMTS13-VWF 
dysregulation in CTEPH may reflect the larger surface area of the vascular endothelium 
involved or alternatively that ADAMTS13-VWF dysregulation is more important in CTEPH 
pathobiology.  Although ADAMTS13 is predominately produced by the liver, the 
contribution to plasma levels from vascular endothelial cells could be substantial given 
the large surface area of the lung vasculature.(177)   
 
Following PEA and removal of proximal thromboembolic material, the ADAMTS13-VWF 
axis remains dysregulated despite normalisation of haemodynamic 
parameters.  Additionally, there is an equal perturbation of the axis in CTED, and no 
correlation with CTEPH disease severity, confirming the changes are not due to the 
presence of pulmonary hypertension or organised thrombus per se.  Interestingly, there 
was no abnormality in ADAMTS13 levels in IPAH despite this group having a higher 
pulmonary vascular resistance, implying that distal pulmonary artery endothelial 
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dysfunction and small vessel vasculopathy are not responsible.(287)  Taken together, 
these observations demonstrate the dysregulation of the ADAMTS13-VWF axis in 
CTEPH pathogenesis.  
 
4.3.3  ADAMTS13-VWF: dysregulation mechanism and role in CTEPH pathobiology 
It has been hypothesised that low ADAMTS13 is driven by activation of fibrinolytic 
pathways and an increase in thrombin and/or plasmin, which have the potential to 
proteolytically inactivate ADAMTS13.(283)  Whilst D-dimer was raised in CTEPH there 
was no correlation with ADAMTS13 implying this was not the mechanism by which 
ADAMTS13 was reduced.  High multimeric forms of VWF appear not to be increased in 
CTEPH.  This is surprising, as increased high multimeric VWF occurs when ADAMTS13 
is reduced in TTP and has been suggested to occur in ischaemic stroke and CAD.(212, 
285)  VWF multimeric size measured systemically may not reflect the local disease 
microenvironment in the pulmonary vascular endothelium.  Additionally, localised flow 
conditions that may be altered in CTEPH are important in VWF structure, cleavage by 
ADAMTS13 and thrombus resolution.(178)  Shear stress is required to unfold VWF and 
expose its A2 binding domain to ADAMTS13 however, pulmonary arterial shear stress is 
decreased in pulmonary hypertension.(178, 288)  This may result in reduced cleavage of 
ultra-large VWF by ADAMTS13 and coupled with reduced ADAMTS13 levels a  
prothrombotic state predisposing to, or causing progression of  CTEPH.  Specific 
ADAMTS13 activity was increased in CTEPH, which may be a consequence of an 
increased ratio due to both ADAMTS13 activity and antigen levels being reduced, but 
antigen levels proportionally more so.  Alternatively, an increased specific ADAMTS13 
activity level may reflect an increased conformational activation of ADAMTS13 by its 
substrate VWF, due to the altered ADAMTS13:VWF ratio in CTEPH patients.(289) 
 
Further evidence of the role of ADAMTS13 in the pathobiology of thrombosis comes from 
animal models.  ADAMTS13 deficiency increases the infarct size in ischaemic stroke and 
myocardial infarction murine models and this can be attenuated by recombinant human 
ADAMTS13 (rhADAMTS13).(290, 291)  Furthermore, rhADAMTS13 decreases fibrotic 
remodelling in a left ventricular pressure overload murine model, which may better reflect 
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elements of the chronic pathological features in CTEPH.(292)  Whilst right ventricular and 
vascular remodelling occur in CTEPH, right ventricular hypertrophy is not a feature of 
CTED, in which ADAMTS13-VWF dysregulation also occurs.(276)  In ischaemic stroke 
and myocardial infarction murine models, the cerebral and myocardial injuries induced by 
ischaemia are VWF-dependent and partially mediated by inflammation.(61, 293)  
 
Inflammation has been linked to CTEPH pathogenesis and some chronic infections are 
associated risk factors.(294)  PEA specimens contain inflammatory cells that correlate 
with circulating inflammatory markers, which are also increased in CTEPH.(46)  The 
ADAMTS13-VWF axis is abnormal in acute and chronic inflammatory conditions and is 
posited as a unifying link between inflammation and thrombosis.(286, 295)  ADAMTS13 
deficiency results in increased leucocyte rolling and adhesion and an increased neutrophil 
recruitment to the infarcted area in stroke models.(290, 295) Recombinant ADAMTS13 
reduces inflammation and platelet recruitment in a left ventricular overload model.(292)  In 
CTEPH, reduced ADAMTS13 would be expected to result in increased inflammation and 
increased platelet recruitment.  No correlation was observed between systemic markers 
of inflammation and ADAMTS13 or VWF levels suggesting the ADAMTS13-VWF 
imbalance is not secondary to systemic inflammation.  There may still be an interaction 
with local inflammation in the pulmonary arteries in CTEPH. 
 
4.3.4  ADAMTS13-VWF and ABO 
ABO blood groups are associated with CTEPH with an over-representation of the non-O 
blood group.(68)  Genetic variation in ABO has also been associated with ischaemic 
stroke, coronary artery disease and venous thromboembolism.(70, 258)  The proposed 
mechanism of this association has been via VWF plasma levels, which are 25% higher in 
non-O individuals.(121)  VWF is increased in some non-O groups within CTEPH however, 
VWF is still significantly higher in the CTEPH O group compared with healthy controls.  
This implies there are other causes of increased VWF and conversely, ABO may have 
additional effects in CTEPH.  This would be consistent with studies in VTE where ABO 
remains an independent risk factor after adjusting for VWF levels.(115)  ABO is a 
pleiotropic locus and may have alternative functional effects in CTEPH including 
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mediating pathways involved in inflammation and angiogenesis.(232)  Inadequate 
angiogenesis with a paucity of neovessels and failure to recanalise obstructed vessels 
has been implicated in CTEPH pathobiology.(45, 46)  Interestingly, ADAMTS13 can 
promote angiogenesis in endothelial cells and therefore, a reduced ADAMTS13 in 
CTEPH may result in inadequate angiogenesis.(296)  Furthermore, in stroke models, 
ADAMTS13 controls key steps of vascular remodelling and rhADAMTS13 enhances 
ischaemic neovascularisation.(297) 
 
4.3.5  ADAMTS13 protein quantitative trait loci in CTEPH 
A protein quantitative trait loci (rs3739893) was identified in the C9orf96 gene (~8kb 5’ of 
the ADAMTS13 gene) that is associated with ADAMTS13 protein levels and has been 
described in two previous studies.(201, 231)  In a GWAS of ADAMTS13 antigen levels in 
a healthy cohort, this SNP is significantly associated with a similar effect size (β = -22.3%).  
The rs3739893 SNP is highly correlated (R2=0.867, p<0.001) with a missense variant 
(rs41314453) that is the most significant association in an ADAMTS13 activity 
GWAS.(231)  Whilst this suggests that ADAMTS13 protein is genetically regulated, this 
SNP only accounts for a small amount of variance (~8%) in ADAMTS13 protein levels 
and is not associated with CTEPH disease risk.  ADAMTS13 rare genetic variants have 
been associated with VTE, which would not have been detected with our minor allele 
frequency threshold of 1%.(298)  Future studies could examine if rare ADAMTS13 genetic 
variants are associated with ADAMTS13 protein in CTEPH and if the frequency is 
different from VTE. 
 
4.3.6  Strengths and limitations 
A strength of this study is that it investigated the ADAMTS13-VWF axis in a spectrum of 
thromboembolic disease from acute PE to chronic thromboembolic disease with and 
without pulmonary hypertension.  The study contains a large sample of well characterised 
CTEPH patients, who have been phenotyped in expert tertiary centres.  ADAMTS13-VWF 
imbalance does not occur in PE when assessed by multivariable regression.  This is 
consistent with the largest study of ADAMTS13 in VTE, which showed it was not reduced 
overall.(195)  Whilst the study may have been underpowered to detect smaller magnitude 
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changes in the PE group, ADAMTS13-VWF dysregulation was observed in CTED, a 
group with a similar sample size.  This raises an intriguing possibility, that there are 
differences in the ADAMTS13-VWF axis in the spectrum of thromboembolic disease 
(Section 7.3). 
 
Immunohistochemistry demonstrated that ADAMTS13 is expressed in vascular 
endothelial cells in control, CTEPH and PEA neovessel samples.  However, a limitation 
was the inability to comprehensively quantify ADAMTS13 in these tissues and establish 
if the expression differed.  Semi-quantitative methods supported by computer-assisted 
image analysis could be used to assess the expression of the ADAMTS13 antigen 
between different samples.(229)  Alternative methods could be used including 
quantitative reverse transcription polymerase chain reaction (qRT-PCR), a means of 
quantifying gene expression by converting ribonucleic acid (RNA) to complementary DNA 
(cDNA) using reverse transcriptase followed by amplification of specific DNA targets by 
PCR.(299)  Transcriptomics (RNA-sequencing) could be used to quantify ADAMTS13 in 
different tissues, again by converting messenger RNA (mRNA) to cDNA followed by high-
throughput sequencing and alignment with a reference genome or reference 
transcripts.(300) 
 
The areas for future research for investigating the ADAMTS13-VWF axis in CTEPH are 
discussed in Section 7.2 and the potential implications for clinical practice are explored 
in Section 7.3. 
 
 
In summary, the ADAMTS13-VWF axis is dysregulated in CTEPH and this is unrelated 
to pulmonary hypertension, disease severity or systemic inflammation.  This implicates 
the ADAMTS13-VWF axis in CTEPH pathogenesis.  
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5  CTEPH phenotype - genotype associations 
 
5.1  Introduction 
 
This chapter explores additional phenotype-genotype associations by utilising deeply 
phenotyped data (Section 5.2.1). 
  
The ABO gene locus was the most signification association in the CTEPH GWAS 
(Chapter 3).  The F11 locus was a putative association that was significant in the 
discovery cohort.  Genetic risk scores have been developed for venous 
thromboembolism, whereby disease risk is increased by each additional risk 
allele.(301, 302)  Furthermore, the combination of factor V Leiden and non-O blood 
group has a supra-additive effect on VTE risk.(115)  The effect of a combination of 
ABO and F11 risk alleles on CTEPH risk is explored in Section 5.2.2.1. 
 
The absence of genetic associations in the CTEPH GWAS may also be revealing 
important insights into the pathobiology of CTEPH.  The majority of CTEPH patients 
have a preceding VTE (three quarters have a PE and half have a DVT), a polygenic 
disease with known SNP associations (Section 1.5.5).  In Section 5.2.2.2, the loci 
associated with VTE are examined in the CTEPH case-control GWAS to identify 
differential associations.  Abnormalities in haemostasis and fibrinolysis are implicated 
in the pathobiology of CTEPH and patients with CTEPH are treated with 
anticoagulation, predominately the drug warfarin.  Previous GWASs have identified 
genetic loci that are associated with warfarin metabolism.(236)  In Section 5.2.2.3, 
these loci are examined to establish whether inadequate anticoagulation due to 
genetic variants related to warfarin metabolism are associated with CTEPH. 
 
ABO is the most significant genetic association in CTEPH however, the 
pathophysiological consequences of this association are unclear.  Evaluation of the 
ADAMTS13-VWF axis in Chapter 4 suggested that ABO may be exerting additional 
effects (Section 4.3.4).  Whilst ABO is associated with CTEPH in a case-control 
GWAS, its role in CTEPH disease severity and outcomes has not been 
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investigated.  Potential associations between ABO and CTEPH haemodynamics and 
survival are examined in Section 5.2.3.1 and Section 5.2.3.2 respectively. 
 
CTEPH is a heterogenous disease with a spectrum of pulmonary arterial disease 
distributions and disease severity.  CTEPH can occur in different anatomical 
distributions from the central, proximal pulmonary arteries to the distal 
vasculature.  Distal and proximal CTEPH have been associated with different risk 
factors that may reflect differing pathobiological mechanisms.(11, 78)  Furthermore, 
patients can have a substantial amount of chronic thromboembolic disease but 
differing degrees of pulmonary hypertension and right ventricular 
adaptation.(237)  Pathobiological mechanisms or adaptive processes related to 
disease distribution and severity may have genetic associations that would not 
necessarily be captured by a case-control analysis.  Separate GWAS analyses 
investigating the common variant associations for CTEPH disease distribution and 
haemodynamics are investigated in Section 5.2.3.3 and Section 5.2.3.4 
respectively.  
 
The aims of this chapter were to investigate: 
1. The effect of combining the ABO and F11 risk alleles on CTEPH risk  
2. The differential genetic associations between CTEPH, VTE and warfarin 
metabolism 
3. The effect of genetic ABO groups on CTEPH disease severity and survival 
4. The genetic associations of CTEPH disease distribution and haemodynamics 
by performing separate GWAS analyses  
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5.2  Results 
 
5.2.1  Data capture, QC and missingness 
To obtain deeply phenotyped CTEPH data for current and future analyses, systematic 
data extraction and QC were performed as described in Section 2.3.1.1.  The 
additional phenotype - genotype analyses in this chapter predominately contain 
phenotype data compiled at a single-centre (Papworth) with the highest recruitment.  
The rationale for this approach is described in Section 2.3.1.  The minimal dataset 
(age, sex and CTEPH disease distribution) missingness varied widely between 
centres (Table 5.1). 
 
There were over 200 parameters available for 619 patients from Royal Papworth 
Hospital included in the GWAS analysis, following QC exclusions.  This included the 
182 parameters detailed in Table 2.2 (Material and Methods) and additional variables 
from echocardiograms, radiological investigations, co-morbidities and demographic 
details. 
 
Extensive QC was performed on the separate datasets as described in Section 
2.3.1.1.  As an exemplar, the QC steps for the haemodynamic parameters (n=30 
variables) from right heart catheterisations at Royal Papworth Hospital (n=3366 
individuals in the starting dataset) will be described.   
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Bad Nauheim  Imperial Leuven  Papworth San Diego  Vienna  Total 
Age  0 (0)  9 (15)  0 (0)  18 (3)  0 (0)  143 (100)  170 (14)  
Sex  0 (0)  7 (12)  0 (0)  18 (3)  0 (0)  0 (0)  25 (2) 
Disease distribution  2 (1)  59 (100)  13 (9)  22 (4)  50 (50)  66 (46)  212 (17)  
 
Table 5.1  Missingness of variables from different recruitment centres in the GWAS minimal dataset following QC 
removals  
n=1250 included in the GWAS analysis (see Figure 3.7 for the numbers included from each centre).   
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Data were harmonised by ensuring the correct data type (e.g. continuous data) and 
units were present.  Physiologically impossible values were removed (e.g. negative 
values) and then physiological rules were applied (e.g. cardiac index is always less 
than cardiac output) with further outlier removal.  Test dates were standardised and 
merged with other datasets to obtain the baseline (closest to the time of diagnosis) 
values.  Additional rules for test dates (e.g. baseline haemodynamic parameters had 
to be prior to surgery for those undergoing PEA) were then applied to select 
appropriate data for the downstream analyses.  The importance of systematic and 
reproducible QC steps is highlighted by the difference in the density plots pre- and 
post-QC shown in Figure 5.1, which are essential for determining the most suitable 
statistical analysis. 
 
 
Figure 5.1  Density plots of selected haemodynamics pre- and post-QC 
A Density plots of CI (cardiac index), mPAP (mean pulmonary artery pressure) and 
PVR (pulmonary vascular resistance) prior to QC and B following QC steps (n=50-100 
removals).  Starting dataset n=3366 (all right heart catheterisations from Royal 
Papworth Hospital).  Subsequently, this dataset was used for the GWAS analysis 
(Section 5.2.3). 
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5.2.2  Additional GWAS case-control analysis 
5.2.2.1  ABO and F11 risk alleles and CTEPH 
The risk of CTEPH is increased as the number of risk (effect) alleles at the significant 
loci in ABO (chr9) and the putative association in F11 (chr4) increase (Figure 
5.2).  CTEPH risk is greater for patients with one risk allele at ABO (rs2519093-T 
allele; OR (95% CI): 2.83 (1.91-4.22)) compared with one risk allele at F11 
(rs2036914-C allele; OR (95% CI): 1.48 (1.09-2.03)).  The combination of one risk 
allele at both the ABO and F11 loci has an additive effect (3.46 (2.49-4.85)), which 
continues with each additional risk allele (Figure 5.2).  Patients with 2 risk alleles at 
both the ABO and F11 loci (4 risk alleles in total) have the highest risk of CTEPH (7.43 
(3.72-15.5)), albeit with a wide 95% confidence interval due to the small group 
size.  Only 7% (n=87) CTEPH patients have no risk alleles compared with 16% 
(n=243) of healthy controls.  
 
 
 
Figure 5.2  ABO and F11 risk alleles and CTEPH 
Odds ratios for CTEPH (with respect to healthy controls) in different ABO and F11 risk 
allele groups calculated using logistic regression adjusted for 5 ancestry 
informative principal components.  The risk allele for rs2519093 (Chr9, ABO) is T and 
the risk allele for rs2036914 (Chr4, F11) is C.  Each additional risk allele generally 
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confers an additive effect on disease risk.  There are some combinations such as 
increasing from 1 to 2 F11 risk alleles (TC / CC versus CC / CC) that may not confer 
an additive effect (OR 1.48 versus 1.70).  However, their 95% CI (1.09-2.03 versus 
1.28-2.37) could still be consistent with an additive effect and moreover the trend of 
increasing risk alleles from 0 to 4 is additive. 
 
 
5.2.2.2  Venous thromboembolism genes in CTEPH 
Of the 9 loci (in 8 gene regions) that are significantly associated with VTE in a GWAS 
meta-analysis (7,507 VTE cases and 52,632 healthy controls), only the ABO locus is 
associated with CTEPH (Figure 5.3 and Table 5.2).(70)  The most significant ABO 
locus SNP in the VTE GWAS (rs529565) is also highly associated with CTEPH (OR 
(95% CI): 1.9 (1.77-2.02), p=4.42x10-23) and moderately correlated with the lead ABO 
SNP association in the CTEPH GWAS (R2=0.433, European (non-Finnish) 
1000Genomes phase 3 data).  The putative SNP association in the F11 locus from 
the CTEPH GWAS (rs2036914) is only in moderate-low correlation with the VTE F11 
SNP association (rs4253417, R2=0.357). 
 
There are no significant CTEPH associations for the other VTE associated SNPs (F5, 
FGG, TSPAN15, SLC44A2 and PROCR) (Figure 5.3 and Table 5.2).  There are 
several non-significant putative association signals particularly in the F5 (lead SNP 
rs2009814, effect allele T, OR (95% CI) = 1.36 (1.22-1.50), p=2.60x10-5), FGA-FGB-
FGG (lead SNP rs13130318, effect allele T, OR (95% CI) = 1.41 (1.28-1.54), 
p=4.45x10-7) and F11 (described in Section 3.2.3) loci (Figure 5.3). 
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Figure 5.3  VTE associated loci in the CTEPH GWAS 
Regional association plots (LocusZoom) from the CTEPH GWAS (1250 CTEPH patients, 1492 healthy controls and 7,675,738 SNPs) 
focusing on the significant loci that have previously been described for VTE.(70)  The significant association in ABO (chr9) detailed 
in Chapter 3 is not shown.  The lead SNPs displayed in the LocusZooms are not necessarily the same as in Table 5.2. 
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VTE CTEPH 
rsID CHR:POS_EA/NAE GENE EAF OR (95% CI) p EAF OR (95% CI) p INFO 
rs4524  1:169511755_T/C  F5  0.736  1.20 (1.14–1.26)  2.65e-11  0.775  1.33 (1.19-1.46)  4.77e-05  1.000  
rs6025  1:169519049_T/C  F5  0.033  3.25 (2.91–3.64)  1.1e-96  0.047  1.02 (0.677-1.36)  9.08e-01  0.588  
rs2066865  4:155525276_A/G  FGG  0.244  1.24 (1.18–1.31)  1.03e-16  0.605  1.38 (1.21-1.55)  1.92e-04  0.525  
rs4253417  4:187199005_C/T  F11  0.405  1.27 (1.22–1.34)  1.21e-23  0.094  0.791 (0.571-1.01)  3.65e-02  0.681  
rs529565  9:136149500_C/T  ABO  0.354  2.29 (1.75–2.99)  1.73e-09  0.463  1.9 (1.77-2.02)  4.42e-23 0.976  
rs78707713  10:71245276_T/C  TSPAN15  0.878  1.15 (1.10–1.21)  1.65e-08  0.907  1.45 (1.25-1.66)  3.29e-04  0.852  
rs1799963 11:46761055_A/G F2  0.010  1.20 (1.13–1.27)  3.48e-09  NA  NA NA  0.030 
rs2288904  19:10742170_G/A  SLC44A2  0.785  1.28 (1.19–1.39)  5.74e-11  0.817  1.32 (1.18-1.47)  2.24e-04  1.000 
rs6087685  20:33777612_C/G  PROCR  0.302  1.19 (1.12–1.26)  1.07e-09  0.192  0.938 (0.769-1.11)  4.55e-01  0.859  
 
Table 5.2  VTE associated loci in the CTEPH GWAS 
The VTE associations shown in the table are from a GWAS meta-analysis and the associations for CTEPH are from the CTEPH 
GWAS (Chapter 3).(70)  The rs1799963 SNP (F2 gene locus) was not analysed in the CTEPH GWAS as it was filtered out due to a 
low effect allele frequency (< 1%) and low information score (INFO < 0.5).  The allele frequencies for the FGG and the F11 gene 
locus SNPs differ markedly between CTEPH, VTE and a European (non-Finnish) reference population (0.239 and 0.403 respectively; 
not shown in table).  This is likely to be related to poorly imputed SNPs reflected by a lower INFO score.  rsID (reference SNP cluster 
ID), CHR (chromosome), POS (Base position, GRCh37 genome build), EF (effect allele), NEA (non-effect allele), GENE (nearest 
gene of the SNP, from ANNOVAR), EAF (effect allele frequency of VTE/CTEPH patients), INFO (information score, imputation 
quality), OR (odds ratio), p (p-value). 
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The F5 SNP (rs6025; the factor V Leiden variant) is the most significant association 
with the highest odds ratio in the VTE GWAS (OR (95% CI): 3.25 (2.91-3.95), 
p=1.1x10-96) but is not significantly associated with CTEPH (OR (95% CI): 1.02 (0.67-
1.36), p=0.908)  The lack of VTE associations in the CTEPH GWAS may be due to 
differing genetic aetiology or a lack of power to detect associations.  To address this, 
power calculations were performed for the F5 locus (Figure 5.4).  With the current 
CTEPH GWAS sample size (cases=1250, controls=1492) there is 100% power to 
detect an rs6025 association assuming a disease prevalence of 0.00003, a disease 
allele frequency of 0.033, an OR of 3.25 (from Table 5.2) and an additive genetic 
model.  However, for the other significant SNP in F5 (rs4524) over 15,000 cases and 
controls would be required to achieve a power of 80% (assuming an OR of 1.2 and 
disease allele frequency of 0.736).  This suggests that we are adequately powered to 
detect a lack of association in rs6025, but under-powered to detect some other VTE 
associations. 
 
5.2.2.3  SNPs associated with warfarin metabolism in the CTEPH GWAS 
The 4 loci (in 3 gene regions: CYP2C9, VKORC1, CYP4F2) associated with warfarin 
metabolism are not associated with CTEPH in the GWAS (Figure 5.5 and Table 
5.3).(236)  Most notably, the SNP in VKORC1 (rs9923231) that explains ~30% of the 
warfarin dose variance does not increase the risk of CTEPH (OR (95% CI): 0.872 
(0.751-0.993), p=0.027). 
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Figure 5.4  Power calculations for the F5 VTE associated loci 
Power calculations for the SNPs rs4524 and rs6025, which are the significant F5 gene 
locus associations in the VTE GWAS.  The power calculations assume an allele 
frequency of 0.736 and OR of 1.2 for rs4524 and an allele frequency of 0.033 and OR 
of 3.25 for rs6025 (taken from the VTE GWAS results shown in Table 5.2).  A disease 
prevalence of 0.00003 and an additive genetic model were used for the 
calculations.  In the top panels power calculations were performed using disease 
cases (n=1250) and healthy controls (n=1492), whereas in the bottom panels only 
disease cases (n=1250) were included in calculations.(303)  Power calculations were 
performed using the GAS online power calculator.(203)   
 
 
 
   
 
 196 
 
0
2
4
6
8
10
-
log
10
(p
−v
alu
e)
0
20
40
60
80
100
Recom
bination rate (cM
/M
b)
●●
●
● ●●●
● ●●
● ●
●
●
●●●●●
●
● ●
●●●●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●●
●●
●
●
●●●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●●●●●
●
●●●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●
●●
●
●
●●
●
●
●●●
●
●
●
●
●●
●
●
●
● ●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●●
●●
●
●
●
●●●
●●
●
●●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●●●●
●
●
●
●
●
●
●
●
●●●●●●
●
●
●●
●
●
●● ●●
●
● ●
●
●
●
●
● ●●● ●● ● ●●● ●
●
●
●
●
● ●
●
●
●●
● ●●
● ●●
●
10:96800354
0.2
0.4
0.6
0.8
r2
CYP2C9CYP2C19 CYP2C8
96.6 96.65 96.7 96.75 96.8
Position on chr10 (Mb)
Plotted SNPs
0
2
4
6
8
10
-
log
10
(p
−v
alu
e)
0
20
40
60
80
100
Recom
bination rate (cM
/M
b)
●●
●
●
●
●●
●●●●
●
●●
●
●●
●
●
●●●●
●
●
●
●
●
●
●
●
●●
●
●●
●
●
●
●●●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●●●●●
●
●
●●●●
●
●
●
●●
●
●
●
●●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●●
●
●
●
●●
●●●●●●●
●●●●●●
●
●
●
●
●
●
●
●
●●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●●
●
●
●
●
●
●●●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●
●
●
●●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●●
●
●
●●
●
●
●●●●
●●●●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●●
●
●●
●
●
●●●
●
●●●
●
●
●
●●●● ● ●
●
● ●●●
●
●●
●
●
●●●
●
●
●●
●
●●
●
●
●
●
●
●●
●
●
●
●●●
19:15965101
0.2
0.4
0.6
0.8
r2
CYP4F2CYP4F24P
OR10H5
OR10H1
UCA1 CYP4F11 OR10H4
15.9 15.95 16 16.05 16.1
Position on chr19 (Mb)
Plotted SNPs
0
2
4
6
8
10
-
log
10
(p
−v
alu
e)
0
20
40
60
80
100
Recom
bination rate (cM
/M
b)
●
●
●● ●
● ●●
●
●
●
●
●●
●●●●●●
●
●●
●●●●
●●●●
●
●●●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●
●
●
●
●
●●
●●
● ●
●●
●●
●
●
●
●
●●●●
●
●●
●
●
●●
●
●
●●●●
●
●
●
●●
●
●●●●●●
●
●
●
●
●
●
●
●
●
●
●● ●● ● ● ●●●●
●● ●●●●●●●
● ●●
●●● ●●●
●
●
●
●
●
16:31182455
0.2
0.4
0.6
0.8
r2
VKORC1STX1B STX4 ZNF668
ZNF646
PRSS53
BCKDK
KAT8
PRSS8
PRSS36 FUS
31.05 31.1 31.15 31.2
Position on chr16 (Mb)
Plotted SNPs
A B
C
   
 
 197 
Figure 5.5  Warfarin metabolism associated loci in the CTEPH GWAS 
Regional association plots (LocusZoom) from the CTEPH GWAS (1250 CTEPH patients, 1492 healthy controls and 7,675,738 SNPs) 
focusing on the significant loci that have previously been described for warfarin metabolism.(236)  The variants annotated in the plots 
are the most significant ones for that region and do not correspond to the SNPs associated with warfarin metabolism described in 
more detail in Table 5.3. 
 
 
rsID  CHR:BP_EA/NEA  GENE EAF_A EAF_U EAF_REF OR (95% CI) p INFO 
rs1799853   10:96702047_C/T   CYP2C9 0.250 0.243 0.1266 0.958 (0.807-
1.11)  
0.581 0.803 
rs1057910   10:96741053_C/A   CYP2C9 0.0604 0.0694 0.0626 0.835 (0.596-
1.07)  
0.129 1.000 
rs9923231   16:31107689_T/C   VKORC1 0.360 0.383 0.368 0.872 (0.751-
0.993)  
0.027 1.000 
rs2108622   19:15990431_T/C   CYP4F2 0.299 0.302 0.287 1.04 (0.91-1.16)  0.583 1.000 
 
Table 5.3  Warfarin metabolism associated loci in the CTEPH GWAS 
The SNPs associated with warfarin metabolism were defined in a GWAS of ~1500 patients taking warfarin from a Swedish 
population.(236)  It was not clear from the Takuchi et al, study what the effect allele (EA) for each SNP was, so this has been defined 
as the minor allele.  The allele frequencies for rs1799853 (CYP2C9) differ between the CTEPH GWAS and a reference population, 
which may be due to the lower quality imputation of this SNP.  EAF_A (effect (minor) allele frequency of affected CTEPH patients), 
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EAF_U (effect (minor) allele frequency of unaffected healthy controls), EAF_REF (effect (minor) allele frequency of reference, 1000 
genomes phase 3 European (non-Finnish) populations).  The additional column headings are described in Table 5.2. 
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5.2.3  Additional phenotype-genotype associations 
 
5.2.3.1  ABO and CTEPH disease severity 
Haemodynamic parameters from right heart catheterisation performed at the time of 
CTEPH diagnosis are a marker of disease severity.  Higher mean pulmonary arterial 
pressure (mPAP) / pulmonary vascular resistance (PVR) and lower cardiac index (CI) 
reflect more severe disease.  The effect of the alleles for the significant chr9 locus 
(ABO) and the putative chr4 locus (F11) in the CTEPH GWAS on baseline 
haemodynamics was investigated.  There was no difference in the baseline 
haemodynamics of all CTEPH patients with risk alleles in ABO or F11 when analysed 
separately or in combination (Figure 5.6). 
 
Haemodynamics do not vary with inferred genetic ABO groups (described in Section 
2.1.8) for CTEPH patients (Figure 5.7A-C).  Additional markers of CTEPH disease 
severity (six-minute walk distance and WHO functional class) also do not vary with 
genetic ABO groups (Figure 5.7D and 5.7E). 
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Chr4 risk alleles Chr9 risk alleles Chr4 and 9 risk alleles
Risk 
alleles 0 1 2 0 1 2 0 1 1 2 2 2 3 3 4
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Figure 5.6  The effect of risk (effect) alleles for Chr4 (F11) and Chr9 (ABO) on haemodynamics 
CTEPH patients were subdivided by their number of risk (effect) alleles from the ABO (risk allele T) and putative F11 (risk allele C) 
associations in the CTEPH GWAS.  Group differences in haemodynamics (CI, mPAP and PVR) were then assessed using the 
Kruskal-Wallis test.  The number of CTEPH patients with available data for CI, mPAP and PVR were: 551, 625 and 610 respectively.  
The nominally significant p-values in E and H are no longer significant when adjusted for multiple testing.  CI (cardiac index, L/min/m2), 
mPAP (mean pulmonary arterial pressure, mmHg), PVR (pulmonary vascular resistance, dynes/sec/cm-5). 
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Figure 5.7  Genetic ABO groups and CTEPH disease severity 
CTEPH patients were subdivided into their inferred genetic ABO group (A, AB, B and 
O).  Group differences in haemodynamics (CI, mPAP and PVR) and 6mwd were 
assessed using the Kruskal-Wallis test and the Cochran-Armitage test for WHO 
functional class.  The number of CTEPH patients with available data for CI, mPAP, 
PVR, 6mwd and WHO functional class were: 535, 604, 589, 455 and 525 
respectively.  The available haemodynamic data differs from Figure 5.6 as a genetic 
ABO group could not be inferred in all CTEPH patients (see Section 2.1.8).  In Figure 
5.7E the percentage for each group is shown above the bars.  CI (cardiac index, 
L/min/m2), mPAP (mean pulmonary artery pressure, mmHg), PVR (pulmonary 
vascular resistance, dynes/sec/cm-5), 6mwd (six-minute walking distance, metres), 
WHO (World Health Organisation).  
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5.2.3.2  ABO groups and CTEPH survival 
Survival was investigated in CTEPH patients following PEA as this represented the 
largest group that received the same intervention.  Mortality data was only available 
from Royal Papworth Hospital.  Of the 619 CTEPH patients from Papworth included 
in the CTEPH GWAS analysis, 454 underwent PEA and 421 of these had both 
mortality data and genetically inferred ABO groups available.  There was no difference 
in survival following surgery between genetic ABO groups in CTEPH (log-rank: 
p=0.29) (Figure 5.8 and Table 5.4).  Survival was worse with increasing age (hazard 
ratio (95% CI) per 1 year increase: 1.04 (1.02-1.06), p<0.001) (Table 5.4). 
 
 
 
Figure 5.8  CTEPH survival following pulmonary endarterectomy in different 
ABO groups 
Kaplan-Meier survival curves of survival time for post-PEA CTEPH patients stratified 
by genetic ABO group.  Group differences were assessed with a log-rank test.   
As multiple variables can influence post-PEA survival in CTEPH, a cox proportional 
hazards model was constructed.(15)  Survival did not vary by genetic ABO groups 
when adjusting for age, sex and baseline pre-operative disease severity (mPAP) 
(Table 5.4).  The small sample size of some ABO groups (e.g. B and AB) made it 
difficult to be definitive on their survival effect. 
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n HR 95% CI p 
ABO:  O 103 Reference 
  
ABO:  A  237 1.05 0.64 - 1.75  0.836  
ABO:  B  34 0.70  0.26 - 1.85  0.467  
ABO:  AB  26 1.89  0.83 - 4.3  0.131  
Female 174 Reference 
  
Male 226 0.94  0.62 - 1.44  0.779  
Age  400 1.04  1.02 - 1.06  <0.001 
mPAP: Baseline 400 1.01  0.99 - 1.03  0.429  
 
Table 5.4  Cox proportional hazards model of post-PEA survival in CTEPH  
Cox proportional hazards model assessing time to death following PEA 
surgery.  There were 400 CTEPH patients (54 removed due to missing variables) and 
89 events (deaths) included in the model.  Hazard Ratios (HR) are shown with 95% 
confidence intervals.  mPAP was included as a covariate to account for baseline pre-
surgical disease severity as it was the haemodynamic measurement with the most 
data points.  Data analysis was performed and models checked using the R packages: 
`survival` and `survminer`.(249, 250) 
 
 
5.2.3.3  CTEPH disease distribution GWAS 
1035 (83%) of patients included in the CTEPH GWAS had a disease subtype (CTEPH 
distal / proximal or CTED) recorded.  Of the 983 patients with CTEPH, 847 (86%) had 
a proximal distribution in the pulmonary arteries and 136 (14%) had a distal 
distribution.  The variation in disease sub-type proportions by centre is shown in 
Figure 5.9. 
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Figure 5.9  CTEPH disease subtypes by recruiting centre 
Barplot of the number of CTEPH disease subtype (CTEPH: proximal or distal, and 
CTED) patients from each centre.  1035 patients had information on disease subtype 
and 215 were missing these data.  The count (n) for each group is shown above the 
bars.  Centres that did not supply data on disease subtype are not included in the plot. 
 
 
A separate GWAS analysis was performed to investigate if there were genetic 
associations with CTEPH disease subtype.  Imputed genotype dosages were used to 
test for an association between proximal (n=847) and distal (n=136) CTEPH patients 
following QC and imputation steps as previously described (Chapter 3).  Association 
testing was performed as described using logistic regression with post-imputation SNP 
dosages (n=7,675,738) assuming an additive model and adjusted for 5 principal 
components, age, sex and centre (Figure 5.10A, C and D).  The additional covariates 
(age, sex and centre) were included as they can vary between proximal and distal 
disease.(11, 78)  No locus was genome-wide significant (p<5x10-8).  The most 
   
 
 206 
significant SNPs are rs2313920 (OR (95% CI) 0.317 (0.303-0.331), p=7.63x10-8) an 
intronic variant in the KSR1 (Kinase Suppressor of Ras 1) gene and rs68044424 (OR 
(95% CI) 4.44 (3.88-5.01), p=2.15x10-7) an intergenic SNP in chromosome 11. 
 
 
 
Figure 5.10  Distal/Proximal CTEPH GWAS association testing 
Analysis of 136 distal CTEPH, 847 proximal CTEPH and 7,675,738 SNPs.  Statistical 
testing of individual SNPs using allelic dosage (range 0-2) for an association with 
CTEPH disease subtype was performed using logistic regression assuming an 
additive genetic model and age, sex and 5 ancestry informative principal components 
were included as covariates.  A p-value of <5x10-8 was considered genome-wide 
significant (grey dotted line).  P-values are transformed to a -log10 scale. 
A Distal vs. Proximal CTEPH association testing.  The most significant associations 
in chromosome 17 (rs2313920) corresponds to 17:25863625, and in chromosome 
11 (rs68044424) to 11:96725054 on the plot. 
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B Distal (including post-PEA residual pulmonary hypertension) (n=349) vs. Proximal 
CTEPH (n=635)  
C and D Regional association plots of chromosomes 11 and 17 showing the most 
significant putative associations from Figure 5.10A. 
 
 
The distal/proximal CTEPH association testing is limited by the small sample size of 
the distal CTEPH group.  Over 50% of patients have persistent pulmonary 
hypertension following pulmonary endarterectomy.(15, 20)  As the majority of proximal 
thromboembolic material is removed during surgery, the residual pulmonary 
hypertension may be a consequence of distal vasculopathy.  There may be an overlap 
in the pathobiology of distal CTEPH and post-PEA residual pulmonary hypertension 
with shared genetic associations.  This was explored by performing a GWAS analysis 
that included post-PEA residual pulmonary hypertension patients (n=213) with distal 
CTEPH (n=136) in one group (n=349 total) and compared them to proximal CTEPH 
(n=635) in the second group.  Association testing was performed as described for the 
original distal/proximal CTEPH groups.  There were no loci that achieved genome-
wide significance (Figure 5.10B). 
 
5.2.3.4  CTEPH haemodynamics GWAS 
Another separate GWAS analysis was performed to investigate if there were genetic 
associations with CTEPH haemodynamics, which are a marker of disease 
severity.  Haemodynamics (mPAP, CI and PVR) obtained at the time of baseline 
(diagnostic) right heart catheterisation were utilised in linear regression with post-
imputation SNP dosages (n=7,675,738).  The model was adjusted for 5 ancestry 
informative principal components and factors that could affect haemodynamics: age, 
sex and recruiting centre.  No locus was genome-wide significant (Figure 5.11).  The 
most significant association occurred in the cardiac index GWAS (rs4240181, b (95% 
CI):-0.148 (-0.150 to -0.146), p=4.16x10-7) and was an intronic variant in the TUSC3 
(Tumour Suppressor Candidate 3) gene.  Another putative association was the SNP 
rs145980813 (b (95% CI):-0.340 (-0.191 to -0.489), p=4.4510-7) an intronic variant in 
MALRD1 (MAM And LDL Receptor Class A Domain Containing 1). 
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Figure 5.11  CTEPH haemodynamic GWAS association testing  
GWAS analysis of baseline (diagnostic) haemodynamics (mPAP, CI and PVR) 
obtained at right heart catheterisation for CTEPH utilising 7,675,738 SNPs.  The 
number of individuals with mPAP, CI and PVR data available were: 610, 537 and 595 
respectively.  Statistical testing of individual SNPs using allelic dosage (range 0-2) for 
association with CTEPH haemodynamics (mPAP, CI or PVR) was performed using 
linear regression assuming an additive genetic model and age, sex and 5 ancestry 
informative principal components were included as covariates.  As some 
haemodynamic parameters had skewed distributions, linear models were first 
constructed without the SNP allelic dosages to evaluate the normality of 
residuals.  Appropriate transformations were then applied if required (square root 
(PVR), log (CI)) and used in the linear models with the SNP allelic dosages and 
covariates.  A p-value of <5x10-8 was considered genome-wide significant (grey dotted 
line).  P-values are transformed to a -log10 scale. 
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D and E Regional association plots for the most significant putative associations in 
chromosomes 8 and 10 from the cardiac index analysis (Figure 5.11B) 
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5.3  Discussion 
 
5.3.1  The effect of combining the ABO and F11 risk alleles on CTEPH risk  
ABO is the most significant genetic association for CTEPH followed by a putative 
association in a F11 locus.  Combining risk alleles at these two loci does not result in 
a supra-additive effect on CTEPH disease risk.  Only 7% of CTEPH patients have no 
risk alleles at ABO and F11 compared with 16% of healthy controls.  However, given 
the common allele frequencies of the ABO and F11 SNPs, these variants are neither 
necessary nor sufficient to develop CTEPH.  
 
5.3.2  The differential genetic associations between CTEPH, VTE and warfarin 
metabolism 
Given that three quarters of CTEPH patients have had a preceding pulmonary 
embolism, we may expect similar common variant genetic associations.  Of the 9 
common genetic loci associated with VTE, only ABO is significantly associated in the 
CTEPH GWAS.  This may be due to a relatively small sample size and lack of power 
to detect associations.  However, the CTEPH GWAS is adequately powered to 
exclude a factor V Leiden variant (rs6025) association.  This suggests that either the 
factor V Leiden variant is not significantly associated with CTEPH, or that an 
association exists but with a smaller effect size. 
 
The factor V Leiden polymorphism is a missense mutation that results in activated 
protein C resistance and a procoagulant state (56).  It affects ~5% of Caucasians and 
is much rarer in other ethnic groups.(254)  Individuals heterozygous for factor V Leiden 
have a 3-5 fold increased lifetime risk of VTE, and in homozygotes the risk is increased 
over 10 fold.(56)  Furthermore, 20-25% of patients with a first episode of unprovoked 
VTE have the factor V Leiden polymorphism.(304)  The risk of VTE recurrence in 
heterozygous carriers of factor V Leiden is only modest (OR ~1.4).(305)  Whilst the 
mutation occurs more frequently in isolated PE than healthy controls (OR ~2), there is 
an even higher frequency in DVT (OR ~4).(106, 306, 307)  The stronger association 
with DVT than PE is termed the factor V paradox.  The reasons for the apparent 
paradox are unclear, but may relate to a reduced embolization risk conferred by factor 
V Leiden.(308)   
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In the CTEPH GWAS, the lack of association with factor V Leiden could be attributable 
to differences in the CTEPH and VTE GWAS cohorts.  All VTE GWAS cohorts have 
pooled patients diagnosed with DVT, PE or a combination of both.(70)  To date, the 
potential genetic differences between DVT and PE have not been explored fully in a 
GWAS.  The CTEPH GWAS cohort is likely to comprise more patients that have had 
a preceding isolated PE than isolated DVT alone.(11)  As our CTEPH cohort is 
enriched for preceding PEs, we may be underpowered to detect more modest genetic 
associations with healthy controls that would manifest with a DVT enriched cohort. 
Alternatively, there could be genuine differential genetic associations between PE and 
CTEPH.  A comparative GWAS could be performed to explore this hypothesis.  This 
would require a well characterised PE cohort to define several phenotypic aspects.  In 
addition to defining isolated PE or combined DVT and PE (and recurrence), the 
radiological resolution of pulmonary arterial perfusion defects should be elucidated to 
confirm the absence of CTED.  Ultimately, access to a deeply phenotyped cohorts of 
patients with resolved DVT/PE, persistence of CTED and CTEPH would be required 
to establish pathobiological and genetic differences. 
 
CTEPH is not associated with the genetic determinants of warfarin 
metabolism.  Ineffective anticoagulation of pulmonary embolism due to SNPs 
associated with warfarin metabolism, is unlikely to be involved in the pathogenesis of 
CTEPH.  Furthermore, genetic differences in the vitamin-K dependent clotting factor 
pathways that may result in increased thrombus formation prior to the introduction of 
anticoagulants are also unlikely to be involved in the aetiology of CTEPH. 
 
5.3.3  The effect of genetic ABO groups on CTEPH disease severity and survival 
Genetic ABO groups were not associated with CTEPH disease severity (baseline 
haemodynamics, 6mwd or WHO functional class) or survival post-PEA.  This suggests 
that the ABO association is related to disease aetiology rather than a confounding 
association from selecting more severe CTEPH phenotypes that would present to 
specialist pulmonary hypertension recruiting centres.  The survival analysis is limited 
by the relatively small sample size and number of deaths.  As peri-operative mortality 
post-PEA is low in expert centres and long-term mortality is not driven by right 
ventricular failure (CTEPH), alternative outcome measures need to be considered for 
future analyses.(7, 15) 
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5.3.4  CTEPH disease distribution and haemodynamics GWASs 
No SNPs were significantly associated in the CTEPH disease subtype 
(proximal/distal) GWAS.  The most significant putative association (rs2313920, OR 
(95% CI) 0.317 (0.303-0.331), p=7.63x10-8) was in KSR1.  KSR1 is a gene in 
chromosome 17 that encodes the protein Kinase suppressor of Ras 1 (KRS1).  KSR1 
is expressed in 27 different tissues including heart and lung.(309)    KRS1 is an 
enzyme that functions in multiple receptor tyrosine kinase pathways and participates 
in the activation of mitogen-activated protein kinase (MAPK) pathways.(310)  SNPs in 
the KSR1 gene have been associated with monocyte count (rs1105527), inflammatory 
bowel disease (rs2945412) and other chronic inflammatory diseases 
(rs10775412).(266, 311, 312)  However, there is very little correlation between these 
SNP associations and the putative KSR1 SNP associations in the CTEPH GWAS (R2: 
0.156, 0.153 and 0.042 respectively).  The other disease distribution putative 
association is an intergenic SNP (rs68044424) in chromosome 11 without any known 
associations in the GWAS catalog or ClinVar database.(140, 313) 
 
There were also no significant associations in the CTEPH haemodynamic (CI, mPAP 
and PVR) GWASs.  The rs4240181 intronic TUSC3 gene variant in chromosome 8 
was the most significant putative association (p=4.16x10-7) in the cardiac index 
GWAS.  TUSC3 is a proposed tumour suppressor gene that encodes the protein 
Tumour suppressor candidate 3 and is downregulated in some epithelial 
cancers.(314)  TUSC3 is expressed in 25 different tissues including heart and 
lung.(309)  Rs4240181 has no trait associations in the GWAS Catalog, but SNPs in 
the TUSC3 gene have been associated with body mass index and DNA 
methylation.(315, 316)   
 
The separate GWASs were limited by the sample sizes which would only be 
adequately powered to detect large effects.  This particularly applied to the 
distal/proximal GWAS, which was limited by the distal disease group size (n=136).  
These analyses should be revisited when the CTEPH GWAS cohort expands and 
there is adequate power to detect associations. 
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In summary, there may be differential genetic associations between CTEPH and VTE 
that could be investigated with a comparative GWAS.  ABO groups are not associated 
with CTEPH disease severity or post-PEA survival.  Separate GWASs for CTEPH 
disease subtype and haemodynamics identified putative, but no genome-wide 
associations. 
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6  Conclusions 
 
This multi-centre international GWAS is the largest study undertaken in CTEPH and 
included 1250 CTEPH cases, 1492 healthy controls and ~7 million SNPs.  The ABO 
locus was identified as the most significant common variant genetic association in 
CTEPH in both a discovery and validation cohort.  In a joint analysis of both the 
discovery and validation cohort combined, an intronic variant (rs2519093) in ABO was 
the most significant association with an OR of 2.4 (95% CI 2.3-2.5; p=3.42x10-31).  Fine 
mapping using statistical methods identified a 99% credible set of 3 genetic variants 
that included the SNP (rs507666) that “tags” the A1 genetic ABO group.  In a 
subsequent reconstruction of genetic ABO groups using haplotypes, the A1 group was 
enriched in CTEPH patients with the A1A1 group having an odds ratio of 4.4 (95% CI 
2.9-6.7) compared with the OO genetic ABO group. 
 
ABO is a pleiotropic locus that has been associated with a number of diseases 
including venous thromboembolism, coronary artery disease and ischaemic 
stroke.(70, 258)  Genetic variation at the ABO locus and thrombotic risk has 
traditionally been attributed to VWF levels, which are 25% lower in O group 
individuals.(81)  Individuals possessing A1 enriched ABO groups have higher plasma 
levels of VWF and factor VIII compared with the O and A2 groups, which is consistent 
with the enrichment of the A1 group in the current study.(253)  However, over 20 
plasma protein levels have been associated with genetic variation within the ABO 
locus that relate to immunology, vascular endothelial cell function and coagulation. 
(272)  Therefore, the ABO association in the CTEPH GWAS may result in functional 
effects in addition to mediating VWF levels.  Fine mapping of the ABO locus using 
genomic functional annotations revealed the lead SNP is associated with SURF1  
gene expression (eQTL) in the heart.  SURF1 is involved in oxidative phosphorylation, 
which is another plausible mechanism in CTEPH right ventricular pathobiology.(275) 
(276) 
 
There was a putative association in the F11 gene locus (rs2036914) in the discovery 
cohort however, this was not replicated in the validation cohort.  This SNP is also 
associated with venous thromboembolism in a GWAS, and the absence of a validated 
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association in the current study may be due to a lack of power.(70)  Exploratory gene-
based analysis, whereby SNPs are assigned to genes and genome-wide gene 
association testing is performed, identified a significant association in the FGG gene.  
There was also a putative association (p<1x10-5) signal at the FGG locus in the single-
variant GWAS analysis.  FGG is part of the FGA-FGB-FGG fibrinogen locus that has 
been associated with VTE.(70)  Therefore, the lack an association in the CTEPH 
GWAS at the FGA-FGB-FGG locus may be due to an under-powered study. 
 
As three quarters of CTEPH patients have had a preceding pulmonary embolism, we 
may expect similar common variant genetic associations that are seen in VTE.(70)  
The absence of the VTE genetic associations in CTEPH may be due to a lack of power 
to detect them (F11 and FGA-FGB-FGG), although the current CTEPH GWAS should 
be adequately powered to detect the factor V Leiden mutation (rs6025).  This may be 
due to differing genetic associations that predispose to pulmonary embolism or 
CTEPH and this is discussed further in Section 7.  The absence of genetic 
associations (e.g. factor V Leiden mutation) may also improve understanding of 
CTEPH pathobiology and rationalise future research.  SNPs associated with other 
types of pulmonary hypertension were not associated with CTEPH, suggesting a lack 
of shared genetic aetiology that is explored further in Section 7.1.  There was no 
association between genetic determinants of warfarin metabolism and CTEPH 
suggesting this process is not involved in aetiology or again, reflecting a lack of study 
power to detect smaller effect sizes. 
 
A large proportion of the variation in VWF levels is genetically determined, with 30% 
due to ABO groups.(200)  The ADAMTS13 gene locus is situated ~200kb downstream 
of ABO and in low-moderate linkage disequilibrium with ABO.  Whilst the ADAMTS13 
locus was initially associated with CTEPH in the pilot GWAS, this was subsequently 
determined not to be independent of the ABO association. 
 
In a study of 208 patients with CTEPH and 68 health controls, plasma ADAMTS13 
levels were markedly reduced in CTEPH and plasma VWF levels were increased.  The 
ADAMTS13 reduction in CTEPH was independent of pulmonary hypertension, 
disease severity or systemic inflammation.  These findings implicate dysregulation of 
the ADAMTS13-VWF axis in CTEPH pathobiology.  The magnitude of ADAMTS13-
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VWF dysregulation appears greater in CTEPH than in other thrombotic diseases (e.g. 
coronary artery disease and ischaemic stroke) suggesting a greater role in CTEPH 
pathobiology.(193, 212)  Furthermore, the combination of low ADAMTS13 and raised 
VWF has a synergistic effect on the odds of CTEPH.  ADAMTS13-VWF dysregulation 
in CTEPH remains after removal of thromboembolic material during PEA and 
haemodynamic normalisation suggesting an aetiological role rather than an 
epiphenomenon.  ADAMTS13 is reduced and VWF increased in CTED but there is no 
marked dysregulation of the axis in pulmonary embolism or idiopathic pulmonary 
arterial hypertension. 
 
Genetic ABO groups had a modest effect on VWF levels in the CTEPH group with 
some non-O groups having higher VWF however, ADAMTS13 protein levels did not 
vary by ABO group.  Given that ABO is known to affect VWF with O group individuals 
having 25% lower levels, this suggests that there are other causes of raised VWF in 
CTEPH other than differences from genetic ABO groups, and conversely suggests 
ABO may be exerting its disease effects via additional mechanisms.(121)  By utilising 
the genomic data, a protein quantitative trait locus was identified near the ADAMTS13 
gene that was associated with ADAMTS13 protein levels and explained ~8% of the 
variance however, this pQTL is not associated with CTEPH disease risk in the GWAS. 
 
Additional phenotype-genotype analyses did not identify an association between ABO 
genetic groups and CTEPH disease severity or post-PEA survival.  This suggests that 
the ABO association is related to disease aetiology rather than a confounding 
association with disease severity.  Separate GWASs for CTEPH disease subtype 
(proximal versus distal chronic thromboembolic distribution) and haemodynamics 
identified putative, but no genome-wide associations. 
 
The main study limitation was the lack of power in the GWAS to detect genetic variants 
with lower allele frequencies or more modest effect sizes.  This limitation also applied 
to much of the phenotype-genotype analyses that were predicated on GWAS 
associations.  Whilst the ABO locus was associated with CTEPH in discovery and 
validation cohorts, additional work is required to identify a causal variant and a 
pathobiological mechanism for its functional effect.  The main limitation of the 
ADAMTS13-VWF work is that whilst dysregulation of the axis was demonstrated in 
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CTEPH the mechanism by which it is perturbed was not clearly defined.  Future 
studies could address some of these limitations and are discussed further in Section 
7. 
 
 
 
  
   
 
 218 
7  Future research 
 
Areas for future research will be discussed for genome-wide association studies, the 
ADAMTS13-VWF axis and clinical studies in the following sections. 
 
7.1  GWAS 
 
The CTEPH GWAS had a modest sample size which is a recognised limitation for 
uncommon diseases.  The most important area for future research will be to increase 
sample size to detect additional common variant associations.  Work is currently 
ongoing to increase CTEPH cases by an additional ~950 and ~4500 for healthy 
controls.  These samples have genotypes available for them from the Affymetrix 6.0 
microarray platform.  As the current CTEPH GWAS has used a microarray platform 
using different SNPs, it is difficult to combine them directly for quality control and 
analysis steps.  However, they can be integrated into the current CTEPH GWAS by 
performing separate GWAS studies, followed by imputation against the same 
reference platform (to harmonise the SNPs) and then combining datasets prior to 
statistical association testing.  An alternative approach would be to perform completely 
separate GWAS analyses for cases and controls genotyped on each microarray 
platform (Illumina and Affymetrix) and then combine the studies using meta-analysis 
of the summary statistics.(150)  The degree to which increasing sample size leads to 
increasing common variant associations is not clear a priori and varies depending on 
disease.(122)  A complementary strategy for uncovering additional association signals 
for uncommon disease is to perform a Bayesian association analysis rather than 
adopting a traditional frequentist approach, as the strength of evidence with Bayes 
factors does not vary with sample size or MAF, unlike p-values.(317, 318) 
 
The current study has identified common genetic associations in CTEPH, and 
previous studies have identified SNPs associated with venous thromboembolism.(70, 
166)  However, a key question is what causes the progression from acute PE to 
CTEPH in a minority of patients.  A comparative GWAS study looking at the difference 
in allele frequencies between resolved PE and CTEPH could uncover further genetic 
associations leading to mechanistic insight.  The ideal comparator group would be PE 
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patients with radiological evidence of resolution (from the pulmonary vasculature) 
several months after the acute episode.  Current VTE GWASs have used a mixture of 
predominately deep vein thrombosis and to a less extent pulmonary embolism patients 
without objective evidence of radiological resolution.  Whilst CTEPH is uncommon 
following PE, there is increasing recognition that post-PE persistence of thrombi and 
right ventricular impairment occur in up to a third of patients.(9)  It would be important 
to define a precise phenotype for any comparative study with CTEPH and ongoing 
prospective studies in VTE that include bio-banked blood sample may represent an 
appropriate cohort.(9, 319)  An aim for future studies would be to establish if there is 
a different genetic risk profile across the spectrum of thromboembolic disease from 
resolved pulmonary embolism through to post-PE changes, CTED and CTEPH.  
Cross-trait GWAS could be performed to investigate shared genetic associations with 
diseases including other forms of pulmonary hypertension (e.g. PAH) and thrombotic 
diseases (e.g. coronary artery disease and ischaemic stroke) to identify common 
disease mechanisms.(262) 
 
A limitation of GWAS is the accuracy and breadth of phenotyping which becomes more 
challenging as sample size increases.  An advantage of the current CTEPH GWAS is 
that the disease has a clear and objective definition that requires multiple radiological 
modalities and an invasive right heart catherisation.  However, future studies could 
explore sub-phenotypes further.  Whilst the phenotype-genotype analyses in Chapter 
5 suggested that genetic associations were not being driven by disease severity, there 
was still an under-representation of CTEPH patients with less severe disease that did 
not undergo PEA.  The proliferation of electronic health records and ability to perform 
natural language processing of semi structured radiological reports will be future 
resources for CTEPH case finding that can be utilised in genomic and other -omic 
studies.(320)  Another potential future resource are large biobanks, such as UK 
Biobank that have been used for a VTE GWAS however, they would currently lack 
sufficient CTEPH cases based on published studies of PE in UK Biobank.(166)  GWAS 
using deeper phenotyping may reveal novel genetic associations  in disease subtypes 
such as the distribution of disease in the pulmonary vasculature.  Identifying CTEPH 
subtypes is clinically relevant as subtypes may have different disease mechanisms, 
natural histories and treatments.(321)  Currently, disease distribution is broadly 
classified as proximal and distal disease, which is of practical importance to guide 
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stratification for PEA assessment.  However, unstandardised discrete categories may 
not be sufficiently accurate to identify differing disease mechanisms and genetic 
associations.  Improved radiological classification of CTEPH by partitioning the 
pulmonary vasculature and supported by deep learning would provide more precise 
phenotypes for future study.(322, 323)  CTPA scans also capture data on the lung 
parenchyma and right heart that are important in CTEPH pathophysiology and would 
supplement a radiological pulmonary vascular phenotype.  Furthermore, radiological 
phenotypes could be tracked longitudinally from the initial CTPA performed for 
pulmonary embolism to the CTEPH diagnostic scan in each individual to enrich this 
novel phenotype.  Another strategy could be an analysis to identify unknown CTEPH 
subtypes using “reverse” GWAS to cluster CTEPH patients using their genomic data 
with or without additional phenotype data.(324, 325) 
 
Future novel CTEPH-SNP associations that arise from increasing study sample size 
or additional statistical methods could be interrogated with fine mapping.  This can be 
achieved by increasing SNP density (genetic imputation or resequencing), statistical 
methods, integration with genomic functional annotations and trans-ethnic fine 
mapping (Section 1.5.4).  GWAS studies in CTEPH performed across different 
populations may provide unique insights given observed differences in VTE and 
CTEPH with ethnicity.  VTE is five times more common in black individuals than those 
with Asian-ancestry, which is not accounted for by known genetic associations.(326)  
The incidence of CTEPH in various populations are not well described however, there 
are apparent epidemiological differences between Japanese and Caucasian 
cohorts.(83)  Expanding the CTEPH GWAS to additional ethnic groups would enable 
trans-ethnic fine mapping and may also reveal novel associations in different 
ethnicities.  An alternative strategy to gain insight into CTEPH pathobiology is to 
perform a transcriptome wide association study (TWAS).  This involves leveraging 
genotypes from a GWAS and combining them with gene expression datasets to 
identify gene-trait associations.(327, 328)  The advantage of this approach is that it 
does not require directly profiling gene expressions across multiple tissues in all 
GWAS individuals.(327) 
 
Genotypes from GWAS can be used in additional analyses to investigate causal 
factors in CTEPH.  Inflammation has been associated with CTEPH, but it is unclear if 
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this is causal or epiphenomenon.  Plasma C-reactive protein is raised in CTEPH and 
has been implicated in disease pathobiology.(50, 51)  Mendelian randomisation is a 
method of investigating causal relationships using GWAS risk variants as genetic 
instruments (Section 1.5.1).  Data on CRP could be collected for the CTEPH GWAS 
cohort combined with CRP data from a healthy control group (i.e. UK Biobank) and 
Mendelian randomisation performed to explore the potential causal relationship 
between CRP and CTEPH.  This strategy has been used to investigate the role of 
CRP in coronary artery disease and more recently, the role of red cell distribution width 
in pulmonary arterial hypertension.(139, 329) 
 
7.2  ADAMTS13-VWF 
 
The ADAMTS13-VWF axis was demonstrated to be dysregulated in CTEPH but the 
mechanisms by which ADAMTS13 was decreased and VWF increased were not fully 
elucidated.  In addition to quantifying ADAMTS13 in vascular endothelial cells in 
selected tissues that was described Section 4.3.6, the site of ADAMTS13 reduction 
could be further explored.  ADAMTS13 is predominately produced by hepatic stellate 
cells in the liver with a contribution from vascular endothelial cells.(177)  To explore 
whether ADAMTS13 production is reduced by either tissue, reprogrammed induced 
pluripotent stem cells (iPSC) could be utilised.(330)  Blood samples from CTEPH 
patients could be used to generate iPSCs and then derived hepatic stellate cells and 
vascular endothelial cells produced.(331, 332)  The advantage of this approach is that 
the derived cell lines would have the same genotype as the CTEPH individual from 
whom the cells were derived.  This would enable an exploration of the effect of 
common genetic variants on ADAMTS13 production in the liver and vascular 
endothelium with the ability to stratify experiments by plasma ADAMTS13-VWF levels 
and genotypes.  If no change in the production of ADAMTS13 is demonstrated in 
CTEPH patients compared with control cells, then the reduction of ADAMTS13 may 
be related to consumption, sequestration or excretion and these areas could be 
investigated further. 
 
Experimental studies of CTEPH using small animal models have not fully recapitulated 
the chronic changes that occur in the pulmonary vasculature or right heart.(55)  This 
is partly due to differential vascular responses to chronic pulmonary vascular 
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obstruction across species.(55)  One of the most promising animal models is a porcine 
model that could be used for future mechanistic work.(333)  Ideally a CTEPH animal 
model could be developed with either ADAMTS13 and/or VWF knockouts or with an 
induced alteration in ADAMTS13-VWF levels.  Whilst Adamts13-/- and Vwf-/- knockouts 
exist for the study of stroke and TTP in mice, there are currently no robust large animal 
models.(334)  Stroke murine models with perturbed ADAMT13-VWF have revealed 
increased inflammatory cells and increased infarct size in the brains of Adamts13-/-  
mice that are improved by an infusion of recombinant human ADAMTS13 
(rhADAMTS13).(290, 335)  Future studies in CTEPH could explore the mechanisms 
of immunothrombosis using similar methodology in an appropriately developed animal 
model. 
 
Whilst ADAMTS13 common variants were not associated with CTEPH in the GWAS, 
this methodology would not have detected rare variant associations.  Rare 
ADAMTS13 variants were overrepresented in a small study of VTE patients and future 
studies could explore if they are overrepresented in CTEPH compared with healthy 
controls and VTE.(298)  Exome sequencing of the ADAMTS13 gene could be 
performed in CTEPH patients enriched with the lowest ADAMTS13 plasma levels. 
 
7.3  Clinical perspectives 
 
Clinical prediction scores for CTEPH following acute PE do not currently incorporate 
blood biomarkers.  Future studies using robustly phenotyped PE cohorts to ascertain 
the presence and extent of residual perfusion defects, could investigate if the 
ADAMTS13-VWF axis varies in the spectrum of disease encompassing post-PE 
syndrome.  Determining if ADAMTS13-VWF axis dysregulation precedes the 
development of chronic thromboembolic pathology could inform CTEPH risk 
stratification.  In population studies, healthy individuals with low ADAMTS13 have 
increased risk of developing ischaemic stroke, which provides a rationale for 
prospective studies following PE.(336)  However, low ADAMTS13 alone is unlikely to 
be sufficiently robust to predict CTEPH following acute PE, given that even patients 
with severe ADAMTS13 deficiency do not always develop TTP and additional 
environmental and/or genetic contributors are required.(337)  A risk prediction score 
utilising clinical variables has been developed in CTEPH but is yet to be 
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validated.(172)  Whether this CTEPH risk prediction model could be improved with the 
addition of ADAMTS13-VWF levels and genetic ABO group together with established 
clinical risk factors could be investigated in subsequent studies.  If ADAMTS13-VWF 
levels post-PE enable patients to be stratified into risk groups then this could inform 
future clinical drug trials.  Currently, pulmonary embolism is treated with 
anticoagulation to prevent further VTE, and if there is haemodynamic compromise, 
thrombolytic therapies that break down blood clots are considered.(198)  Thrombolysis 
improves right ventricular function in acute PE but does not prevent CTEPH and is 
associated with bleeding complications.(18)  Therefore, alternative treatment 
strategies will require future evaluation including whether ADAMTS13-VWF levels 
following acute PE can be used to stratify CTEPH preventative treatment modalities 
and durations.  In stroke murine models, rhADAMTS13 decreases infarct size and is 
not associated with the excess major bleeding seen with tissue plasminogen activator 
(tPA) thrombolysis.(290)  Furthermore, some thrombotic occlusions in stroke are 
resistant to thrombolysis with tPA but can be thrombolysed with ADAMTS13 
infusions.(338)  Recombinant ADAMTS13 improved neovascularisation, vascular 
repair and stroke outcome in murine models even when administered in the recovery 
phase at 7 days.(297)  Moreover, in stroke patients plasma ADAMTS13 can predict 
response to thrombolytic reperfusion strategies.(339)  Therefore, if risk prediction for 
developing CTEPH following acute PE improves, then future studies could address 
the effect of rhADAMTS13 infusions in a high risk stratified PE population to prevent 
CTEPH. 
 
 
  
   
 
 224 
References 
 
1. Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 
ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: 
The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of 
the European Society of Cardiology (ESC) and the European Respiratory Society 
(ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology 
(AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart 
J. 2016;37(1):67-119. 
2. Matthews DT, Hemnes AR. Current concepts in the pathogenesis of chronic 
thromboembolic pulmonary hypertension. Pulm Circ. 2016;6(2):145-54. 
3. Moser KM, Bloor CM. Pulmonary vascular lesions occurring in patients with 
chronic major vessel thromboembolic pulmonary hypertension. Chest. 
1993;103(3):685-92. 
4. Galiè N, Kim HS. Pulmonary microvascular disease in chronic 
thromboembolic pulmonary hypertension. Proc Am Thorac Soc. 2006;3(7):571-6. 
5. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, 
Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based 
study. J Thromb Haemost. 2007;5(4):692-9. 
6. Ende-Verhaar YM, Cannegieter SC, Vonk Noordegraaf A, Delcroix M, 
Pruszczyk P, Mairuhu AT, et al. Incidence of chronic thromboembolic pulmonary 
hypertension after acute pulmonary embolism: a contemporary view of the published 
literature. Eur Respir J. 2017;49(2):1601792. 
7. Jenkins D, Madani M, Fadel E, D'Armini AM, Mayer E. Pulmonary 
endarterectomy in the management of chronic thromboembolic pulmonary 
hypertension. Eur Respir Rev. 2017;26(143):160111. 
8. Gopalan D, Delcroix M, Held M. Diagnosis of chronic thromboembolic 
pulmonary hypertension. Euro Respir Rev. 2017;26(143):160108. 
9. Klok FA, van der Hulle T, den Exter PL, Lankeit M, Huisman MV, 
Konstantinides S. The post-PE syndrome: a new concept for chronic complications 
of pulmonary embolism. Blood Rev. 2014;28(6):221-6. 
10. Taboada D, Pepke-Zaba J, Jenkins DP, Berman M, Treacy CM, Cannon JE, 
et al. Outcome of pulmonary endarterectomy in symptomatic chronic 
thromboembolic disease. Eur Respir J. 2014;44(6):1635-45. 
11. Pepke-Zaba J, Delcroix M, Lang I, Mayer E, Jansa P, Ambroz D, et al. 
Chronic thromboembolic pulmonary hypertension (CTEPH): results from an 
international prospective registry. Circulation. 2011;124(18):1973-81. 
12. Bonderman D, Wilkens H, Wakounig S, Schafers HJ, Jansa P, Lindner J, et 
al. Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J. 
2009;33(2):325-31. 
13. Zhang M, Wang N, Zhai Z, Zhou R, Liu Y, Yang Y. Incidence and risk factors 
of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: 
a systematic review and meta-analysis of cohort studies. J Thorac Dis. 
2018;10(8):4751-63. 
14. Lang IM, Simonneau G, Pepke-Zaba JW, Mayer E, Ambroz D, Blanco I, et al. 
Factors associated with diagnosis and operability of chronic thromboembolic 
pulmonary hypertension. A case-control study. Thromb Haemost. 2013;110(1):83-
91. 
   
 
 225 
15. Cannon JE, Su L, Kiely DG, Page K, Toshner M, Swietlik E, et al. Dynamic 
Risk Stratification of Patient Long-Term Outcome After Pulmonary Endarterectomy: 
Results From the United Kingdom National Cohort. Circulation. 2016;133(18):1761-
71. 
16. Bunclark K, Newnham M, Chiu Y-D, Ruggiero A, Villar SS, Cannon JE, et al. 
A multicenter study of anticoagulation in operable chronic thromboembolic 
pulmonary hypertension. J Thromb Haemost. 2020;18(1):114-22. 
17. Kim NH, Delcroix M, Jais X, Madani MM, Matsubara H, Mayer E, et al. 
Chronic thromboembolic pulmonary hypertension. Eur Respir J. 2019;53(1): 
1801915. 
18. Konstantinides SV, Vicaut E, Danays T, Becattini C, Bertoletti L, Beyer-
Westendorf J, et al. Impact of Thrombolytic Therapy on the Long-Term Outcome of 
Intermediate-Risk Pulmonary Embolism. J Am Coll Cardiol. 2017;69(12):1536-44. 
19. Jenkins D. Pulmonary endarterectomy: the potentially curative treatment for 
patients with chronic thromboembolic pulmonary hypertension. Euro Respir Rev. 
2015;24(136):263-71. 
20. Newnham M, Hernandez-Sanchez J, Dunning J, Ng C, Tsui S, Bunclark K, et 
al. Age should not be a barrier for pulmonary endarterectomy in carefully selected 
patients. Eur Respir J. 2017;50(6):1701804. 
21. Shimura N, Kataoka M, Inami T, Yanagisawa R, Ishiguro H, Kawakami T, et 
al. Additional percutaneous transluminal pulmonary angioplasty for residual or 
recurrent pulmonary hypertension after pulmonary endarterectomy. Int J Cardiol. 
2015;183:138-42. 
22. Robbins IM, Pugh ME, Hemnes AR. Update on chronic thromboembolic 
pulmonary hypertension. Trends Cardiovasc Med. 2017;27(1):29-37. 
23. Tanabe N, Kawakami T, Satoh T, Matsubara H, Nakanishi N, Ogino H, et al. 
Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: 
A systematic review. Respir Investig. 2018;56(4):332-41. 
24. Ghofrani HA, D'Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, et 
al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N 
Engl J Med. 2013;369(4):319-29. 
25. Ghofrani HA, Simonneau G, D'Armini AM, Fedullo P, Howard LS, Jaïs X, et 
al. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary 
hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-
blind, placebo-controlled study. The Lancet Respir Med. 2017;5(10):785-94. 
26. Madani MM, Jamieson SW. Technical advances of pulmonary 
endarterectomy for chronic thromboembolic pulmonary hypertension. Semin Thorac 
Cardiovasc Surg. 2006;18(3):243-9. 
27. Simonneau G, Torbicki A, Dorfmuller P, Kim N. The pathophysiology of 
chronic thromboembolic pulmonary hypertension. Eur Respir Rev. 2017;26(143): 
160112 
28. Bernard J, Yi ES. Pulmonary thromboendarterectomy: a clinicopathologic 
study of 200 consecutive pulmonary thromboendarterectomy cases in one institution. 
Hum Pathol. 2007;38(6):871-7. 
29. Blauwet LA, Edwards WD, Tazelaar HD, McGregor CG. Surgical pathology of 
pulmonary thromboendarterectomy: a study of 54 cases from 1990 to 2001. Hum 
Pathol. 2003;34(12):1290-8. 
30. St Croix CM, Steinhorn RH. New Thoughts about the Origin of Plexiform 
Lesions. Am J Respir Crit Care Med. 2016;193(5):484-5. 
   
 
 226 
31. Dorfmuller P, Gunther S, Ghigna MR, Thomas de Montpreville V, Boulate D, 
Paul JF, et al. Microvascular disease in chronic thromboembolic pulmonary 
hypertension: a role for pulmonary veins and systemic vasculature. Eur Respir J. 
2014;44(5):1275-88. 
32. Lang IM, Dorfmuller P, Vonk Noordegraaf A. The Pathobiology of Chronic 
Thromboembolic Pulmonary Hypertension. Ann Am Thorac Soc. 2016;13 Suppl 
3:S215-21. 
33. Gale AJ. Continuing education course #2: current understanding of 
hemostasis. Toxicol Pathol. 2011;39(1):273-80. 
34. Wolf M, Boyer-Neumann C, Parent F, Eschwege V, Jaillet H, Meyer D, et al. 
Thrombotic risk factors in pulmonary hypertension. Eur Respir J. 2000;15(2):395-9. 
35. Bonderman D, Turecek PL, Jakowitsch J, Weltermann A, Adlbrecht C, 
Schneider B, et al. High prevalence of elevated clotting factor VIII in chronic 
thromboembolic pulmonary hypertension. Thromb and haemost. 2003;90(3):372-6. 
36. Olman MA, Marsh JJ, Lang IM, Moser KM, Binder BR, Schleef RR. 
Endogenous fibrinolytic system in chronic large-vessel thromboembolic pulmonary 
hypertension. Circulation. 1992;86(4):1241-8. 
37. Wong L, Szydlo R, Gibbs S, Laffan M. Hereditary and acquired thrombotic risk 
factors for chronic thromboembolic pulmonary hypertension. Blood Coagul 
Fibrinolysis. 2010;21(3):201-6 
38. Wikipedia. 2020. Coagulation. [Online]. [Accessed 1 March 2020]. Available 
from: https://en.wikipedia.org/wiki/Coagulation 
39. Morris TA, Marsh JJ, Chiles PG, Auger WR, Fedullo PF, Woods VL, Jr. Fibrin 
derived from patients with chronic thromboembolic pulmonary hypertension is 
resistant to lysis. Am J Respir Crit Care Med. 2006;173(11):1270-5. 
40. Morris A, Marsh J, Chiles G, Magaña M, Liang N-C, Soler X, et al. High 
prevalence of dysfibrinogenemia among patients with chronic thromboembolic 
pulmonary hypertension. Blood. 2009;114(9):1929-36. 
41. Miniati M, Fiorillo C, Becatti M, Monti S, Bottai M, Marini C, et al. Fibrin 
resistance to lysis in patients with pulmonary hypertension other than 
thromboembolic. Am J Respir Crit Care Med. 2010;181(9):992-6. 
42. Li JF, Lin Y, Yang YH, Gan HL, Liang Y, Liu J, et al. Fibrinogen Aa Thr312Ala 
polymorphism specifically contributes to chronic thromboembolic pulmonary 
hypertension by increasing fibrin resistance. PLoS One. 2013;8(7):e69635. 
43. Yaoita N, Satoh K, Satoh T, Sugimura K, Tatebe S, Yamamoto S, et al. 
Thrombin-Activatable Fibrinolysis Inhibitor in Chronic Thromboembolic Pulmonary 
Hypertension. Arterioscler Thromb Vasc Biol. 2016;36(6):1293-301. 
44. Wikipedia. 2020. Fibrinolysis. [Online]. [Accessed 1 March 2020]. Available 
from: https://en.wikipedia.org/wiki/Fibrinolysis 
45. Alias S, Redwan B, Panzenboeck A, Winter MP, Schubert U, Voswinckel R, et 
al. Defective angiogenesis delays thrombus resolution: a potential pathogenetic 
mechanism underlying chronic thromboembolic pulmonary hypertension. Arterioscler 
Thromb Vasc Biol. 2014;34(4):810-9. 
46. Quarck R, Wynants M, Verbeken E, Meyns B, Delcroix M. Contribution of 
inflammation and impaired angiogenesis to the pathobiology of chronic 
thromboembolic pulmonary hypertension. Eur Respir J. 2015;46(2):431-43. 
47. Zabini D, Nagaraj C, Stacher E, Lang IM, Nierlich P, Klepetko W, et al. 
Angiostatic factors in the pulmonary endarterectomy material from chronic 
thromboembolic pulmonary hypertension patients cause endothelial dysfunction. 
PLoS One. 2012;7(8):e43793. 
   
 
 227 
48. Price LC, Wort SJ, Perros F, Dorfmuller P, Huertas A, Montani D, et al. 
Inflammation in pulmonary arterial hypertension. Chest. 2012;141(1):210-21. 
49. Bonderman D, Jakowitsch J, Redwan B, Bergmeister H, Renner MK, 
Panzenbock H, et al. Role for staphylococci in misguided thrombus resolution of 
chronic thromboembolic pulmonary hypertension. Arterioscler Thromb Vasc Biol. 
2008;28(4):678-84. 
50. Quarck R, Nawrot T, Meyns B, Delcroix M. C-reactive protein: a new predictor 
of adverse outcome in pulmonary arterial hypertension. J Am Coll Cardiol. 
2009;53(14):1211-8. 
51. Wynants M, Quarck R, Ronisz A, Alfaro-Moreno E, Van Raemdonck D, 
Meyns B, et al. Effects of C-reactive protein on human pulmonary vascular cells in 
chronic thromboembolic pulmonary hypertension. Eur Respir J. 2012;40(4):886-94. 
52. Kimura H, Okada O, Tanabe N, Tanaka Y, Terai M, Takiguchi Y, et al. Plasma 
monocyte chemoattractant protein-1 and pulmonary vascular resistance in chronic 
thromboembolic pulmonary hypertension. Am J Respir Crit Care Med. 
2001;164(2):319-24. 
53. Zabini D, Heinemann A, Foris V, Nagaraj C, Nierlich P, Balint Z, et al. 
Comprehensive analysis of inflammatory markers in chronic thromboembolic 
pulmonary hypertension patients. Eur Respir J. 2014;44(4):951-62. 
54. Toshner M, Pepke-Zaba J. Chronic thromboembolic pulmonary hypertension: 
time for research in pathophysiology to catch up with developments in treatment. 
F1000Prime Rep. 2014;6:38. 
55. Mercier O, Fadel E. Chronic thromboembolic pulmonary hypertension: animal 
models. Eur Respir J. 2013;41(5):1200-6. 
56. MacCallum P, Bowles L, Keeling D. Diagnosis and management of heritable 
thrombophilias. BMJ. 2014;349:g4387. 
57. Hotoleanu C. Genetic Risk Factors in Venous Thromboembolism. Adv Exp 
Med Biol. 2017;906:253-72. 
58. Khan S, Dickerman JD. Hereditary thrombophilia. Thromb J. 2006;4:15. 
59. Bloomenthal D, von Dadelszen P, Liston R, Magee L, Tsang P. The effect of 
factor V Leiden carriage on maternal and fetal health. CMAJ. 2002;167(1):48-54. 
60. Jadaon MM. Epidemiology of Prothrombin G20210A Mutation in the 
Mediterranean Region. Mediterr J Hematol Infect Dis. 2011;3(1):e2011054. 
61. Khan MM, Motto DG, Lentz SR, Chauhan AK. ADAMTS13 reduces VWF-
mediated acute inflammation following focal cerebral ischemia in mice. J thromb 
haemost. 2012;10(8):1665-71. 
62. Dinarvand P, Moser KA. Protein C Deficiency. Arch Pathol Lab Med. 
2019;143(10):1281-5. 
63. ten Kate MK, van der Meer J. Protein S deficiency: a clinical perspective. 
Haemophilia. 2008;14(6):1222-8. 
64. Patnaik MM, Moll S. Inherited antithrombin deficiency: a review. Haemophilia. 
2008;14(6):1229-39. 
65. Lang IM, Klepetko W, Pabinger I. No increased prevalence of the factor V 
Leiden mutation in chronic major vessel thromboembolic pulmonary hypertension 
(CTEPH). Thromb Haemost. 1996;76(3):476-7. 
66. Suntharalingam J, Goldsmith K, van Marion V, Long L, Treacy CM, Dudbridge 
F, et al. Fibrinogen Aalpha Thr312Ala polymorphism is associated with chronic 
thromboembolic pulmonary hypertension. Eur Respir J. 2008;31(4):736-41. 
67. Franchini M, Makris M. Non-O blood group: an important genetic risk factor for 
venous thromboembolism. Blood Transfus. 2013;11(2):164-5. 
   
 
 228 
68. Delcroix M, Lang I, Pepke-Zaba J, Jansa P, D'Armini AM, Snijder R, et al. 
Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary 
Hypertension: Results From an International Prospective Registry. Circulation. 
2016;133(9):859-71. 
69. Lotta LA, Wang M, Yu J, Martinelli I, Yu F, Passamonti SM, et al. Identification 
of genetic risk variants for deep vein thrombosis by multiplexed next-generation 
sequencing of 186 hemostatic/pro-inflammatory genes. BMC Med Genomics. 
2012;5:7. 
70. Germain M, Chasman DI, de Haan H, Tang W, Lindstrom S, Weng LC, et al. 
Meta-analysis of 65,734 individuals identifies TSPAN15 and SLC44A2 as two 
susceptibility loci for venous thromboembolism. Am J Hum Genet. 2015;96(4):532-
42. 
71. Rasmussen-Torvik LJ, Cushman M, Tsai MY, Zhang Y, Heckbert SR, 
Rosamond WD, et al. The association of alpha-fibrinogen Thr312Ala polymorphism 
and venous thromboembolism in the LITE study. Thromb Res. 2007;121(1):1-7. 
72. Humbert M, Guignabert C, Bonnet S, Dorfmüller P, Klinger JR, Nicolls MR, et 
al. Pathology and pathobiology of pulmonary hypertension: state of the art and 
research perspectives. Eur Respir J. 2019;53(1):1801887. 
73. Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka 
M, et al. Haemodynamic definitions and updated clinical classification of pulmonary 
hypertension. Eur Respir J. 2019;53(1): 1801913. 
74. Thenappan T, Ormiston ML, Ryan JJ, Archer SL. Pulmonary arterial 
hypertension: pathogenesis and clinical management. BMJ. 2018;360:j5492. 
75. Southgate L, Machado RD, Gräf S, Morrell NW. Molecular genetic framework 
underlying pulmonary arterial hypertension. Nat Rev Cardiol. 2020;17(2):85-95. 
76. Morrell NW, Aldred MA, Chung WK, Elliott CG, Nichols WC, Soubrier F, et al. 
Genetics and genomics of pulmonary arterial hypertension. Eur Respir J. 2019;53(1): 
1801899. 
77. Xi Q, Liu Z, Zhao Z, Luo Q, Huang Z. High Frequency of Pulmonary 
Hypertension-Causing Gene Mutation in Chinese Patients with Chronic 
Thromboembolic Pulmonary Hypertension. PLoS One. 2016;11(1):e0147396. 
78. Suntharalingam J, Machado RD, Sharples LD, Toshner MR, Sheares KK, 
Hughes RJ, et al. Demographic features, BMPR2 status and outcomes in distal 
chronic thromboembolic pulmonary hypertension. Thorax. 2007;62(7):617-22. 
79. Ulrich S, Szamalek-Hoegel J, Hersberger M, Fischler M, Garcia JS, Huber 
LC, et al. Sequence variants in BMPR2 and genes involved in the serotonin and 
nitric oxide pathways in idiopathic pulmonary arterial hypertension and chronic 
thromboembolic pulmonary hypertension: relation to clinical parameters and 
comparison with left heart disease. Respiration. 2010;79(4):279-87. 
80. Stearman RS, Cornelius AR, Lu X, Conklin DS, Del Rosario MJ, Lowe AM, et 
al. Functional prostacyclin synthase promoter polymorphisms. Impact in pulmonary 
arterial hypertension. Am J Respir Crit Care Med. 2014;189(9):1110-20. 
81. Amano S, Tatsumi K, Tanabe N, Kasahara Y, Kurosu K, Takiguchi Y, et al. 
Polymorphism of the promoter region of prostacyclin synthase gene in chronic 
thromboembolic pulmonary hypertension. Respirology. 2004;9(2):184-9. 
82. Graf S, Haimel M, Bleda M, Hadinnapola C, Southgate L, Li W, et al. 
Identification of rare sequence variation underlying heritable pulmonary arterial 
hypertension. Nat Commun. 2018;9(1):1416. 
83. Nakamura M, Okada O, Sakuma M, Nakanishi N, Miyahara Y, Yamada N, et 
al. Incidence and clinical characteristics of chronic pulmonary thromboembolism in 
   
 
 229 
Japan compared with acute pulmonary thromboembolism: results of a multicenter 
registry of the Japanese Society of Pulmonary Embolism Research. Circ J. 
2002;66(3):257-60. 
84. Kominami S, Tanabe N, Ota M, Naruse K, Katsuyama Y, Nakanishi N, et al. 
HLA-DPB1 and NFKBIL1 may confer the susceptibility to chronic thromboembolic 
pulmonary hypertension in the absence of deep vein thrombosis. J Hum Genet. 
2009;54(2):108-14. 
85. Tanabe N, Kimura A, Amano S, Okada O, Kasahara Y, Tatsumi K, et al. 
Association of clinical features with HLA in chronic pulmonary thromboembolism. Eur 
Respir J. 2005;25(1):131-8. 
86. Reinders J, Rozemuller EH, van Gent R, Arts-Hilkes YH, van den Tweel JG, 
Tilanus MG. Extended HLA-DPB1 polymorphism: an RNA approach for HLA-DPB1 
typing. Immunogenetics. 2005;57(10):790-4. 
87. Albertella MR, Campbell RD. Characterization of a novel gene in the human 
major histocompatibility complex that encodes a potential new member of the I 
kappa B family of proteins. Hum Mol Genet. 1994;3(5):793-9. 
88. Tanabe N, Amano S, Tatsumi K, Kominami S, Igarashi N, Shimura R, et al. 
Angiotensin-converting enzyme gene polymorphisms and prognosis in chronic 
thromboembolic pulmonary hypertension. Circ J. 2006;70(9):1174-9. 
89. Zou L, Li W, Han J, Yang Y, Jin J, Xiao F, et al. Identification of a low 
frequency missense mutation in MUC6 contributing to pulmonary artery hypertension 
by whole-exome sequencing. Pulm Circ. 2018;8(3):2045894018794374. 
90. Desmarais J, Elliott CG. Familial Chronic Thromboembolic Pulmonary 
Hypertension. Chest. 2016;149(4):e99-e101. 
91. Kataoka M, Momose Y, Aimi Y, Fukuda K, Gamou S, Satoh T. Familial 
Chronic Thromboembolic Pulmonary Hypertension in a Pair of Japanese Brothers. 
Chest. 2016;150(3):748-9. 
92. Dodson MW, Allen-Brady K, Brown LM, Elliott CG, Cannon-Albright LA. 
Chronic Thromboembolic Pulmonary Hypertension Cases Cluster in Families. Chest. 
2019;155(2):384-90. 
93. Bush WS, Moore JH. Chapter 11: Genome-Wide Association Studies. PLoS 
computational biology. 2012;8(12):e1002822. 
94. Rhodes CJ, Batai K, Bleda M, Haimel M, Southgate L, Germain M, et al. 
Genetic determinants of risk in pulmonary arterial hypertension: international 
genome-wide association studies and meta-analysis. Lancet Respir Med. 
2019;7(3):227-38. 
95. Opitz I, Kirschner MB. Molecular Research in Chronic Thromboembolic 
Pulmonary Hypertension. Int J Mol Sci. 2019;20(3):784. 
96. Gu S, Su P, Yan J, Zhang X, An X, Gao J, et al. Comparison of gene 
expression profiles and related pathways in chronic thromboembolic pulmonary 
hypertension. Int J Mol Med. 2014;33(2):277-300. 
97. Guo L, Yang Y, Liu J, Wang L, Li J, Wang Y, et al. Differentially expressed 
plasma microRNAs and the potential regulatory function of Let-7b in chronic 
thromboembolic pulmonary hypertension. PloS one. 2014;9(6): e101055. 
98. Wang Y, Huang X, Leng D, Li J, Wang L, Liang Y, et al. DNA methylation 
signatures of pulmonary arterial smooth muscle cells in chronic thromboembolic 
pulmonary hypertension. Physiol Genomics. 2018;50(5):313-22. 
99. Deng C, Wu D, Yang M, Chen Y, Wang C, Zhong Z, et al. Expression of 
tissue factor and forkhead box transcription factor O-1 in a rat model for chronic 
thromboembolic pulmonary hypertension. J Thromb Thrombolysis. 2016;42(4):520-8. 
   
 
 230 
100. Crous-Bou M, Harrington LB, Kabrhel C. Environmental and Genetic Risk 
Factors Associated with Venous Thromboembolism. Semin Thromb Hemost. 
2016;42(8):808-20. 
101. Heit JA, Phelps MA, Ward SA, Slusser JP, Petterson TM, De Andrade M. 
Familial segregation of venous thromboembolism. J Thromb Haemost. 
2004;2(5):731-6. 
102. Margaglione M, Grandone E. Population genetics of venous 
thromboembolism. A narrative review. Thromb Haemost. 2011;105(2):221-31. 
103. Rosendaal FR, Reitsma PH. Genetics of venous thrombosis. J Thromb 
Haemost. 2009;7 Suppl 1:301-4. 
104. Gohil R, Peck G, Sharma P. The genetics of venous thromboembolism. A 
meta-analysis involving approximately 120,000 cases and 180,000 controls. Thromb 
Haemost. 2009;102(2):360-70. 
105. Uitte de Willige S, de Visser MC, Houwing-Duistermaat JJ, Rosendaal FR, 
Vos HL, Bertina RM. Genetic variation in the fibrinogen gamma gene increases the 
risk for deep venous thrombosis by reducing plasma fibrinogen gamma' levels. 
Blood. 2005;106(13):4176-83. 
106. Emmerich J, Rosendaal FR, Cattaneo M, Margaglione M, De Stefano V, 
Cumming T, et al. Combined effect of factor V Leiden and prothrombin 20210A on 
the risk of venous thromboembolism--pooled analysis of 8 case-control studies 
including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous 
Thromboembolism. Thromb Haemost. 2001;86(3):809-16. 
107. Gerhardt A, Scharf RE, Beckmann MW, Struve S, Bender HG, Pillny M, et al. 
Prothrombin and factor V mutations in women with a history of thrombosis during 
pregnancy and the puerperium. N Engl J Med. 2000;342(6):374-80. 
108. Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal 
FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers 
of factor V Leiden mutation. Lancet. 1994;344(8935):1453-7. 
109. Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS, et 
al. Estrogen plus progestin and risk of venous thrombosis. JAMA. 
2004;292(13):1573-80. 
110. Stevens SM, Woller SC, Bauer KA, Kasthuri R, Cushman M, Streiff M, et al. 
Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. 
J Thromb Thrombolysis. 2016;41(1):154-64. 
111. Kearon C. Natural history of venous thromboembolism. Circulation. 
2003;107(23 Suppl 1):I22-30. 
112. van Stralen KJ, Doggen CJ, Bezemer ID, Pomp ER, Lisman T, Rosendaal 
FR. Mechanisms of the factor V Leiden paradox. Arterioscler Thromb Vasc Biol. 
2008;28(10):1872-7. 
113. Dentali F, Ageno W, Bozzato S, Malato A, Gianni M, Squizzato A, et al. Role 
of factor V Leiden or G20210A prothrombin mutation in patients with symptomatic 
pulmonary embolism and deep vein thrombosis: a meta-analysis of the literature. J 
Thromb Haemost. 2012;10(4):732-7. 
114. Dentali F, Sironi AP, Ageno W, Turato S, Bonfanti C, Frattini F, et al. Non-O 
blood type is the commonest genetic risk factor for VTE: results from a meta-analysis 
of the literature. Semin Thromb Hemost. 2012;38(5):535-48. 
115. Ohira T, Cushman M, Tsai MY, Zhang Y, Heckbert SR, Zakai NA, et al. ABO 
blood group, other risk factors and incidence of venous thromboembolism: the 
Longitudinal Investigation of Thromboembolism Etiology (LITE). J Thromb Haemost. 
2007;5(7):1455-61. 
   
 
 231 
116. Gandara E, Kovacs MJ, Kahn SR, Wells PS, Anderson DA, Chagnon I, et al. 
Non-OO blood type influences the risk of recurrent venous thromboembolism. A 
cohort study. Thromb Haemost. 2013;110(6):1172-9. 
117. Wolpin BM, Kabrhel C, Varraso R, Kraft P, Rimm EB, Goldhaber SZ, et al. 
Prospective study of ABO blood type and the risk of pulmonary embolism in two 
large cohort studies. Thromb Haemost. 2010;104(5):962-71. 
118. Jenkins PV, O'Donnell JS. ABO blood group determines plasma von 
Willebrand factor levels: a biologic function after all? Transfusion. 2006;46(10):1836-
44. 
119. Seltsam A, Hallensleben M, Kollmann A, Blasczyk R. The nature of diversity 
and diversification at the ABO locus. Blood. 2003;102(8):3035-42. 
120. O'Donnell J, Laffan MA. The relationship between ABO histo-blood group, 
factor VIII and von Willebrand factor. Transfus Med. 2001;11(4):343-51. 
121. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ, Jr., Montgomery RR. The 
effect of ABO blood group on the diagnosis of von Willebrand disease. Blood. 
1987;69(6):1691-5. 
122. Visscher PM, Wray NR, Zhang Q, Sklar P, McCarthy MI, Brown MA, et al. 10 
Years of GWAS Discovery: Biology, Function, and Translation. Am J Hum Genet. 
2017;101(1):5-22. 
123. Manolio TA. Genomewide association studies and assessment of the risk of 
disease. New Engl J Med. 2010;363(2):166-76. 
124. Visscher PM, Brown MA, McCarthy MI, Yang J. Five years of GWAS 
discovery. Am J Hum Genet. 2012;90(1):7-24. 
125. Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, et al. A 
global reference for human genetic variation. Nat Med. 2015;526(7571):68-74. 
126. Bomba L, Walter K, Soranzo N. The impact of rare and low-frequency genetic 
variants in common disease. Genome Biol. 2017;18(1):77. 
127. Reich DE, Lander ES. On the allelic spectrum of human disease. Trends 
Genet. 2001;17(9):502-10. 
128. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, et al. 
Complement factor H polymorphism in age-related macular degeneration. Science. 
2005;308(5720):385-9. 
129. Buniello A, MacArthur JAL, Cerezo M, Harris LW, Hayhurst J, Malangone C, 
et al. The NHGRI-EBI GWAS Catalog of published genome-wide association 
studies, targeted arrays and summary statistics 2019. Nucleic acids Res. 
2019;47(D1):D1005-D12. 
130. Yengo L, Sidorenko J, Kemper KE, Zheng Z, Wood AR, Weedon MN, et al. 
Meta-analysis of genome-wide association studies for height and body mass index in ∼700000 individuals of European ancestry. Hum Mol Genet. 2018;27(20):3641-9. 
131. Ioannidis JP, Tarone R, McLaughlin JK. The false-positive to false-negative 
ratio in epidemiologic studies. Epidemiology. 2011;22(4):450-6. 
132. Pearson TA, Manolio TA. How to interpret a genome-wide association study. 
JAMA. 2008;299(11):1335-44. 
133. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK 
Biobank resource with deep phenotyping and genomic data. Nat Med. 
2018;562(7726):203-9. 
134. Gudbjartsson DF, Arnar DO, Helgadottir A, Gretarsdottir S, Holm H, 
Sigurdsson A, et al. Variants conferring risk of atrial fibrillation on chromosome 4q25. 
Nat Med. 2007;448(7151):353-7. 
   
 
 232 
135. Torkamani A, Wineinger NE, Topol EJ. The personal and clinical utility of 
polygenic risk scores. Nat Rev Genet. 2018;19(9):581-90. 
136. Bush WS, Oetjens MT, Crawford DC. Unravelling the human genome-
phenome relationship using phenome-wide association studies. Nat Rev Genet. 
2016;17(3):129-45. 
137. Claussnitzer M, Cho JH, Collins R, Cox NJ, Dermitzakis ET, Hurles ME, et al. 
A brief history of human disease genetics. Nat Med. 2020;577(7789):179-89. 
138. Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation 
studies: a guide, glossary, and checklist for clinicians. BMJ. 2018;362:k601. 
139. Wensley F, Gao P, Burgess S, Kaptoge S, Di Angelantonio E, Shah T, et al. 
Association between C reactive protein and coronary heart disease: mendelian 
randomisation analysis based on individual participant data. BMJ. 2011;342:d548. 
140. Welter D, MacArthur J, Morales J, Burdett T, Hall P, Junkins H, et al. The 
NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids 
Res. 2014;42:D1001-6. 
141. LaFramboise T. Single nucleotide polymorphism arrays: a decade of 
biological, computational and technological advances. Nucleic Acids Res. 
2009;37(13):4181-93. 
142. Anderson CA, Pettersson FH, Clarke GM, Cardon LR, Morris AP, Zondervan 
KT. Data quality control in genetic case-control association studies. Nat Protoc. 
2010;5(9):1564-73. 
143. McCarthy MI, Abecasis GR, Cardon LR, Goldstein DB, Little J, Ioannidis JP, 
et al. Genome-wide association studies for complex traits: consensus, uncertainty 
and challenges. Nature Rev Genet. 2008;9(5):356-69. 
144. Slatkin M. Linkage disequilibrium--understanding the evolutionary past and 
mapping the medical future. Nat Rev Genet. 2008;9(6):477-85. 
145. Clarke GM, Anderson CA, Pettersson FH, Cardon LR, Morris AP, Zondervan 
KT. Basic statistical analysis in genetic case-control studies. Nat Protoc. 
2011;6(2):121-33. 
146. Pettersson FH, Anderson CA, Clarke GM, Barrett JC, Cardon LR, Morris AP, 
et al. Marker selection for genetic case-control association studies. Nat Protoc. 
2009;4(5):743-52. 
147. Cardon LR, Palmer LJ. Population stratification and spurious allelic 
association. Lancet. 2003;361(9357):598-604. 
148. Marchini J, Cardon LR, Phillips MS, Donnelly P. The effects of human 
population structure on large genetic association studies. Nat Genet. 
2004;36(5):512-7. 
149. Marchini J, Howie B. Genotype imputation for genome-wide association 
studies. Nat Rev Genet. 2010;11(7):499-511. 
150. Zeggini E, Ioannidis JP. Meta-analysis in genome-wide association studies. 
Pharmacogenomics. 2009;10(2):191-201. 
151. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, et al. 
Finding the missing heritability of complex diseases. Nat Med. 2009;461(7265):747-
53. 
152. Visscher PM, Medland SE, Ferreira MA, Morley KI, Zhu G, Cornes BK, et al. 
Assumption-free estimation of heritability from genome-wide identity-by-descent 
sharing between full siblings. PLoS Genet. 2006;2(3):e41. 
153. Boyle EA, Li YI, Pritchard JK. An Expanded View of Complex Traits: From 
Polygenic to Omnigenic. Cell. 2017;169(7):1177-86. 
   
 
 233 
154. Yang J, Benyamin B, McEvoy BP, Gordon S, Henders AK, Nyholt DR, et al. 
Common SNPs explain a large proportion of the heritability for human height. Nat 
Genet. 2010;42(7):565-9. 
155. Marouli E, Graff M, Medina-Gomez C, Lo KS, Wood AR, Kjaer TR, et al. Rare 
and low-frequency coding variants alter human adult height. Nat Med. 
2017;542(7640):186-90. 
156. Zhang F, Lupski JR. Non-coding genetic variants in human disease. Hum Mol 
Genet. 2015;24(R1):R102-10. 
157. Bulik-Sullivan B, Finucane HK, Anttila V, Gusev A, Day FR, Loh PR, et al. An 
atlas of genetic correlations across human diseases and traits. Nat Genet. 
2015;47(11):1236-41. 
158. Schaid DJ, Chen W, Larson NB. From genome-wide associations to 
candidate causal variants by statistical fine-mapping. Nat Rev Genet. 
2018;19(8):491-504. 
159. Spiegelhalter DJ, Myles JP, Jones DR, Abrams KR. Methods in health service 
research. An introduction to bayesian methods in health technology assessment. 
BMJ. 1999;319(7208):508-12. 
160. Maller JB, McVean G, Byrnes J, Vukcevic D, Palin K, Su Z, et al. Bayesian 
refinement of association signals for 14 loci in 3 common diseases. Nat Genet. 
2012;44(12):1294-301. 
161. Wang X, Liu X, Sim X, Xu H, Khor CC, Ong RT, et al. A statistical method for 
region-based meta-analysis of genome-wide association studies in genetically 
diverse populations. Eur J Hum Genet. 2012;20(4):469-75. 
162. Klemm SL, Shipony Z, Greenleaf WJ. Chromatin accessibility and the 
regulatory epigenome. Nat Rev Genet. 2019;20(4):207-20. 
163. Consortium EP. An integrated encyclopedia of DNA elements in the human 
genome. Nat Med. 2012;489(7414):57-74. 
164. Kundaje A, Meuleman W, Ernst J, Bilenky M, Yen A, Heravi-Moussavi A, et al. 
Integrative analysis of 111 reference human epigenomes. Nat Med. 
2015;518(7539):317-30. 
165. ENCODE Project Consortium. The Genotype-Tissue Expression (GTEx) 
project. Nat Genet. 2013;45(6):580-5. 
166. Klarin D, Emdin CA, Natarajan P, Conrad MF, Kathiresan S. Genetic Analysis 
of Venous Thromboembolism in UK Biobank Identifies the ZFPM2 Locus and 
Implicates Obesity as a Causal Risk Factor. Circ Cardiovasc Genet. 2017;10(2): 
e001643. 
167. Hinds DA, Buil A, Ziemek D, Martinez-Perez A, Malik R, Folkersen L, et al. 
Genome-wide association analysis of self-reported events in 6135 individuals and 
252 827 controls identifies 8 loci associated with thrombosis. Hum Mol Genet. 
2016;25(9):1867-74. 
168. Bruzelius M, Strawbridge RJ, Tregouet DA, Wiggins KL, Gertow K, Sabater-
Lleal M, et al. Influence of coronary artery disease-associated genetic variants on 
risk of venous thromboembolism. Thromb Res. 2014;134(2):426-32. 
169. Gregson J, Kaptoge S, Bolton T, Pennells L, Willeit P, Burgess S, et al. 
Cardiovascular Risk Factors Associated With Venous Thromboembolism. JAMA 
Cardiol. 2019;4(2):163-73. 
170. Kim J, Kraft P, Hagan KA, Harrington LB, Lindstroem S, Kabrhel C. 
Interaction of a genetic risk score with physical activity, physical inactivity, and body 
mass index in relation to venous thromboembolism risk. Genet Epidemiol. 
2018;42(4):354-65. 
   
 
 234 
171. Wassel CL, Rasmussen-Torvik LJ, Callas PW, Denenberg JO, Durda JP, 
Reiner AP, et al. A genetic risk score comprising known venous thromboembolism 
loci is associated with chronic venous disease in a multi-ethnic cohort. Thromb Res. 
2015;136(5):966-73. 
172. Klok FA, Dzikowska-Diduch O, Kostrubiec M, Vliegen HW, Pruszczyk P, 
Hasenfuss G, et al. Derivation of a clinical prediction score for chronic 
thromboembolic pulmonary hypertension after acute pulmonary embolism. J Thromb 
Haemost. 2016;14(1):121-8. 
173. Lindstrom S, Germain M, Crous-Bou M, Smith EN, Morange PE, van 
Hylckama Vlieg A, et al. Assessing the causal relationship between obesity and 
venous thromboembolism through a Mendelian Randomization study. Hum Genet. 
2017;136(7):897-902. 
174. Satoh T, Satoh K, Yaoita N, Kikuchi N, Omura J, Kurosawa R, et al. Activated 
TAFI Promotes the Development of Chronic Thromboembolic Pulmonary 
Hypertension: A Possible Novel Therapeutic Target. Circ Res. 2017;120(8):1246-62. 
175. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev 
Biochem. 1998;67:395-424. 
176. Dong JF, Moake JL, Nolasco L, Bernardo A, Arceneaux W, Shrimpton CN, et 
al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor 
multimers on the endothelial surface under flowing conditions. Blood. 
2002;100(12):4033-9. 
177. Zheng XL. Structure-function and regulation of ADAMTS-13 protease. J 
Thromb Haemost. 2013;11 Suppl 1:11-23. 
178. Baldauf C, Schneppenheim R, Stacklies W, Obser T, Pieconka A, 
Schneppenheim S, et al. Shear-induced unfolding activates von Willebrand factor A2 
domain for proteolysis. J Thromb Haemost. 2009;7(12):2096-105. 
179. Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood. 
2017;129(21):2836-46. 
180. Sadler JE. What's new in the diagnosis and pathophysiology of thrombotic 
thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program. 
2015;2015:631-6. 
181. Rieger M, Mannucci PM, Kremer Hovinga JA, Herzog A, Gerstenbauer G, 
Konetschny C, et al. ADAMTS13 autoantibodies in patients with thrombotic 
microangiopathies and other immunomediated diseases. Blood. 2005;106(4):1262-7. 
182. Mariotte E, Azoulay E, Galicier L, Rondeau E, Zouiti F, Boisseau P, et al. 
Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy 
with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-
sectional analysis of the French national registry for thrombotic microangiopathy. 
Lancet Haematol. 2016;3(5):e237-45. 
183. Terrell DR, Motto DG, Kremer Hovinga JA, Lämmle B, George JN, Vesely SK. 
Blood group O and black race are independent risk factors for thrombotic 
thrombocytopenic purpura associated with severe ADAMTS13 deficiency. 
Transfusion. 2011;51(10):2237-43. 
184. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, et al. 
Comparison of plasma exchange with plasma infusion in the treatment of thrombotic 
thrombocytopenic purpura. Canadian Apheresis Study Group. New Engl J Med. 
1991;325(6):393-7. 
185. Balduini CL, Gugliotta L, Luppi M, Laurenti L, Klersy C, Pieresca C, et al. High 
versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic 
thrombocytopenic purpura: a randomized study. Ann Hematol. 2010;89(6):591-6. 
   
 
 235 
186. Scully M, McDonald V, Cavenagh J, Hunt BJ, Longair I, Cohen H, et al. A 
phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute 
acquired thrombotic thrombocytopenic purpura. Blood. 2011;118(7):1746-53. 
187. Plaimauer B, Kremer Hovinga JA, Juno C, Wolfsegger MJ, Skalicky S, 
Schmidt M, et al. Recombinant ADAMTS13 normalizes von Willebrand factor-
cleaving activity in plasma of acquired TTP patients by overriding inhibitory 
antibodies. J Thromb Haemost. 2011;9(5):936-44. 
188. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, et al. 
Mutations in a member of the ADAMTS gene family cause thrombotic 
thrombocytopenic purpura. Nat Med. 2001;413(6855):488-94. 
189. Pérez-Rodríguez A, Lourés E, Rodríguez-Trillo Á, Costa-Pinto J, García-
Rivero A, Batlle-López A, et al. Inherited ADAMTS13 deficiency (Upshaw-Schulman 
syndrome): a short review. Thrombosis research. 2014;134(6):1171-5. 
190. Veyradier A, Lavergne JM, Ribba AS, Obert B, Loirat C, Meyer D, et al. Ten 
candidate ADAMTS13 mutations in six French families with congenital thrombotic 
thrombocytopenic purpura (Upshaw-Schulman syndrome). J Thromb Haemost. 
2004;2(3):424-9. 
191. Sonneveld MA, de Maat MP, Leebeek FW. Von Willebrand factor and 
ADAMTS13 in arterial thrombosis: a systematic review and meta-analysis. Blood 
Rev. 2014;28(4):167-78. 
192. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Tracy RP, Aleksic N, et 
al. Coagulation factors, inflammation markers, and venous thromboembolism: the 
longitudinal investigation of thromboembolism etiology (LITE). Am J Med. 
2002;113(8):636-42. 
193. Maino A, Siegerink B, Lotta LA, Crawley JT, le Cessie S, Leebeek FW, et al. 
Plasma ADAMTS-13 levels and the risk of myocardial infarction: an individual patient 
data meta-analysis. J Thromb Haemost. 2015;13(8):1396-404. 
194. Mazetto BM, Orsi FL, Barnabe A, De Paula EV, Flores-Nascimento MC, 
Annichino-Bizzacchi JM. Increased ADAMTS13 activity in patients with venous 
thromboembolism. Thromb Res. 2012;130(6):889-93. 
195. Llobet D, Tirado I, Vilalta N, Vallve C, Oliver A, Vazquez-Santiago M, et al. 
Low ADAMTS13 levels are associated with venous thrombosis risk in women. 
Thromb Res. 2017;157:38-40. 
196. Gouvea CP, Matsuda SS, Vaez R, Pinheiro PNB, Noguti MAE, Lourenço DM, 
et al. The Role Of High Von Willebrand Factor and Low ADAMTS13 Levels In The 
Risk Of Venous Thromboembolism. Blood. 2013;122(21):1128. 
197. Domingueti CP, Dusse LM, Fóscolo RB, Reis JS, Annichino-Bizzacchi JM, 
Orsi FL, et al. Von Willebrand Factor, ADAMTS13 and D-Dimer Are Correlated with 
Different Levels of Nephropathy in Type 1 Diabetes Mellitus. PLoS One. 
2015;10(7):e0132784. 
198. Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galie N, 
et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary 
embolism. Eur Heart J. 2014;35(43):3033-69, 69a-69k. 
199. Skoro-Sajer N, Gerges C, Gerges M, Panzenböck A, Jakowitsch J, Kurz A, et 
al. Usefulness of thrombosis and inflammation biomarkers in chronic 
thromboembolic pulmonary hypertension-sampling plasma and surgical specimens. 
J Heart Lung Transplant. 2018;37(9):1067-74. 
200. Orstavik KH, Magnus P, Reisner H, Berg K, Graham JB, Nance W. Factor VIII 
and factor IX in a twin population. Evidence for a major effect of ABO locus on factor 
VIII level. Am J Hum Genet. 1985;37(1):89-101. 
   
 
 236 
201. Ma Q, Jacobi PM, Emmer BT, Kretz CA, Ozel AB, McGee B, et al. Genetic 
variants in ADAMTS13 as well as smoking are major determinants of plasma 
ADAMTS13 levels. Blood Adv. 2017;1(15):1037-46. 
202. Chion CK, Doggen CJ, Crawley JT, Lane DA, Rosendaal FR. ADAMTS13 and 
von Willebrand factor and the risk of myocardial infarction in men. Blood. 
2007;109(5):1998-2000. 
203. Skol AD, Scott LJ, Abecasis GR, Boehnke M. Joint analysis is more efficient 
than replication-based analysis for two-stage genome-wide association studies. Nat 
Genet. 2006;38(2):209-13. 
204. Genome-wide association study of 14,000 cases of seven common diseases 
and 3,000 shared controls. Nat Med. 2007;447(7145):661-78. 
205. Bland JM, Altman DG. Statistics notes. The odds ratio. BMJ. 
2000;320(7247):1468. 
206. GenomeStudio Data Analysis Sofware. Genotyping module v2.0. 
https://emea.illumina.com/techniques/microarrays/array-data-analysis-experimental-
design/genomestudio.html. Accessed Feb 2017. 
207. Guo Y, He J, Zhao S, Wu H, Zhong X, Sheng Q, et al. Illumina human exome 
genotyping array clustering and quality control. Nat Protoc. 2014;9(11):2643-62. 
208. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-
generation PLINK: rising to the challenge of larger and richer datasets. Gigascience. 
2015;4:7. 
209. Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, et al. A 
global reference for human genetic variation. Nat Med. 2015;526(7571):68-74. 
210. Price AL, Weale ME, Patterson N, Myers SR, Need AC, Shianna KV, et al. 
Long-range LD can confound genome scans in admixed populations.  Am J Hum 
Genet. 2008;83(1):132-5. 
211. Zheng X, Levine D, Shen J, Gogarten SM, Laurie C, Weir BS. A high-
performance computing toolset for relatedness and principal component analysis of 
SNP data. Bioinformatics. 2012;28(24):3326-8. 
212. Andersson HM, Siegerink B, Luken BM, Crawley JT, Algra A, Lane DA, et al. 
High VWF, low ADAMTS13, and oral contraceptives increase the risk of ischemic 
stroke and myocardial infarction in young women. Blood. 2012;119(6):1555-60. 
213. Turner S, Armstrong LL, Bradford Y, Carlson CS, Crawford DC, Crenshaw 
AT, et al. Quality control procedures for genome-wide association studies. Curr 
Protoc Hum Genet. 2011;Chapter 1:Unit1.19. 
214. Loh PR, Danecek P, Palamara PF, Fuchsberger C, Y AR, H KF, et al. 
Reference-based phasing using the Haplotype Reference Consortium panel. Nat 
Genet. 2016;48(11):1443-8. 
215. Durbin R. Efficient haplotype matching and storage using the positional 
Burrows-Wheeler transform (PBWT). Bioinformatics. 2014;30(9):1266-72. 
216. McCarthy S, Das S, Kretzschmar W, Delaneau O, Wood AR, Teumer A, et al. 
A reference panel of 64,976 haplotypes for genotype imputation. Nat Genet. 
2016;48(10):1279-83. 
217. Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring 
population-specific haplotype structure and linking correlated alleles of possible 
functional variants. Bioinformatics. 2015;31(21):3555-7. 
218. Svensson L, Rydberg L, de Mattos LC, Henry SM. Blood group A(1) and A(2) 
revisited: an immunochemical analysis. Vox Sang. 2009;96(1):56-61. 
   
 
 237 
219. Pare G, Chasman DI, Kellogg M, Zee RY, Rifai N, Badola S, et al. Novel 
association of ABO histo-blood group antigen with soluble ICAM-1: results of a 
genome-wide association study of 6,578 women. PLoS Genet. 2008;4(7):e1000118. 
220. Marchini J, Howie B, Myers S, McVean G, Donnelly P. A new multipoint 
method for genome-wide association studies by imputation of genotypes. Nat Genet. 
2007;39(7):906-13. 
221. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping 
and annotation of genetic associations with FUMA. Nat Commun. 2017;8(1):1826. 
222. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic 
variants from high-throughput sequencing data. Nucleic Acids Res. 
2010;38(16):e164. 
223. Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J. A general 
framework for estimating the relative pathogenicity of human genetic variants. Nat 
Genet. 2014;46(3):310-5. 
224. Boyle AP, Hong EL, Hariharan M, Cheng Y, Schaub MA, Kasowski M, et al. 
Annotation of functional variation in personal genomes using RegulomeDB. Genome 
Res. 2012;22(9):1790-7. 
225. Ernst J, Kellis M. ChromHMM: automating chromatin-state discovery and 
characterization. Nat Methods. 2012;9(3):215-6. 
226. de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-
set analysis of GWAS data. PLoS Comput Biol. 2015;11(4):e1004219. 
227. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, 
Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 
2011;27(12):1739-40. 
228. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first 
fluorogenic substrate for ADAMTS13 assay. Br J Haematol. 2005;129(1):93-100. 
229. Matos LL, Trufelli DC, de Matos MG, da Silva Pinhal MA. 
Immunohistochemistry as an important tool in biomarkers detection and clinical 
practice. Biomark Insights. 2010;5:9-20. 
230. Kim SW, Roh J, Park CS. Immunohistochemistry for Pathologists: Protocols, 
Pitfalls, and Tips. J Pathol Transl Med. 2016;50(6):411-8. 
231. de Vries PS, Boender J, Sonneveld MA, Rivadeneira F, Ikram MA, 
Rottensteiner H, et al. Genetic variants in the ADAMTS13 and SUPT3H genes are 
associated with ADAMTS13 activity. Blood. 2015;125(25):3949-55. 
232. Suhre K, Arnold M, Bhagwat AM, Cotton RJ, Engelke R, Raffler J, et al. 
Connecting genetic risk to disease end points through the human blood plasma 
proteome. Nat Commun. 2017;8:14357. 
233. Groemping U. Relative Importance for Linear Regression in R: The Package 
relaimpo. Stat Softw. 2006;17(1):27. 
234. Pena EA, Slate EH. gvlma: Global Validation of Linear Models Assumptions. 
R package version 1.0.0.2. 2014. 
235. R Core Team. R: A Language and Environment for Statistical Computing. R 
Foundation for Statistical Computing, Vienna, Austria. 2017. 
236. Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N, et 
al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as 
principal genetic determinants of warfarin dose. PLoS Genet. 2009;5(3):e1000433. 
237. McCabe C, White PA, Hoole SP, Axell RG, Priest AN, Gopalan D, et al. Right 
ventricular dysfunction in chronic thromboembolic obstruction of the pulmonary 
artery: a pressure-volume study using the conductance catheter. J Appl Physiol 
(1985). 2014;116(4):355-63. 
   
 
 238 
238. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The 
Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009;25(16):2078-9. 
239. Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, et al. 
LocusZoom: regional visualization of genome-wide association scan results. 
Bioinformatics. 2010;26(18):2336-7. 
240. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al. 
Analysis of protein-coding genetic variation in 60,706 humans. Nat Med. 
2016;536(7616):285-91. 
241. Aken BL, Achuthan P, Akanni W, Amode MR, Bernsdorff F, Bhai J, et al. 
Ensembl 2017. Nucleic Acids Res. 2017;45:D635-42. 
242. RStudio Team. RStudio: Integrated Development Environment for R. RStudio, 
Inc., Boston, MA. 2016. 
243. Venables WN, Ripley BD. Modern Applied Statistics with S. 4 ed: Springer, 
New York. 2002. 
244. Hothorn T HK, van de Wiel MA, Zeileis A. Implementing a Class of 
Permutation Tests: The coin Package. J Stat Softw. 2008;28(8):23. 
245. Pohlert T. The Pairwise Multiple Comparison of Mean Ranks Package 
(PMCMR). R package. 2014. 
246. Long JA. jtools: Analysis and Presentation of Social Scientific Data. R 
package version 0.9.3. 2017. 
247. Kennedy N. forestmodel: Forest Plots from Regression Models. R package 
version 0.4.3. 2017. 
248. Gordon M, Lumley T. forestplot: Advanced Forest Plot Using 'grid' Graphics. 
R package version 1.9. 2017. 
249. Therneau T. A Package for Survival Analysis in S. R package version 2.38. 
2015. 
250. Kassambara A, Kosinski M. survminer: Drawing Survival Curves using 
'ggplot2'. R package version 0.4.4. 2019. 
251. Wickham H. tidyverse: Easily Install and Load the 'Tidyverse'. R package 
version 1.2.1. 2017. 
252. Teo YY, Inouye M, Small KS, Gwilliam R, Deloukas P, Kwiatkowski DP, et al. 
A genotype calling algorithm for the Illumina BeadArray platform. Bioinformatics. 
2007;23(20):2741-6. 
253. Schleef M, Strobel E, Dick A, Frank J, Schramm W, Spannagl M. Relationship 
between ABO and Secretor genotype with plasma levels of factor VIII and von 
Willebrand factor in thrombosis patients and control individuals. Br J Haematol. 
2005;128(1):100-7. 
254. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet. 
1995;346(8983):1133-4. 
255. Schmitt AD, Hu M, Jung I, Xu Z, Qiu Y, Tan CL, et al. A Compendium of 
Chromatin Contact Maps Reveals Spatially Active Regions in the Human Genome. 
Cell Rep. 2016;17(8):2042-59. 
256. GTEx Consortium. The Genotype-Tissue Expression (GTEx) pilot analysis: 
Multitissue gene regulation in humans. Science. 2015;348(6235):648-60. 
257. Spain SL, Barrett JC. Strategies for fine-mapping complex traits. Hum Mol 
Genet. 2015;24(R1):R111-9. 
258. Dichgans M, Malik R, Konig IR, Rosand J, Clarke R, Gretarsdottir S, et al. 
Shared genetic susceptibility to ischemic stroke and coronary artery disease: a 
genome-wide analysis of common variants. Stroke. 2014;45(1):24-36. 
   
 
 239 
259. Heit JA, Armasu SM, Asmann YW, Cunningham JM, Matsumoto ME, 
Petterson TM, et al. A genome-wide association study of venous thromboembolism 
identifies risk variants in chromosomes 1q24.2 and 9q. J Thromb Haemost. 
2012;10(8):1521-31. 
260. Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, Kanoni S, et al. A 
comprehensive 1,000 Genomes-based genome-wide association meta-analysis of 
coronary artery disease. Nat Genet. 2015;47(10):1121-30. 
261. Malik R, Chauhan G, Traylor M, Sargurupremraj M, Okada Y, Mishra A, et al. 
Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci 
associated with stroke and stroke subtypes. Nat Genet. 2018;50(4):524-37. 
262. Pickrell JK, Berisa T, Liu JZ, Segurel L, Tung JY, Hinds DA. Detection and 
interpretation of shared genetic influences on 42 human traits. Nat Genet. 
2016;48(7):709-17. 
263. Scott RA, Scott LJ, Magi R, Marullo L, Gaulton KJ, Kaakinen M, et al. An 
Expanded Genome-Wide Association Study of Type 2 Diabetes in Europeans. 
Diabetes. 2017;66(11):2888-902. 
264. Desch KC, Ozel AB, Siemieniak D, Kalish Y, Shavit JA, Thornburg CD, et al. 
Linkage analysis identifies a locus for plasma von Willebrand factor undetected by 
genome-wide association. Proc Natl Acad Sci U S A. 2013;110(2):588-93. 
265. Kamatani Y, Matsuda K, Okada Y, Kubo M, Hosono N, Daigo Y, et al. 
Genome-wide association study of hematological and biochemical traits in a 
Japanese population. Nat Genet. 2010;42(3):210-5. 
266. Astle WJ, Elding H, Jiang T, Allen D, Ruklisa D, Mann AL, et al. The Allelic 
Landscape of Human Blood Cell Trait Variation and Links to Common Complex 
Disease. Cell. 2016;167(5):1415-29.e19. 
267. Qi L, Cornelis MC, Kraft P, Jensen M, van Dam RM, Sun Q, et al. Genetic 
variants in ABO blood group region, plasma soluble E-selectin levels and risk of type 
2 diabetes. Hum Mol Genet. 2010;19(9):1856-62. 
268. Barbalic M, Dupuis J, Dehghan A, Bis JC, Hoogeveen RC, Schnabel RB, et 
al. Large-scale genomic studies reveal central role of ABO in sP-selectin and sICAM-
1 levels. Hum Mol Genet. 2010;19(9):1863-72. 
269. Spracklen CN, Chen P, Kim YJ, Wang X, Cai H, Li S, et al. Association 
analyses of East Asian individuals and trans-ancestry analyses with European 
individuals reveal new loci associated with cholesterol and triglyceride levels. Hum 
Mol Genet. 2017;26(9):1770-84. 
270. Lieb W, Chen MH, Larson MG, Safa R, Teumer A, Baumeister SE, et al. 
Genome-wide association study for endothelial growth factors. Circ Cardiovasc 
Genet. 2015;8(2):389-97. 
271. Pare G, Ridker PM, Rose L, Barbalic M, Dupuis J, Dehghan A, et al. Genome-
wide association analysis of soluble ICAM-1 concentration reveals novel 
associations at the NFKBIK, PNPLA3, RELA, and SH2B3 loci. PLoS Genet. 
2011;7(4):e1001374. 
272. Sun BB, Maranville JC, Peters JE, Stacey D, Staley JR, Blackshaw J, et al. 
Genomic atlas of the human plasma proteome. Nat Med. 2018;558(7708):73-9. 
273. Tang W, Schwienbacher C, Lopez LM, Ben-Shlomo Y, Oudot-Mellakh T, 
Johnson AD, et al. Genetic associations for activated partial thromboplastin time and 
prothrombin time, their gene expression profiles, and risk of coronary artery disease. 
Am J Hum Genet. 2012;91(1):152-62. 
274. Puy C, Rigg RA, McCarty OJ. The hemostatic role of factor XI. Thromb Res. 
2016;141 Suppl 2:S8-s11. 
   
 
 240 
275. Zhu Z, Yao J, Johns T, Fu K, De Bie I, Macmillan C, et al. SURF1, encoding a 
factor involved in the biogenesis of cytochrome c oxidase, is mutated in Leigh 
syndrome. Nat Genet. 1998;20(4):337-43. 
276. Delcroix M, Vonk Noordegraaf A, Fadel E, Lang I, Simonneau G, Naeije R. 
Vascular and right ventricular remodelling in chronic thromboembolic pulmonary 
hypertension. Eur Respir J. 2013;41(1):224-32. 
277. Standeven KF, Grant PJ, Carter AM, Scheiner T, Weisel JW, Ariëns RA. 
Functional analysis of the fibrinogen Aalpha Thr312Ala polymorphism: effects on 
fibrin structure and function. Circulation. 2003;107(18):2326-30. 
278. Smemo S, Tena JJ, Kim KH, Gamazon ER, Sakabe NJ, Gómez-Marín C, et 
al. Obesity-associated variants within FTO form long-range functional connections 
with IRX3. Nat Med. 2014;507(7492):371-5. 
279. Groot HE, Villegas Sierra LE, Said MA, Lipsic E, Karper JC, van der Harst P. 
Genetically Determined ABO Blood Group and its Associations With Health and 
Disease. Arterioscler Thromb Vasc Biol. 2020;40(3):830-8. 
280. Dean L. Medical Genetics Summaries: ABO blood group. [Online]. [Accessed 
1 March 2020] Available from: https://www.ncbi.nlm.nih.gov/books/NBK100894/. 
281. Lippert C, Listgarten J, Liu Y, Kadie CM, Davidson RI, Heckerman D. FaST 
linear mixed models for genome-wide association studies. Nat Methods. 
2011;8(10):833-5. 
282. Zaykin DV, Kozbur DO. P-value based analysis for shared controls design in 
genome-wide association studies. Genet Epidemiol. 2010;34(7):725-38. 
283. Crawley JT, Lam JK, Rance JB, Mollica LR, O'Donnell JS, Lane DA. 
Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. Blood. 
2005;105(3):1085-93. 
284. Feys HB, Vandeputte N, Palla R, Peyvandi F, Peerlinck K, Deckmyn H, et al. 
Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic 
thrombocytopenic purpura. J Thromb Haemost. 2010;8(9):2053-62. 
285. Moake JL, Rudy CK, Troll JH, Weinstein MJ, Colannino NM, Azocar J, et al. 
Unusually large plasma factor VIII:von Willebrand factor multimers in chronic 
relapsing thrombotic thrombocytopenic purpura. N Engl J Med. 1982;307(23):1432-
5. 
286. Schwameis M, Schorgenhofer C, Assinger A, Steiner MM, Jilma B. VWF 
excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation 
to thrombosis in DIC, malaria, and TTP. Thromb Haemost. 2015;113(4):708-18. 
287. Wolff B, Lodziewski S, Bollmann T, Opitz CF, Ewert R. Impaired peripheral 
endothelial function in severe idiopathic pulmonary hypertension correlates with the 
pulmonary vascular response to inhaled iloprost. Am Heart J. 2007;153(6):1088.e1-
7. 
288. Schäfer M, Kheyfets VO, Schroeder JD, Dunning J, Shandas R, Buckner JK, 
et al. Main pulmonary arterial wall shear stress correlates with invasive 
hemodynamics and stiffness in pulmonary hypertension. Pulm Circ. 2016;6(1):37-45. 
289. South K, Freitas MO, Lane DA. A model for the conformational activation of 
the structurally quiescent metalloprotease ADAMTS13 by von Willebrand factor. J 
Biol Chem. 2017;292(14):5760-9. 
290. Zhao BQ, Chauhan AK, Canault M, Patten IS, Yang JJ, Dockal M, et al. von 
Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in 
experimental stroke. Blood. 2009;114(15):3329-34. 
   
 
 241 
291. De Meyer SF, Savchenko AS, Haas MS, Schatzberg D, Carroll MC, Schiviz A, 
et al. Protective anti-inflammatory effect of ADAMTS13 on myocardial 
ischemia/reperfusion injury in mice. Blood. 2012;120(26):5217-23. 
292. Witsch T, Martinod K, Sorvillo N, Portier I, De Meyer SF, Wagner DD. 
Recombinant Human ADAMTS13 Treatment Improves Myocardial Remodeling and 
Functionality After Pressure Overload Injury in Mice. J Am Heart Assoc. 2018;7(3): 
e007004. 
293. Gandhi C, Motto DG, Jensen M, Lentz SR, Chauhan AK. ADAMTS13 
deficiency exacerbates VWF-dependent acute myocardial ischemia/reperfusion 
injury in mice. Blood. 2012;120(26):5224-30. 
294. Bonderman D, Jakowitsch J, Adlbrecht C, Schemper M, Kyrle PA, Schonauer 
V, et al. Medical conditions increasing the risk of chronic thromboembolic pulmonary 
hypertension. Thromb Haemost. 2005;93(3):512-6. 
295. Chauhan AK, Kisucka J, Brill A, Walsh MT, Scheiflinger F, Wagner DD. 
ADAMTS13: a new link between thrombosis and inflammation. J Exp Med. 
2008;205(9):2065-74. 
296. Lee M, Rodansky ES, Smith JK, Rodgers GM. ADAMTS13 promotes 
angiogenesis and modulates VEGF-induced angiogenesis. Microvasc Res. 
2012;84(2):109-15. 
297. Xu H, Cao Y, Yang X, Cai P, Kang L, Zhu X, et al. ADAMTS13 controls 
vascular remodeling by modifying VWF reactivity during stroke recovery. Blood. 
2017;130(1):11-22. 
298. Lotta LA, Tuana G, Yu J, Martinelli I, Wang M, Yu F, et al. Next-generation 
sequencing study finds an excess of rare, coding single-nucleotide variants of 
ADAMTS13 in patients with deep vein thrombosis. J Thromb Haemost. 
2013;11(7):1228-39. 
299. Freeman WM, Walker SJ, Vrana KE. Quantitative RT-PCR: pitfalls and 
potential. Biotechniques. 1999;26(1):112-22, 24-5. 
300. Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for 
transcriptomics. Nat Rev Genet. 2009;10(1):57-63. 
301. Folsom AR, Tang W, Weng LC, Roetker NS, Cushman M, Basu S, et al. 
Replication of a genetic risk score for venous thromboembolism in whites but not in 
African Americans. J Thromb Haemost. 2016;14(1):83-8. 
302. de Haan HG, Bezemer ID, Doggen CJ, Le Cessie S, Reitsma PH, Arellano 
AR, et al. Multiple SNP testing improves risk prediction of first venous thrombosis. 
Blood. 2012;120(3):656-63. 
303. Hong EP, Park JW. Sample size and statistical power calculation in genetic 
association studies. Genomics Inform. 2012;10(2):117-22. 
304. Kujovich JL. Factor V Leiden thrombophilia. Genet Med. 2011;13(1):1-16. 
305. Kyrle PA, Rosendaal FR, Eichinger S. Risk assessment for recurrent venous 
thrombosis. Lancet. 2010;376(9757):2032-9. 
306. Pomero F, Ageno W, Serraino C, Borretta V, Gianni M, Fenoglio L, et al. The 
role of inherited thrombophilia in patients with isolated pulmonary embolism: a 
systematic review and a meta-analysis of the literature. Thromb Res. 
2014;134(1):84-9. 
307. de Moerloose P, Reber G, Perrier A, Perneger T, Bounameaux H. Prevalence 
of factor V Leiden and prothrombin G20210A mutations in unselected patients with 
venous thromboembolism. Br J Haematol. 2000;110(1):125-9. 
   
 
 242 
308. Corral J, Roldán V, Vicente V. Deep venous thrombosis or pulmonary 
embolism and factor V Leiden: enigma or paradox.  Haematologica. 2010;95(6):863-
6. 
309. Fagerberg L, Hallström BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J, 
et al. Analysis of the human tissue-specific expression by genome-wide integration 
of transcriptomics and antibody-based proteomics. Mol Cell Proteomics. 
2014;13(2):397-406. 
310. Therrien M, Chang HC, Solomon NM, Karim FD, Wassarman DA, Rubin GM. 
KSR, a novel protein kinase required for RAS signal transduction. Cell. 
1995;83(6):879-88. 
311. Liu JZ, van Sommeren S, Huang H, Ng SC, Alberts R, Takahashi A, et al. 
Association analyses identify 38 susceptibility loci for inflammatory bowel disease 
and highlight shared genetic risk across populations. Nat Genet. 2015;47(9):979-86. 
312. Ellinghaus D, Jostins L, Spain SL, Cortes A, Bethune J, Han B, et al. Analysis 
of five chronic inflammatory diseases identifies 27 new associations and highlights 
disease-specific patterns at shared loci. Nat Genet. 2016;48(5):510-8. 
313. Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, Church DM, et al. 
ClinVar: public archive of relationships among sequence variation and human 
phenotype. Nucleic Acids Res. 2014;42:D980-5. 
314. Kratochvílová K, Horak P, Ešner M, Souček K, Pils D, Anees M, et al. Tumor 
suppressor candidate 3 (TUSC3) prevents the epithelial-to-mesenchymal transition 
and inhibits tumor growth by modulating the endoplasmic reticulum stress response 
in ovarian cancer cells. Int J Cancer. 2015;137(6):1330-40. 
315. Kichaev G, Bhatia G, Loh PR, Gazal S, Burch K, Freund MK, et al. 
Leveraging Polygenic Functional Enrichment to Improve GWAS Power. Am J Hum 
Genet. 2019;104(1):65-75. 
316. Zhang Q, Marioni RE, Robinson MR, Higham J, Sproul D, Wray NR, et al. 
Genotype effects contribute to variation in longitudinal methylome patterns in older 
people. Genome Med. 2018;10(1):75. 
317. Tam V, Patel N, Turcotte M, Bossé Y, Paré G, Meyre D. Benefits and 
limitations of genome-wide association studies. Nat Rev Genet. 2019;20(8):467-84. 
318. Stephens M, Balding DJ. Bayesian statistical methods for genetic association 
studies. Nat Rev Genet. 2009;10(10):681-90. 
319. Ten Cate V, Koeck T, Panova-Noeva M, Rapp S, Prochaska JH, Lenz M, et 
al. A prospective cohort study to identify and evaluate endotypes of venous 
thromboembolism: Rationale and design of the Genotyping and Molecular 
Phenotyping in Venous ThromboEmbolism project (GMP-VTE). Throm Res. 
2019;181:84-91. 
320. Yu S, Kumamaru KK, George E, Bedayat A, Rybicki FJ, Dunne RM, et al. 
Classification of CT pulmonary angiography reports by presence, chronicity, and 
location of pulmonary embolism with natural language processing. J Biomed Inform. 
2014;52:386-93. 
321. Cho JH, Feldman M. Heterogeneity of autoimmune diseases: 
pathophysiologic insights from genetics and implications for new therapies. Nat Med. 
2015;21(7):730-8. 
322. Rahaghi FN, Argemí G, Nardelli P, Domínguez-Fandos D, Arguis P, Peinado 
VI, et al. Pulmonary vascular density: comparison of findings on computed 
tomography imaging with histology. Eur Respir J. 2019;54(2):1900370. 
   
 
 243 
323. Rahaghi FN, Ross JC, Agarwal M, González G, Come CE, Diaz AA, et al. 
Pulmonary vascular morphology as an imaging biomarker in chronic thromboembolic 
pulmonary hypertension. Pulm Circ. 2016;6(1):70-81. 
324. Dahl A, Cai N, Ko A, Laakso M, Pajukanta P, Flint J, et al. Reverse GWAS: 
Using genetics to identify and model phenotypic subtypes. PLoS genetics. 
2019;15(4):e1008009. 
325. Li L, Cheng WY, Glicksberg BS, Gottesman O, Tamler R, Chen R, et al. 
Identification of type 2 diabetes subgroups through topological analysis of patient 
similarity. Sci Transl Med. 2015;7(311):311ra174. 
326. Zakai NA, McClure LA. Racial differences in venous thromboembolism. J 
Thromb Haemost. 2011;9(10):1877-82. 
327. Cano-Gamez E, Trynka G. From GWAS to Function: Using Functional 
Genomics to Identify the Mechanisms Underlying Complex Diseases. Front Genet. 
2020;11:424. 
328. Wainberg M, Sinnott-Armstrong N, Mancuso N, Barbeira AN, Knowles DA, 
Golan D, et al. Opportunities and challenges for transcriptome-wide association 
studies. Nat Genet. 2019;51(4):592-9. 
329. Ulrich A, Wharton J, Thayer TE, Swietlik EM, Assad TR, Desai AA, et al. 
Mendelian randomisation analysis of red cell distribution width in pulmonary arterial 
hypertension. Eur Respir J. 2020;55(2): 1901486. 
330. Malik N, Rao MS. A review of the methods for human iPSC derivation. 
Methods Mol Biol. 2013;997:23-33. 
331. Coll M, Perea L, Boon R, Leite SB, Vallverdú J, Mannaerts I, et al. Generation 
of Hepatic Stellate Cells from Human Pluripotent Stem Cells Enables In Vitro 
Modeling of Liver Fibrosis. Cell Stem Cell. 2018;23(1):101-13.e7. 
332. Adams WJ, Zhang Y, Cloutier J, Kuchimanchi P, Newton G, Sehrawat S, et 
al. Functional vascular endothelium derived from human induced pluripotent stem 
cells. Stem Cell Reports. 2013;1(2):105-13. 
333. Mercier O, Tivane A, Dorfmüller P, de Perrot M, Raoux F, Decante B, et al. 
Piglet model of chronic pulmonary hypertension. Pulm Circ. 2013;3(4):908-15. 
334. Nichols TC, Bellinger DA, Merricks EP, Raymer RA, Kloos MT, Defriess N, et 
al. Porcine and canine von Willebrand factor and von Willebrand disease: 
hemostasis, thrombosis, and atherosclerosis studies. Thrombosis. 
2010;2010:461238. 
335. Fujioka M, Hayakawa K, Mishima K, Kunizawa A, Irie K, Higuchi S, et al. 
ADAMTS13 gene deletion aggravates ischemic brain damage: a possible 
neuroprotective role of ADAMTS13 by ameliorating postischemic hypoperfusion. 
Blood. 2010;115(8):1650-3. 
336. Sonneveld MA, de Maat MP, Portegies ML, Kavousi M, Hofman A, Turecek 
PL, et al. Low ADAMTS13 activity is associated with an increased risk of ischemic 
stroke. Blood. 2015;126(25):2739-46. 
337. Banno F, Kokame K, Okuda T, Honda S, Miyata S, Kato H, et al. Complete 
deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause 
thrombotic thrombocytopenic purpura. Blood. 2006;107(8):3161-6. 
338. Denorme F, Langhauser F, Desender L, Vandenbulcke A, Rottensteiner H, 
Plaimauer B, et al. ADAMTS13-mediated thrombolysis of t-PA-resistant occlusions in 
ischemic stroke in mice. Blood. 2016;127(19):2337-45. 
339. Bustamante A, Ning M, García-Berrocoso T, Penalba A, Boada C, Simats A, 
et al. Usefulness of ADAMTS13 to predict response to recanalization therapies in 
acute ischemic stroke. Neurology. 2018;90(12):e995-e1004. 
   
 
 244 
Appendix 
 
Below are the listed copyright permissions for figures reproduced in this thesis. 
 
Figure 1.1 
Reproduced with permission of the © ERS 2020: European Respiratory Review 2015; 
24: 263-271; DOI: 10.1183/16000617.00000815 (Figure 1) 
Permission from Elin Reeves, Director of Publications, European Respiratory Society, 
15th July 2020. 
 
Figure 1.2 
Reproduced with permission of the © Elsevier: Seminars in Thoracic and 
Cardiovascular Surgery 2006; 18(3): 243-249 (Figure 4) 
Permission and license via the Copyright Clearance Center, license number 
4857220717385, 27th June 2020. For reuse in thesis: electronic and print. 
 
Figure 1.3 
Reproduced under creative commons license: CC BY-SA 3.0 
 
Figure 1.4 
Reproduced under creative commons license: CC BY-SA 3.0 
 
Figure 1.5 
Reproduced with permission of the © CMAJ group (www.cmaj.ca): Canadian Medical 
Association Journal 2002; 167(1): 48-54 (Figure 1) 
Permission from Holly Bodger, Publisher, The CMAJ Group, 15th July 2020. 
 
Figure 1.6 
Reproduced with permission of the © BMJ Publishing Group Ltd: The British Medical 
Journal 2014; 349: g4387 (Figure on page 9) 
Permission and license via the Copyright Clearance Center, license number 
4857230439576, 27th June 2020. For reuse in thesis: electronic and print. 
 
   
 
 245 
Figure 1.7 
Reproduced with permission of the © Springer Nature: Nature Reviews Cardiology 
2020; 17(2): 85-95 (Figure 1) 
Permission and license via the Copyright Clearance Center, license number 
4870230134454, 15th July 2020. For reuse in thesis: electronic and print. 
 
Figure 1.8 
Reproduced with permission of the Copyright: © 2012 Bush, Moore: PLoS 
computational biology 2012; 8(12):e1002822 (Figure 1) 
This is an open-access article distributed under the terms of the Creative Commons 
Attribution License, which permits unrestricted use, distribution, and reproduction in 
any medium, provided the original author and source are credited. 
 
Figure 1.9 
Reproduced with permission of the © Elsevier: The American Journal of Human 
Genetics 2017; 101(1):5-22 (Figure 2) 
Permission and license via the Copyright Clearance Center, license number 
4870270384354, 15th July 2020. For reuse in thesis: electronic and print. 
 
Figure 1.10 
Reproduced with permission of the © Illumina: 
https://dnatech.genomecenter.ucdavis.edu/infinium-assay/ (Figure 1) 
Permission from, Rufus Knight, Direct Marketing Specialist (EMEA), Illumina, 16th July 
2020. 
 
Figure 1.11 
Reproduced with permission of the © Massachusetts Medical Society: The New 
England Journal of Medicine 2010; 363(2): 166-76 (Figure 1) 
Content (full-text or portions thereof) may be used in print and electronic versions of a 
dissertation or thesis without formal permission from the Massachusetts Medical 
Society (MMS), Publisher of the New England Journal of Medicine. 
 
 
 
   
 
 246 
Figure 1.12 
Reproduced with permission of the Copyright: © 2012 Bush, Moore: PLoS 
computational biology 2012; 8(12):e1002822 (Figure 2) 
This is an open-access article distributed under the terms of the Creative Commons 
Attribution License, which permits unrestricted use, distribution, and reproduction in 
any medium, provided the original author and source are credited. 
 
Figure 1.13 
Reproduced with permission of the © Springer Nature: Nature Reviews Genetics 
2010; 11(7): 499-511 (Figure in Box 1) 
Permission and license via the Copyright Clearance Center, license number 
4870271354233, 15th July 2020. For reuse in thesis: electronic and print. 
 
Figure 1.14 
Reproduced with permission of the © Elsevier: The American Journal of Human 
Genetics 2015; 96(4): 532-42 (Figure S1) 
Permission and license via the Copyright Clearance Center, license number 
4870280118598, 15th July 2020. For reuse in thesis: electronic and print. 
 
Figure 1.15 
This research was originally published in Blood. Joly BS, Coppo P, Veyradier A. 
Thrombotic thrombocytopenic purpura. Blood. 2017;129(21):2836-46 (Figure 2) 
© the American Society of Hematology 
 
